{ "moduleName": "webapps", "moduleDescriptor": { "templatePath": "/Layouts/WebApps/Press Releases/list.html", "parameters": "id=\"14242\",filter=\"all\",resultsPerPage=\"50\",collection=\"news\",template=\"\"", "apiEndpoint": "/api/v3/webapps", "objectType": 34, "objectId": -1, "adminUrl": "/Admin/CustomContent_ItemList.aspx?CustomContentID=-1" }, "editableFieldTypes": { "description": "Html", "itemId": "Id", "name": "Text", "url": "Text", "releaseDate": "Date", "expiryDate": "Date", "lastUpdateDate": "Date", "weight": "Number" }, "items": [ { "description": "

 

\n

VANCOUVER, November 29, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical\n company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three and nine months\n ended September 30, 2018 and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.

\n

Q3 2018 Key Highlights

\n\n\n\n\n\n

“Our strong promotional efforts across Canada continue to yield positive results with our largest quarterly revenue in company history,” said Ian Ball,\n CCO of Aequus. “Our position within Canada continues to strengthen, with our commercial team consistently building relationships with key contacts\n in the industry. These relationships, along with the formation of our Strategic Advisory Board in Ophthalmology will be paramount as we continue to\n expand our product portfolio moving forward.”

\n

Commercial Activities

\n

The Company’s commercial activity generated revenues of $420,158 in Q3 2018, representing 44% growth as compared to the same period in 2017. On a year-to-date\n basis, the Company recorded $1,173,013 in revenues in the nine-month period ending September 30, 2018, an increase of 52% compared to the same period\n in 2017. The increase in revenues were primarily attributable to increased promotional activities being focused in markets with positive market access\n and reimbursement listings.

\n

Subsequent to the end of the quarter, Aequus has formed a Strategic Advisory Board in Ophthalmology to assist in assessing and rationalizing the many ophthalmology\n pipeline opportunities, both in therapeutics and medical devices, available to the Company. The Advisory Board will help Aequus in determining whether\n a product can improve patient outcomes, integrate into a clinician’s workflow, and navigate the Canadian reimbursement and commercial landscape.

\n

Development Program Activities\n

\n

Aequus announced an expanded market opportunity for its reformulated anti-nausea transdermal patch, AQS1303, into the European market with the approval\n of Diclectin®, the oral reference product for AQS1303 for the treatment of nausea and vomiting of pregnancy, having recently received marketing authorization\n in the United Kingdom under the brand name Xonvea®. Aequus plans to launch AQS1303 in countries where an original oral form has been approved and an\n accelerated path to approval may exist for reformulated products

\n

Operating Expenses\n

\n

Sales and marketing expenses for Q3 2018 were $449,932 and $310,163 in the same period last year. The 45% increase was primarily the result of higher marketing\n costs related to Zepto and staff vacancies in Q3 2017 that were no longer vacant in Q3 2018.The expenses include non-cash expenses of $54,720 related\n to amortization and share based payments expenses. Depreciation and amortization, and share-based payments for Q3 2018 were $44,555 and $10,165, respectively,\n compared to $45,918 and $15,053, respectively, in Q3 2017. The amortization costs were primarily related to the acquisition costs of TeOra.As the sales\n and marketing infrastructure is now established, new products, like Zepto, can be marketed to the same customer base without material impact to overall\n sales related costs.

\n

The Company incurred research and development expenses of $76,275 in Q3 2018 as compared to $415,173 in Q3 2017. The decrease was primarily attributable\n to lower subcontractor research costs and reduced regulatory consulting for AQS1301 and AQS1303 pre-IND related work, which completed in Q3 2017. The\n main development work in Q3 2018 was the advancement and optimization of AQS1303 in preparation for clinical studies. The costs of which are being\n realized by its partner, Corium, in exchange for exclusive manufacturing of the product. This resulted in a $328,383 decrease in Q3 2018 cost relative\n to Q3 2017.

\n

General administration expenses were consistent with prior quarters at $546,827 during Q3 2018 as compared to $532,085 in Q3 2017.

\n

FINANCIAL STATEMENTS AND MD&A

\n

Investors are encouraged to review Aequus’ complete Financial Statements and Management’s Discussion and Analysis (“MD&A”) for the three and nine months\n ended September 30, 2018, which are available on the Company’s website at www.aequuspharma.ca and on SEDAR\n at www.sedar.com.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS\n ,\n OTCQB:AQSZF) is a\n growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its pipeline\n to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of\n addressing the need for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology, our most recent\n addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade\n delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established\n medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on\n its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition\n or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca\n .\n

\n

FORWARD-LOOKING STATEMENT DISCLAIMER

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; the Company’s expected revenues; Aequus’ sales and marketing efforts; the Company’s potential regional partnerships for its internal programs; the regulatory requirements for its transdermal pyridoxine/doxylamine program. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2018, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.\n

\n

VistitanTM: Trademark owned or used under license by Sandoz Canada Inc.

\n

Zepto® is a registered trademark of Mynosys Cellular Devices.\n

\n

CONTACT INFORMATION

\n

Aequus Investor Relations

\n

Email: investors@aequuspharma.ca

\n

Phone: 604-336-7906

\n

 

", "itemId": 8303700, "name": "Aequus Reports Largest Quarterly Revenue in Company History and Provides Management Update", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-reports-largest-quarterly-revenue-in-company-history-and-provides-management-update", "url": "/en/news/aequus-reports-largest-quarterly-revenue-in-company-history-and-provides-management-update", "releaseDate": "2018-11-29T00:00:00", "releaseDate_raw": "2018-11-29T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-11-29T16:21:34.5", "lastUpdateDate_raw": "2018-11-30T10:21:34.5", "counter": 1, "weight": 20181129, "commentCount": 0, "editUrl": "/en/news/aequus-reports-largest-quarterly-revenue-in-company-history-and-provides-management-update?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8303700&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

 

\n

VANCOUVER, November 15, 2018– Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with\n a focus on developing, advancing and promoting differentiated products, is pleased to announce the addition of Dr. Vikram Lekhi, a Comprehensive Ophthalmologist\n of Seema Eye Care, Ken Patterson, National Director of Business Development at Vision Group Canada, and an undisclosed regulatory consultant to the\n previously announced strategic advisory board in ophthalmology.

\n

“We are pleased to have a full compliment of expertise on our advisory board that spans clinical, commercial, and regulatory,” said Doug Janzen, CEO of\n Aequus. “The board will be an invaluable resource moving forward as we continue to validate global products for use in the Canadian market and make\n strategic decisions on current and future internal development programs within Ophthalmology.”

\n

Aequus has formed the Advisory Board to assist in assessing and rationalizing the many ophthalmology pipeline opportunities, both in therapeutics and medical\n devices, available to the Company. The advisory board will help Aequus in determining whether a product can improve patient outcomes, integrate into\n a clinician’s workflow, and navigate the Canadian reimbursement and commercial landscape. Dr. Vikram Lekhi, Ken Patterson, and the undisclosed regulatory\n consultant will join the previously announced advisory board members, Dr. Rosa Braga-Mele and Dr. Ike Ahmed.

\n

ABOUT DR VIKRAM LEKHI

\n

Dr. Vikram Lekhi is a medical and surgical Comprehensive Ophthalmologist with a broad clinical practice, including but not limited to pediatric cases,\n lid lesions, meibomian gland disease, corneal dystrophies, degenerations and infections, glaucoma and retinal pathology. Dr. Lekhi regularly presents\n at conferences around the country and internationally. His work has appeared in various publications, such as Canadian Family Physician and BioSpectrum.\n Dr. Lekhi serves the rural population in Alberta through his own practice, High River Eye Surgeons. He also sees residents of Calgary as a part of\n the well-established Seema Eye Care Centre. Apart from his clinical and surgical duties, Dr. Lekhi is a clinical lecturer with the University of Calgary’s\n department of surgery.

\n

ABOUT KEN PATTERSON, MBA

\n

Mr. Ken Patterson is the National Director of Business Development at Vision Group Canada. Vision Group Canada oversees and manages a network of over 40\n of Canada’s leading vision correction providers including LASIK MD, TLC, and the London Eye Centre. Prior to his position as National Director, Mr.\n Patterson dedicated over 15 years to the commercial space with Alcon, Bausch and Lomb, and Johnson and Johnson. He has built a reputation for developing\n business strategies and incubating new business models while remaining sensitive to supporting a positive patient experience. Ken holds an MBA and\n bachelor’s degree majoring in Economics.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS\n \n , OTCQB:AQSZF\n ) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown\n its pipeline to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry\n with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology,\n our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable\n and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current\n portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally\n or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit\n www.aequuspharma.ca.

\n

FORWARD-LOOKING STATEMENT DISCLAIMER

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”,“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: rationalizing the company’s pipeline opportunities; determining whether a product can improve patient outcomes, integrate into a clinician’s workflow, and navigate the Canadian commercial landscape; our ability to assess the utility of products for Canadian patients and physicians; our ability to provide access to promising technologies not currently available to Canadian patients. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.\n

\n

CONTACT INFORMATION

\n

Aequus Investor Relations

\n

Email: investors@aequuspharma.ca

\n

 

\n

 

\n

 

", "itemId": 8295649, "name": "Aequus Strengthens Clinical Experience on Strategic Advisory Board in Ophthalmology, and Adds Commercial and Regulatory Expertise", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-strengthens-clinical-experience-on-strategic-advisory-board-in-ophthalmology-and-adds-commerc", "url": "/en/news/aequus-strengthens-clinical-experience-on-strategic-advisory-board-in-ophthalmology-and-adds-commerc", "releaseDate": "2018-11-15T00:00:00", "releaseDate_raw": "2018-11-15T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-11-15T11:23:56.623", "lastUpdateDate_raw": "2018-11-16T05:23:56.623", "counter": 2, "weight": 20181115, "commentCount": 0, "editUrl": "/en/news/aequus-strengthens-clinical-experience-on-strategic-advisory-board-in-ophthalmology-and-adds-commerc?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8295649&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

\n

VANCOUVER, November 13, 2018– Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company\n with a focus on developing, advancing, and promoting differentiated products, is pleased to announce the successful presentation of a live webinar\n demonstrating the Zepto® Precision Pulse Capsulotomy (“Zepto”) device’s ability to address challenging capsulotomy cases during cataract\n surgery. The webinar, hosted by Dr. Ike Ahmed, took place on Monday, November 12 and was attended by ophthalmologists across Canada interested\n in learning more about the product’s features and use within the clinic. Dr. Ahmed presented pre-recorded video of cases he had performed recently\n in his clinic and addressed questions live with fellow colleagues.

\n

“I would like to thank Dr. Ahmed and his colleagues across Canada for their time,” said Ian Ball, CCO of Aequus. “The Zepto system is a true value\n add to clinics performing cataract surgery and this webinar was a great step forward in educating our customers around the benefits of the device.\n We heard plenty of positive feedback during the webinar and look forward to working with physicians to bring the innovative device into their clinic.”\n

\n

“I want to thank Aequus for bringing innovative ophthalmology products to Canada and leading the way with web discussions around new technology,” said\n Dr. Ike Ahmed. “It was a fun event and I look forward to seeing the progress of Zepto in Canada with Aequus.”

\n

ABOUT THE ZEPTO PRECISION PULSE CAPSULOTOMY SYSTEM\n

\n

The Zepto capsulotomy system provides consistent, high quality anterior lens capsulotomies during cataract surgery in a convenient, cost-effective,\n disposable format. Zepto integrates seamlessly into the routine steps of cataract surgery with phacoemulsification. The Zepto System consists of\n a disposable Zepto capsulotomy handpiece that is attached to a small control console. Zepto uses the precision pulse capsulotomy method, a proprietary\n combination of calibrated suction and a 4-millisecond multipulse energy algorithm to produce highly accurate capsulotomies. Zepto is ideal for\n surgery using premium lenses as well as difficult cases and creates a capsulotomy with an edge strength greater than conventional methods or femtosecond\n lasers. For more information, please visit https://www.zeptocapsulotomy.ca. \n

\n

ABOUT AEQUUS PHARMACEUTICALS INC. \n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS,\n OTCQB:AQSZF)\n is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown\n its pipeline to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry\n with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology,\n our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable\n and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current\n portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally\n or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit\n www.aequuspharma.ca.\n

\n

FORWARD-LOOKING STATEMENT DISCLAIMER

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, \n

\n

“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: working with physicians to bring the device to their clinic. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements. \n

\n

CONTACT INFORMATION \n

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca

\n

 \n

\n

 

\n

", "itemId": 8294572, "name": "Aequus Hosts Live Webinar Demonstrating the Zepto® Capsulotomy System, Led by Dr. Ike Ahmed", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-hosts-live-webinar-demonstrating-the-zepto-capsulotomy-system-led-by-dr-ike-ahmed", "url": "/en/news/aequus-hosts-live-webinar-demonstrating-the-zepto-capsulotomy-system-led-by-dr-ike-ahmed", "releaseDate": "2018-11-13T00:00:00", "releaseDate_raw": "2018-11-13T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-11-13T08:55:23.053", "lastUpdateDate_raw": "2018-11-14T02:55:23.053", "counter": 3, "weight": 20181113, "commentCount": 0, "editUrl": "/en/news/aequus-hosts-live-webinar-demonstrating-the-zepto-capsulotomy-system-led-by-dr-ike-ahmed?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8294572&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

 

\n

VANCOUVER, November 5, 2018– Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with\n a focus on developing, advancing and promoting differentiated products, today announced the formation of a strategic advisory board in ophthalmology\n with the appointment of its first two members, Dr. Ike Ahmed of the Prism Eye Institute joining as Chairman, and Dr. Rosa Braga-Mele of the University\n of Toronto.

\n

Aequus has formed the Advisory Board to assist in assessing and rationalizing the many ophthalmology pipeline opportunities, both in therapeutics and medical\n devices, available to the Company. The advisory board will help Aequus in determining whether a product can improve patient outcomes, integrate into\n a clinician’s workflow, and navigate the Canadian reimbursement and commercial landscape.

\n

“The formation of our advisory board is another step in our continued commitment to the ophthalmic space in Canada,” said Doug Janzen, Chairman and CEO\n of Aequus Pharmaceuticals. “This initial appointment of Dr. Ahmed and Dr. Braga-Mele, both innovators and global leaders in ophthalmology, provides\n robust insight and guidance from within the clinic and strengthens our ability to assess the utility of products for Canadian patients and physicians.”

\n

“I’m excited to work with Aequus to help advance ophthalmic care within Canada,” said Dr. Ike Ahmed. “With innovative product technologies routinely targeting\n the major markets of the USA and Europe, I’m happy to work with a company that is championing for Canadian patients, as evidenced by the launch of\n the Zepto Capsulotomy System. Working alongside my colleagues on the advisory board, we’ll look to address barriers experienced in the clinic and provide\n access to promising technologies not currently available to Canadian patients.”

\n

“It has been refreshing working with a company committed to the Canadian ophthalmology landscape,” said Dr. Braga-Mele. “Aequus has quickly developed a\n reputation of responding to patient and physician feedback with the launch of Vistitan™ and the Zepto Capsulotomy system. I look forward to sharing\n best-practices, product concepts, and innovative techniques seen within our intimate global community with my colleagues on the advisory board to help\n advance ophthalmic care in Canada.”

\n

Dr. Ahmed and Dr. Braga-Mele will be working with the Aequus team to add additional members to the Advisory Board over the coming weeks.  

\n

ABOUT DR IKE AHMED

\n

Dr. Ike Ahmed has become world renowned for his skills and ground-breaking work in the diagnosis and surgical treatment of highly complex eye diseases\n including glaucoma and surgical complications. He has been at the leading edge of novel treatments for glaucoma, cataract, and lens implant surgery,\n having performed the first laser cataract surgery in Canada, and designing devices, implants, and techniques for ophthalmic applications. Dr. Ahmed\n has a keen interest in the development of advanced microsurgical devices, developing and coining the term “Micro-Invasive Glaucoma Surgery (MIGS)”\n for a new genre of surgical approaches and devices for treating glaucoma. Dr. Ahmed has published over 150-peer reviewed papers and given over 1000\n scientific presentations thus far in his career. He is an ophthalmologist at the Prism Eye Institute (Ontario, Canada), Assistant Professor at the\n University of Toronto, and Clinical Professor at the University of Utah.

\n

ABOUT DR. ROSA BRAGA-MELE

\n

Dr. Rosa Braga-Mele is a cataract specialist and educator who speaks frequently at both the national and international level on advanced surgical techniques,\n innovations in phacoemulsification surgery, complicated cataract cases, and IOL development. She was voted by her peers as one of the top 50 opinion\n leaders in cataract and refractive surgery and has over 150 published abstracts and papers within the field. She has been involved in clinical trials\n pertaining to wavefront IOL’s, multifocal IOL’s, and phacoemulsification surgery. Dr. Braga-Mele has been active within the ophthalmic community throughout\n her career, currently serving as Chair of the Education Clinical Committee for the American Society of Cataract and Refractive Surgery (ASCRS), holding\n various roles in the past with the American Academy of Ophthalmology and the Canadian Ophthalmology Society, and achieving several awards for her contributions\n to mentorship and volunteer service within the community. Dr. Braga-Mele is a Professor of Ophthalmology, Faculty of Medicine, at the University of\n Toronto and the Cataract Director at the Kensington Eye Institute.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS\n \n , OTCQB:AQSZF\n ) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown\n its pipeline to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry\n with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology,\n our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable\n and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current\n portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally\n or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit\n www.aequuspharma.ca.

\n

FORWARD-LOOKING STATEMENT DISCLAIMER

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”,

\n

“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: rationalizing the company’s pipeline opportunities; determining whether a product can improve patient outcomes, integrate into a clinician’s workflow, and navigate the Canadian commercial landscape; our ability to assess the utility of products for Canadian patients and physicians; our ability to provide access to promising technologies not currently available to Canadian patients. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

\n

VistitanTM: Trademark owned or used under license by Sandoz Canada Inc.

\n

CONTACT INFORMATION\n
\n

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca

\n

 

\n

 

\n

 

", "itemId": 8290526, "name": "Aequus forms Strategic Advisory Board in Ophthalmology, Chaired by Dr. Ike Ahmed", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-forms-strategic-advisory-board-in-ophthalmology-chaired-by-dr-ike-ahmed", "url": "/en/news/aequus-forms-strategic-advisory-board-in-ophthalmology-chaired-by-dr-ike-ahmed", "releaseDate": "2018-11-05T00:00:00", "releaseDate_raw": "2018-11-05T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-11-05T08:54:42.827", "lastUpdateDate_raw": "2018-11-06T02:54:42.827", "counter": 4, "weight": 20181105, "commentCount": 0, "editUrl": "/en/news/aequus-forms-strategic-advisory-board-in-ophthalmology-chaired-by-dr-ike-ahmed?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8290526&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

 

\n

VANCOUVER, August 27, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical\n company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended June\n 30, 2018 (“Q2 2018”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.

\n

Q2 2018 Key Highlights

\n\n\n\n\n\n\n\n

Commercial Activities\n
\n

\n

The Company recorded revenues of $377,855 in Q2 2018, representing 103% growth as compared to the same period in 2017. On a year-to-date basis, the Company\n recorded $752,855 in revenues in the six-month period ending June 30, 2018, an increase of 57% compared to the same period in 2017. The increase in\n revenues were primarily attributable to increased promotional activities being focused in markets with positive market access and reimbursement listings.\n

\n

In Q2 2018, Aequus added to its commercial pipeline as it entered into a commercial agreement with Mynosys Cellular Devices (“Mynosys”) to promote the\n Zepto® Capsulotomy System in Canada. Aequus has leveraged its existing commercial infrastructure to promote and support the launch Zepto.\n Following multiple successful trial cases with leading cataract surgeons such as Dr. Ike Ahmed, Aequus expects Zepto to contribute to revenues in the\n second half of 2018.

\n

During the current quarter, Aequus also successfully improved commercial terms for the continued and extended promotion of Vistitan in Canada. Under the\n revised terms, Aequus will benefit from improved economics with a tiered split of net profits ranging from 42% and up to 47%, dependent on certain\n market access and sales milestones being met. The term of the agreement was also extended to 2021.

\n

“We are extremely pleased with the progress and growth we are seeing in our commercial division, particularly in our ophthalmology franchise, as we are\n becoming recognized by our customers as a committed partner by introducing novel products to Canada such as Zepto,” said Doug Janzen, CEO and Chairman\n at Aequus. “We expect revenues to continue to grow as we work to add additional commercial products to our pipeline.”

\n

Development Program Activities\n
\n

\n

Aequus received positive feedback from a pre-Investigational Drug Application (“pre-IND”) meeting with the US Food and Drug Administration (“FDA”) for\n the Company’s lead development program, AQS1303, a long-acting transdermal anti-nausea program for use in pregnancy. Upon review of the Company’s pre-IND\n submission, the FDA agreed that AQS1303 is a suitable candidate for the 505(b)2 abbreviated regulatory pathway for approval in the United States.

\n

Following the regulatory guidance provided by the FDA, Aequus and Corium have expanded their pre-existing relationship to further advance AQS1303. Under\n the terms of the agreement, Corium will use its Corplex™ technology to optimize AQS1303 in preparation for clinical studies. Corium will fund\n the development work and in exchange will be the exclusive clinical and commercial manufacturer for the product.\n
\n

\n

Operating Expenses\n
\n

\n

Sales and marketing expenses for Q2 2018 were $363,018, which is consistent with prior quarters and includes non-cash expenses of $59,046 related to amortization\n and share based payments expenses. Depreciation and amortization, and share-based payments for Q2 2018 were $47,279 and $11,767, respectively, compared\n to $45,916 and $24,041, respectively, in Q2 2017. The amortization costs were primarily related to the acquisition costs of TeOra.As the sales and\n marketing infrastructure is now established, new products, like Zepto, can be marketed to the same customer base with relatively little change to sales\n related costs.\n
\n

\n

The Company incurred research and development expenses of $179,963 in Q2 2018 as compared to $581,670 in Q2 2017. The decrease was primarily attributable\n to lower subcontractor research costs and reduced regulatory consulting for AQS1301 and AQS1303 pre-IND related work, which completed in Q2 2017. The\n main development work in Q2 2018 was the advancement and optimization of AQS1303 in preparation for clinical studies. The costs of which are being\n realized by the Company’s development partner, Corium, in exchange for exclusive manufacturing of the product. This resulted in a $362,058 decrease,\n or 98% reduction in Q2 2018 cost relative to Q2 2017.\n
\n

\n

General administration expenses were $503,799 during Q2 2018 as compared to $623,315 in Q2 2017, a decrease of $119,516 or 19%. The decrease was primarily\n due to a decrease in consulting and legal expenses.\n
\n

\n

Other\n
\n

\n

Subsequent to the end of the quarter, on July 31, 2018, the Company issued 4,000,000 units at a price of $0.20 per share for total proceeds of $800,000.\n Each unit consists of one common share and one-half share purchase warrant exercisable at a price of $0.30 for a period of 48 months under the prospectus\n supplement to the Company’s base shelf prospectus.\n
\n

\n

On August 10, 2018, the Company also issued 3,875,000 units at a price of $0.20 per share for total proceeds of $775,000. Each unit consists of one common\n share and one-half share purchase warrant exercisable at a price of $0.30 for a period of four years following the date of closing. The Company paid\n a fee to certain arm’s length finders in connection with the Units issued to investors introduced to the Company by the Finders, consisting of (i)\n a 7% cash payment on certain subscriptions in the aggregate amount of $33,250 and (ii) issued an aggregate of 166,250 Common Share purchase warrants.\n
\n

\n

FINANCIAL STATEMENTS AND MD&A\n
\n

\n

Investors are encouraged to review Aequus’ complete Financial Statements and Management’s Discussion and Analysis (“MD&A”) for the three and six months\n ended June 30, 2018, which are available on the Company’s website at www.aequuspharma.ca and on SEDAR at\n www.sedar.com.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a\n growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its pipeline\n to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of\n addressing the need for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology, our most recent\n addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade\n delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established\n medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on\n its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition\n or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca\n .\n

\n

FORWARD-LOOKING STATEMENT DISCLAIMER

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; the Company’s expected revenues; Aequus’ sales and marketing efforts; the Company’s potential regional partnerships for its internal programs; the regulatory requirements for its transdermal pyridoxine/doxylamine program; and the Company’s expectations regarding the market potential and launch timing of the Zepto Capsulotomy System. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2018, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

\n

VistitanTM: Trademark owned or used under license by Sandoz Canada Inc.
Zepto® is a registered trademark of Mynosys Cellular Devices.\n

\n

CONTACT INFORMATION

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

\n

 

", "itemId": 8233988, "name": "Aequus Reports 5th Consecutive Quarter of Revenue Growth", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-reports-5th-consecutive-quarter-of-revenue-growth", "url": "/en/news/aequus-reports-5th-consecutive-quarter-of-revenue-growth", "releaseDate": "2018-08-27T00:00:00", "releaseDate_raw": "2018-08-27T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-08-27T10:15:47.423", "lastUpdateDate_raw": "2018-08-28T03:15:47.423", "counter": 5, "weight": 20180827, "commentCount": 0, "editUrl": "/en/news/aequus-reports-5th-consecutive-quarter-of-revenue-growth?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8233988&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

\n

VANCOUVER, British Columbia, Aug. 10, 2018--Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical\n company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it has closed the balance of a\n non-brokered private placement announced August 9, 2018 for an aggregate 3,875,000 units of the Company (the “Units”) at a price of $0.20 per Unit\n (the “Offering Price”), for aggregate gross proceeds of $775,000 (the “Private Placement”). 2,375,000 Units were issued in the second closing,\n which Units are subject to a four month hold period expiring December 10, 2018. Each Unit consists of one common share of the Company and one-half\n of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one common share at\n an exercise price of $0.30 for a period of four years following the closing date. The Warrants include an acceleration provision, exercisable at\n the Company’s option, if the Company's daily volume weighted average share price is greater than $0.45 for 10 consecutive trading days.

\n

\n

In connection with the Private Placement, Company paid a fee to certain arm’s length finders (the “Finders”) in connection with the Units issued\n to investors introduced to the Company by the Finders, consisting of (i) a 7% cash payment on certain subscriptions in the aggregate amount\n of $33,250 and (ii) issued an aggregate of 166,250 Common Share purchase warrants (the “Finders’ Warrants”), each Finders’ Warrant entitling\n the holder thereof to acquire one Common Share (a “Finders’ Warrant Share”) at a price of $0.30 per Finders’ Warrant Share for a period of\n two years from the closing date of the Private Placement.

\n

Aequus intends to use the net proceeds of the Private Placement for general corporate and working capital purposes, including commercial and marketing\n activities, advancing internal programs and supporting on-going business development.

\n

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, are \"restricted\n securities\" as defined in U.S. federal securities laws and may not be offered or sold to persons in the United States absent registration or\n an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer\n to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

\n

About Aequus Pharmaceuticals\n

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high\n quality, differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development\n stage pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.\n As a complement to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where\n there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships\n that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch\n of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized\n therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

Contact Information:\n

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

\n

Forward-Looking Statements:\n

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the Company’s intention to commercialize its internal programs in Canada, form strategic partnerships and build its Canadian commercial platform. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully market it services and in-license and develop new products, the assumption that the Company’s current good relationships with third party suppliers or service providers will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2018, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n

\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release\n .\n

\n

\n

", "itemId": 8225709, "name": "Aequus Closes Balance of $775,000 Equity Financing", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-closes-balance-of-775-000-equity-financing", "url": "/en/news/aequus-closes-balance-of-775-000-equity-financing", "releaseDate": "2018-08-10T00:00:00", "releaseDate_raw": "2018-08-10T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-08-13T10:46:34.733", "lastUpdateDate_raw": "2018-08-14T03:46:34.733", "counter": 6, "weight": 20180810, "commentCount": 0, "editUrl": "/en/news/aequus-closes-balance-of-775-000-equity-financing?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8225709&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

VANCOUVER, BC. August 9, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company\n with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it intends to complete a non-brokered private\n placement (the “Placement”) of 3,875,000 units of the Company (the “Units”) at a price of $0.20 per Unit (the “Offering Price”), for aggregate gross\n proceeds of $775,000 (the “Private Placement”). Each Unit shall consist of one common share of the Company and one-half of one common share purchase\n warrant (each whole warrant, a “Warrant”). Each Warrant shall entitle the holder thereof to purchase one common share at an exercise price of $0.30\n for a period of four years following the Closing Date. The Warrants will include an acceleration provision, exercisable at the Company’s option, if\n the Company's daily volume weighted average share price is greater than $0.45 for 10 consecutive trading days.\n
\n

\n

Aequus has received subscription agreements for all 3,875,000 units and closed an initial 1,500,000 Units of the Placement for aggregate gross proceeds\n of $300,000. All of the common shares and the Warrants are subject to a hold period until December 9, 2018. Aequus expects the balance of the Placement\n to close this week, subject to a number of conditions, including the execution of definitive documentation and receipt of final approval of the TSX\n Venture Exchange for the listing of the common shares issuable on closing and issuable upon the exercise of the Warrants and Finders’ Warrants.

\n

The Company will pay a fee to certain finders (the “Finders”) in connection with the Units issued to investors introduced to the Company by the Finders,\n such fee to consist of (i) a cash payment (the “Cash Payment”) equal to 7.0% of the gross proceeds received from the investors introduced to the Company\n by the Finders and (ii) Common Share purchase warrants equal to 7.0% of the number of Units sold to investors introduced to the Company by the Finders\n (the “Finders’ Warrants”, and together with the Cash Payment, the “Finders’ Fee”), each Finders’ Warrant entitling the holder thereof to acquire one\n Common Share (a “Finders’ Warrant Share”) at a price of $0.30 per Finders’ Warrant Share for a period of two years from the date that the Private Placement\n closes.

\n

Aequus intends to use the net proceeds of the Placement for general corporate and working capital purposes, including commercial and marketing activities,\n advancing internal programs and supporting on-going business development. Securities issued under the Private Placement will be subject to a four month hold period in Canada following the date of closing and will be \"restricted securities\" as defined in U.S. federal securities laws.

\n

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, and may not be\n offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not\n constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such\n offer, solicitation or sale would be unlawful.

\n

About Aequus Pharmaceuticals 

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage\n pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement\n to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need\n for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in\n Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach\n of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either\n created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information,\n please visit www.aequuspharma.ca.

\n

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca
Phone: 604-336-7906

\n

Forward-Looking Statements: 

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the Company’s intention to commercialize its internal programs in Canada, form strategic partnerships and build its Canadian commercial platform, and the timing and closing of the Placement. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully market it services and in-license and develop new products, the assumption that the Company’s current good relationships with third party suppliers or service providers will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2018, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com , and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release .\n

\n

 

", "itemId": 8223353, "name": "Aequus Announces Fully-subscribed $775,000 Equity Financing", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-fully-subscribed-775-000-equity-financing", "url": "/en/news/aequus-announces-fully-subscribed-775-000-equity-financing", "releaseDate": "2018-08-09T00:00:00", "releaseDate_raw": "2018-08-09T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-08-09T08:24:05.517", "lastUpdateDate_raw": "2018-08-10T01:24:05.517", "counter": 7, "weight": 20180809, "commentCount": 0, "editUrl": "/en/news/aequus-announces-fully-subscribed-775-000-equity-financing?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8223353&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

 

\n

VANCOUVER, BC. July 31, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),\n a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that, further\n to its news release dated July 23, 2018 announcing the proposed $800,000 equity financing, Aequus has now completed the equity financing of 4,000,000\n units of the Company (the \"Units\") at a price of $0.20 per Unit (the \"Offering Price\"), for aggregate gross proceeds of $800,000 (the \"Offering\") to\n Next Edge Bio-Tech Plus Fund, under a prospectus supplement to the Company’s base shelf prospectus dated August 15, 2017, which was filed in the provinces\n of British Columbia, Alberta, Ontario, Saskatchewan and Manitoba. Each Unit consists of one common share of the Company and one-half of one non-transferrable\n common share purchase warrant (each whole warrant, a \"Warrant\"). Each Warrant entitles the holder thereof to purchase one common share at an exercise\n price of $0.30 for a period of four (4) years following the closing date. The Warrants include an acceleration provision, exercisable at the Company’s\n option, if the Company's daily volume weighted average share price is greater than $0.45 for 10 consecutive trading days.

\n

Aequus intends to use the net proceeds of the Offering and Private Placement for general corporate and working capital purposes, including commercial and\n marketing activities, advancing internal programs and supporting on-going business development. Securities issued under the Offering will be \"restricted\n securities\" as defined in U.S. federal securities laws.

\n

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, and may not be\n offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not\n constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such\n offer, solicitation or sale would be unlawful.

\n

About Aequus Pharmaceuticals 

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage\n pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement\n to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need\n for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in\n Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach\n of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either\n created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information,\n please visit www.aequuspharma.ca.

\n

 

", "itemId": 8214831, "name": "Aequus Announces Closing of $800,000 Equity Financing", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-closing-of-800-000-equity-financing", "url": "/en/news/aequus-announces-closing-of-800-000-equity-financing", "releaseDate": "2018-07-31T00:00:00", "releaseDate_raw": "2018-07-31T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-08-01T11:41:45.073", "lastUpdateDate_raw": "2018-08-02T04:41:45.073", "counter": 8, "weight": 20180731, "commentCount": 0, "editUrl": "/en/news/aequus-announces-closing-of-800-000-equity-financing?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8214831&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the Company’s intention to commercialize its internal programs in Canada, form strategic partnerships, build its Canadian commercial platform and the timing and closing of the Private Placement. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully market it services and in-license and develop new products, the assumption that the Company’s current good relationships with third party suppliers or service providers will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2018, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com , and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release .

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca
Phone: 604-336-7906

" }, { "description": "

VANCOUVER, BC. July 24, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”\n or the “Company”), Aequus is pleased to announce it has granted incentive stock options to Damien King,\n a new director of the Company for the right to purchase up to an aggregate of 350,000 common shares of the Company. These stock options are exercisable\n at a price of $0.20 per share, for a term of eight years, and vest in tranches over a 2 year period. The terms of the stock options granted on July\n 23, 2016 are in accordance with the Company’s Stock Option Plan.\n
\n

\n

About Aequus Pharmaceuticals

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage\n pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement\n to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need\n for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in\n Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach\n of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either\n created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information,\n please visit www.aequuspharma.ca.\n

", "itemId": 8205613, "name": "Issuance of Stock Options", "urlWithHost": "http://www.aequuspharma.ca/en/news/issuance-of-stock-options", "url": "/en/news/issuance-of-stock-options", "releaseDate": "2018-07-24T00:00:00", "releaseDate_raw": "2018-07-24T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:16:35.417", "lastUpdateDate_raw": "2018-08-01T07:16:35.417", "counter": 9, "weight": 20180724, "commentCount": 0, "editUrl": "/en/news/issuance-of-stock-options?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8205613&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the Offering, including the use of proceeds of the Offering and the timing and successful completion of the Offering; and the Company’s intention to commercialize its internal programs in Canada, form strategic partnerships and build its Canadian commercial platform. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully market it services and in-license and develop new products, the assumption that the Company’s current good relationships with third party suppliers or service providers will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2018, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

 

\n

VANCOUVER, BC. July 23, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),\n a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it intends\n to complete a proposed equity financing of 4,000,000 units of the Company (the \"Units\") at a price of $0.20per Unit (the \"Offering Price\"),\n for aggregate gross proceeds of $800,000 (the \"Offering\") to the Next Edge Bio-Tech Plus Fund under a prospectus supplement to the\n Company’s base shelf prospectus dated August 15, 2017, which prospectus supplement will be filed in the provinces of British Columbia, Alberta, Ontario,\n Saskatchewan and Manitoba. Each Unit shall consist of one common share of the Company and one-half of one non-transferrable common share purchase warrant\n (each, a \"Warrant\"). Each whole Warrant shall entitle the holder thereof to purchase one common share at an exercise price of $0.30\n for a period of forty-eight (48) months following the closing date of the Offering. The Warrants will include an acceleration provision, exercisable\n at the Company’s option, if the Company's daily volume weighted average share price is greater than $0.45 for 10 consecutive trading days.

\n

The Next Edge Bio-Tech Plus Fund is pleased to support Aequus in its efforts to commercialize essential therapies that address both patient and physician needs in Canada,”\n said Portfolio Manager Eden Rahim. “In our assessment, Aequus is a promising, emerging Canadian healthcare company with potential for significant growth\n through commercializing a portfolio of therapeutics targeting, Ophthalmology, Transplant, Women’s Health and Neurology, including the anti-epileptic\n drugs Trokendi and Oxtellar. We look forward to being their financial partner as they continue to execute on their business plan.”\n
\n

\n

“Eden Rahim is one of the most successful and experienced biotech investors in Canada and has been so for over two decades”, says Doug Janzen, Aequus Chairman\n and CEO. “Our business is growing and we are very excited about the future and are delighted to have institutional biotech money like the Next Edge\n Biotech Fund as a financial partner as we continue to grow our business.”\n
\n

\n

Aequus intends to use the net proceeds of the Offering forgeneral corporate and working capital purposes, including commercial and marketing activities,\n advancing internal programs and supporting on-going business development. Securities issued under the Offering will be \"restricted securities\" as defined\n in U.S. federal securities laws.The Offering is expected to close on or about the week of July 23, 2018. Completion of the Offering is subject to a\n number of conditions, including receipt of any required regulatory approvals, including receipt of the approval of the TSX Venture Exchange for the\n listing of the common shares issuable on closing of the Offering and issuable upon the exercise of the Warrants.\n
\n

\n

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, and may not be\n offered or sold to persons in the United States absent registration or an exemption from such registration requirements.This press release shall not\n constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such\n offer, solicitation or sale would be unlawful.\n
\n

\n

About the Next Edge Biotech Plus Fund\n
\n

\n

The Next Edge Bio-Tech Plus Fund (the “Fund”) is invested primarily in US and Canadian biotech and healthcare\n companies. The Fund is focused on providing capital to help companies conduct late stage clinical trials and commercialization of their therapeutics.\n Following a discipline refined over two decades, the Fund aspires to deliver superior returns to its unitholders over the long term. The Fund is the\n only dedicated biotech mutual fund in Canada. The Fund’s Portfolio Manager, Eden Rahim, has over two decades experience managing healthcare mandates.\n Eden is a regular guest speaker about the biotech industry as a panelist, in press articles and on BNN and Bloomberg TV.\n
\n

\n

Next Edge Capital Corp. was formed as Man Investments Canada Corp. in July 2006 and was renamed Next Edge Capital Corp. (“Next Edge”)\n after the spinout of Man Investments Canada Corp. to management from Man Group plc in June 2014. Next Edge is registered as an Exempt Market Dealer,\n Portfolio Manager and/or Investment Fund Manager in certain jurisdictions. The Next Edge management team have been responsible for raising over CDN\n $3 Billion of alternative assets in Canada since 2000.\n
\n

\n

About Aequus Pharmaceuticals\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage\n pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement\n to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need\n for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in\n Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach\n of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either\n created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information,\n please visit www.aequuspharma.ca.

\n

 

\n

 

", "itemId": 8204279, "name": "Aequus Announces Proposed $800,000 Equity Financing To Next Edge Biotech Plus Fund", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-proposed-800-000-equity-financing-to-next-edge-biotech-plus-fund", "url": "/en/news/aequus-announces-proposed-800-000-equity-financing-to-next-edge-biotech-plus-fund", "releaseDate": "2018-07-23T00:00:00", "releaseDate_raw": "2018-07-23T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T15:41:53.557", "lastUpdateDate_raw": "2018-07-27T08:41:53.557", "counter": 10, "weight": 20180723, "commentCount": 0, "editUrl": "/en/news/aequus-announces-proposed-800-000-equity-financing-to-next-edge-biotech-plus-fund?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8204279&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the Offering, including the use of proceeds of the Offering and the timing and successful completion of the Offering; and the Company’s intention to commercialize its internal programs in Canada, form strategic partnerships and build its Canadian commercial platform. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully market it services and in-license and develop new products, the assumption that the Company’s current good relationships with third party suppliers or service providers will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2018, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

 

\n

European market represents latest opportunity for anti-nausea transdermal patch in development by Aequus Pharmaceuticals Inc.

\n

VANCOUVER, BC July 19, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce\n a recent expansion of the market opportunity for its reformulated anti-nausea transdermal patch, AQS1303, into the European market. Diclectin®, the\n oral reference product for AQS1303 for the treatment of nausea and vomiting of pregnancy, has recently received marketing authorization in the United\n Kingdom under the brand name Xonvea®. Aequus plans to launch AQS1303 in countries where an original oral form has been approved and an accelerated\n path to approval may exist for reformulated products. Previously, the focus had been on the United States and Canada, where Diclegis®/Diclectin® has\n been approved since 2013 and 1983, respectively. In those two markets alone, an estimated annual $200M USD market opportunity currently exists.

\n

“The potential for our long acting anti-nausea transdermal patch to enter the European market following a UK approval of Diclectin is a very exciting development\n for this product,” said Anne Stevens, COO and Director of Aequus. “With over five million pregnancies in European countries every year, this is a significant\n market for us and we are delighted at the possibility of offering this easy to use alternative for women suffering from nausea and vomiting during\n their pregnancy.”

\n

Following a review by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM) in June 2018, Xonvea®\n is expected to be available in the UK later this year, followed by further filings for approval in additional European territories. These approvals\n could provide the basis for a regulatory approval via a hybrid (accelerated) route for Aequus’ anti-nausea patch in the European market.

\n

Aequus is developing a long acting transdermal anti-nausea patch containing pyridoxine and doxylamine to provide patients with an easy to use alternative\n to the oral form, which would help alleviate the nausea and vomiting symptoms of pregnant women. Aequus will be pursuing partnership opportunities\n in the European countries following this advancement.  

\n

ABOUT AQS1303

\n

Aequus’ extended release transdermal anti-nausea patch, AQS1303, contains the combination of pyridoxine and doxylamine (the active ingredients\n in Diclegis®/Diclectin®) currently used to treat nausea and vomiting of pregnancy. AQS1303 is designed to provide patients with a convenient\n and reliable delivery system as an alternative to the currently marketed oral form, which is dosed up to four times per day. According to IQVIA\n data, Diclegis® sales in the United States were approximately $186M USD for 2017.

\n

Aequus has advanced AQS1303 through an initial Proof of Concept clinical study, completed in September 2017. The Proof of Concept study was a single-dose\n cross-over comparative bioavailability study versus the currently approved oral version, Diclegis®/Diclectin®, and was successfully completed\n in nine healthy female volunteers. The results suggested that sustained delivery of therapeutic levels of the active ingredients through the\n skin over a multi-day period is possible with the current formulation. The formulation was well tolerated with no serious adverse events reported.

\n

Based on FDA feedback, this product is expected to follow a Section 505(b)(2) New Drug Application, an abbreviated clinical pathway in which the\n FDA would allow for the Company to reference safety and efficacy data of the original oral tablet form of the medication. Aequus would expect\n this product to follow a hybrid pathway in the European market, similar to the 505(b)2 pathway in the US. 

\n

ABOUT AEQUUS PHARMACEUTICALS INC.

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing\n high quality, differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant,\n and a development stage pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through\n enhanced delivery systems. As a complement to its focus in neurology, our most recent addition to the development pipeline was a long-acting\n form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients.\n Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will\n look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian\n commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or\n license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca

\n

 

\n

 

", "itemId": 8198621, "name": "Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal Patch", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-expansion-of-market-opportunity-for-its-long-acting-anti-nausea-transdermal-patch", "url": "/en/news/aequus-announces-expansion-of-market-opportunity-for-its-long-acting-anti-nausea-transdermal-patch", "releaseDate": "2018-07-19T00:00:00", "releaseDate_raw": "2018-07-19T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:00:27.323", "lastUpdateDate_raw": "2018-08-01T07:00:27.323", "counter": 11, "weight": 20180719, "commentCount": 0, "editUrl": "/en/news/aequus-announces-expansion-of-market-opportunity-for-its-long-acting-anti-nausea-transdermal-patch?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8198621&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based\n on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,\n “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us\n in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe\n are appropriate. Forward-looking statements include but are not limited to statements relating to: the further advancement of AQS1303, the regulatory\n requirements for AQS1303, and the Company’s ability to form strategic partnerships for its internal programs. Such statements reflect our current views\n with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that,\n while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and\n contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance,\n or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release,\n the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory\n approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and\n develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained;\n the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and\n technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking\n statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in\n the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com,\n and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently\n known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from\n those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation,\n to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements\n are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking\n statements.

\n

Diclegis® and Diclectin® are registered trademarks of Duchesnay Inc. \n
Xonvea® is a registered trademark of Alliance Pharma plc

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n
Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906\n

Follow Aequus on LinkedIn and on Twitter for more news about our company, partners and products.\n

" }, { "description": "

VANCOUVER, BC. July 16, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”\n or the “Company”), is pleased to announce that it has agreed to new terms for its promotional service\n agreement with Sandoz on PRVistitan™ (“Vistitan”) with improved economics and a term extension of an additional year. Aequus began\n promotional efforts in May 2016 for Vistitan (bimatoprost 0.03%, ophthalmic solution), which is approved in Canada for the reduction of elevated intraocular\n pressure (“IOP”) in patients with open angle glaucoma or ocular hypertension. Under the previous agreement, Aequus and Sandoz split revenues based\n upon an agreed to tiered structure over the term. With this amendment, revenue splits as of 2019 will increase from the originally agreed to tiering\n schedule by an additional 7% of net product sales and up to an additional 12% if certain milestones are met. The term has been extended to June 2021,\n with an option for renewal if mutually agreed to.\n
\n

\n

“Sandoz has proven to be a great partner through the successful launch of Vistitan, and we are very pleased to extend our promotional efforts for this\n product. We have consistently grown market share for Vistitan and have achieved reimbursement in many key provinces since its launch. There is room\n for continued growth, and this improvement on terms allows us to continue our investments in Vistitan to accomplish that growth,” said Ian Ball, Chief\n Commercial Officer. “Our dedicated ophthalmology sales team will continue to share the benefits of Vistitan with clinicians and patients for the duration\n of the extended term.”\n
\n

\n

“We are delighted to sign this extension and improvement on commercial terms with Sandoz. We see this as validation of our efforts and partnership model\n as we continue to commercialize medications that serve an unmet need in Canada,” said Doug Janzen, Chairman and CEO of Aequus. “We are on track to\n meet our revenue targets in 2018 for this product, and this further enhances our expected trajectory for the coming years.”\n
\n

\n

About VISTITAN\n
\n

\n

 

\n

Aequus’ ophthalmology focused salesforce has been marketing and promoting the branded ophthalmology product, Vistitan (bimatoprost 0.03%, ophthalmic solution)\n in Canada since May 2016. Aequus splits revenues of this product with its partner in a tiered structure.\n
\n

\n

Bimatoprost 0.03% is a prostaglandin approved by Health Canada for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension.\n There are an estimated 400,000 people living with glaucoma in Canada in 2018, according to the Glaucoma Research Society of Canada. The disease is\n the second leading cause of blindness worldwide, but is asymptomatic, which means that more than half of people are unaware they have it. The incidence\n of glaucoma is highest in patients above the age of 80, but onset may be as early as 40 years of age. IOP lowering drugs are prescribed as soon as\n the disease is diagnosed and must be taken chronically to prevent vision loss, with prostaglandins remaining as one of the primary treatment options\n for lowering IOP in glaucoma. Vistitan, which was approved by Health Canada in 2014, is currently the only marketed version of 0.03% bimatoprost ophthalmic\n solution in Canada for this indication. Since its launch, and with the support of Aequus’ promotional efforts, Vistitan™ has been successfully\n listed among 90% of private payor groups as well as a benefit under key provincial formularies, including the Ontario Drug Benefit Plan, Alberta Health\n and Manitoba Health.\n
\n

\n

About Aequus Pharmaceuticals, Inc.\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage\n pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement\n to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need\n for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in\n Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach\n of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either\n created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information,\n please visit www.aequuspharma.ca

\n

 

\n

 

\n

 

", "itemId": 8196283, "name": "Aequus Extends and Enhances Commercial Agreement to Promote Vistitan in Canada", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-extends-and-enhances-commercial-agreement-to-promote-vistitan-in-canada", "url": "/en/news/aequus-extends-and-enhances-commercial-agreement-to-promote-vistitan-in-canada", "releaseDate": "2018-07-16T00:00:00", "releaseDate_raw": "2018-07-16T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:05:47.347", "lastUpdateDate_raw": "2018-08-01T07:05:47.347", "counter": 12, "weight": 20180716, "commentCount": 0, "editUrl": "/en/news/aequus-extends-and-enhances-commercial-agreement-to-promote-vistitan-in-canada?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8196283&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, the implementation of our business model and strategic plans, Aequus’ sales and marketing efforts, and the expected impact of the Vistitan co-promotion amendment on Aequus and its revenues . Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: the success of Aequus’ sales and marketing efforts, general business and economic conditions, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations

\n

Email: investors@aequuspharma.ca

\n

Phone: 604-336-7906

" }, { "description": "

 

\n

Vancouver, British Columbia, June 13, 2018. Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty\n pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that following the completion of its\n Annual General Meeting held on July 10, 2018, Mr. Damien King has joined its Board of Directors to fill the seat previously held by Dr. Fotios Plakogiannis\n who did not stand for re-election.

\n

Mr. King is currently the Director of Sales with Merz Pharma Canada (“Merz”) and sits as a founding member of their Senior Leadership Team. Over the past\n 9 years, Mr. King has been instrumental in transforming Merz from a single brand entity, to an integrated product portfolio organization with five\n divisions and multiple high performing teams.

\n

“We welcome Damien to our Board. He is an industry veteran with a track record for operating and creating shareholder value within rapidly growing pharmaceutical\n companies. I have no doubt Damien will provide valuable strategic and operational guidance to Aequus’ Board and business, as we continue to grow our\n commercial division,” said Doug Janzen, Chairman and CEO of Aequus. “Damien’s addition to the Board marks another milestone in the company’s growth\n as we add Directors and advisors with strategic growth expertise in the Canadian pharmaceutical industry.”

\n

Mr. Janzen continued, “I would like to personally thank Dr Plakogiannis for his contributions to the Company as a founder and past director. We value Fotios’ contributions and expertise and look forward to continuing to engage with him as it relates to our transdermal programs.”

\n

Aequus’ five incumbent directors, Doug Janzen, Anne Stevens, Chris Clark, Jason Flowerday and Rodoula Plakogiannis, were all re-elected as directors of\n the Company by shareholders at its annual general meeting held on July 10, 2018.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage\n pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement\n to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need\n for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in\n Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach\n of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either\n created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information,\n please visit www.aequuspharma.ca.

\n

 

\n

 

\n

 

", "itemId": 8194628, "name": "Aequus Announces New Independent Director to its Board", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-new-independent-director-to-its-board", "url": "/en/news/aequus-announces-new-independent-director-to-its-board", "releaseDate": "2018-07-13T00:00:00", "releaseDate_raw": "2018-07-13T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:00:54.173", "lastUpdateDate_raw": "2018-08-01T07:00:54.173", "counter": 13, "weight": 20180713, "commentCount": 0, "editUrl": "/en/news/aequus-announces-new-independent-director-to-its-board?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8194628&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the Company’s expectations of growth for its commercial division. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2018, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

\n
", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

 

\n

Key Highlights

\n\n

Vancouver, British Columbia, June 21, 2018. Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty\n pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today an expansion of its relationship\n with Corium International, Inc. (“Corium”) to include the Company’s long-acting transdermal patch, AQS1303, for the treatment of nausea and vomiting\n in pregnancy. Under the terms of the agreement, Corium will use its Corplex™ technology to improve the clinical performance of AQS1303 and will\n be the exclusive clinical and commercial manufacturer for the product. Aequus previously received positive FDA feedback for an accelerated regulatory\n pathway for AQS1303 compared to what a New Chemical Entity would require.

\n

“The momentum of our anti-nausea program continues to build with this collaboration. We had multiple parties express interest in the commercial manufacturing\n rights as we continue to advance this program.We are delighted to have engaged with Corium, who will be performing the formulation activities required\n for the next stage of development on this program at its own cost and in return will be the exclusive clinical and commercial manufacturer for this\n product,” said Doug Janzen, CEO and Chairman of Aequus. “We have been working with the team at Corium for a number of years and are very pleased to\n be expanding our relationship to include this very exciting program.”

\n

“We look forward to advancing this product opportunity through the application of our Corplex technology platform,” added Parminder \"Bobby\" Singh, Ph.D.,\n Corium's Chief Technology Officer and Vice President, Research and Development.“Nausea and vomiting associated with pregnancy are clear unmet needs\n where a transdermal route of administration has the potential to provide significant relief to affected women.”

\n

The two parties previously signed a Multi-Product Collaboration Agreement, where Corium advanced Aequus’ extended release transdermal aripiprazole antipsychotic\n program, AQS1301. Corium has also performed certain scale up activities for the current formulation of the extended release anti-nausea patch.

\n

Aequus recently announced its planned clinical strategy, with positive feedback from the FDA indicating that a pharmacokinetic bridging strategy, to allow\n bridging to the safety and clinical pharmacology information from Diclegis®, and a single clinical efficacy study, would likely be acceptable\n for an NDA submission. The FDA also outlined additional standard studies required of a transdermal patch to evaluate the local safety and to ensure\n that consistent and predictable dosing is achieved over the dosing period.

\n

Aequus owns global rights to this program and is excited about advancing AQS1303 towards commercialization in major markets.

\n

ABOUT AQS1303

\n

Aequus’ extended release transdermal anti-nausea patch, AQS1303, contains the combination of pyridoxine and doxylamine (the active ingredients in Diclegis®/Diclectin®)\n currently used to treat nausea and vomiting of pregnancy. AQS1303 is designed to provide patients with a convenient and reliable delivery system as\n an alternative to the currently marketed oral form, which is dosed up to four times per day. According to IQVIA data, Diclegis® sales in\n the United States were approximately $186M USD for 2017.

\n

Aequus has advanced AQS1303 through an initial Proof of Concept clinical study, completed in September 2017. The Proof of Concept study was a single-dose cross-over comparative bioavailability study versus the currently approved oral version, Diclegis®/Diclectin®, and was successfully completed in nine healthy female volunteers. The results suggested that sustained delivery of therapeutic levels of the active ingredients through the skin over a multi-day period is possible with the current formulation. The formulation was well tolerated with no serious adverse events reported.

\n

Based on FDA feedback, this product is expected to follow a Section 505(b)(2) New Drug Application, an abbreviated clinical pathway in which the FDA would\n allow for the Company to reference safety and efficacy data of the original oral tablet form of the medication.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage\n pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement\n to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need\n for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in\n Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach\n of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either\n created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information,\n please visit www.aequuspharma.ca.

\n

 

", "itemId": 8175468, "name": "Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-and-corium-join-forces-to-advance-anti-nausea-transdermal-patch", "url": "/en/news/aequus-and-corium-join-forces-to-advance-anti-nausea-transdermal-patch", "releaseDate": "2018-06-20T00:00:00", "releaseDate_raw": "2018-06-20T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T13:56:54.653", "lastUpdateDate_raw": "2018-08-01T06:56:54.653", "counter": 14, "weight": 20180621, "commentCount": 0, "editUrl": "/en/news/aequus-and-corium-join-forces-to-advance-anti-nausea-transdermal-patch?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8175468&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the further advancement of AQS1303, the regulatory requirements for AQS1303, and the Company’s ability to form strategic partnerships for its internal programs . Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

\n

Diclegis® and Diclectin® are registered trademarks of Duchesnay Inc.

\n

Corplex™ is a trademark of Corium International, Inc.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

VANCOUVER, BC. June 18, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”\n or the “Company”), is pleased to announce the first four cataract procedures in Canada using the Zepto® Capsulotomy\n System (“Zepto”), a precision pulse capsulotomy device, have been successfully completed this week by Dr. Ike Ahmed at the Kensington Eye Institute\n in Toronto, Ontario. Dr. Ike Ahmed is world-renowned for his skills in the diagnosis and surgical treatment of highly complex eye diseases. He is recognized\n as being one of the most experienced complex eye surgeons in the world and has trained numerous surgeons in innovative surgical techniques.\n
\n

\n

“The creation of a consistent, circular, well-centered and sized capsulotomy for every patient is every cataract surgeon’s dream. Our first experience\n with Zepto was flawless with great intraoperative performance. We look forward to more experience and data in our evaluation of this promising technology,”\n said Dr. Ike Ahmed.

\n

“We are absolutely delighted with the introduction of Zepto in Canada at a leading centre for cataract procedures in Canada, and thank Dr Ahmed and his\n team for their remarkable enthusiasm,” said Doug Janzen, CEO and Chairman of Aequus Pharmaceuticals. “All four cases were performed with great outcomes: perfect capsulorhexis’ within the expected timeframe. We look forward to our continued introduction of Zepto to surgeons across Canada.”

\n

About Zepto Precision Pulse Capsulotomy System\n
\n

\n

The Zepto capsulotomy system provides consistent, high quality anterior lens capsulotomies during cataract surgery in a convenient, cost-effective, disposable\n format. One of the key features is a collapsible super-elastic nitinol capsulotomy ring element with micron scale elements to create the unique and\n strong Zepto capsulotomy edge. It also has a clear silicone suction cup to enable suction and generate Zepto’s proprietary capsulotomy action and to\n allow Zepto capsulotomies on the patient’s individual visual axis.The AMA has recently given a category III code in the US as they see the distinctive\n application and benefit of aligning on the patient’s own visual axis. \n
\n

\n

Zepto integrates seamlessly into the routine steps of cataract surgery with phacoemulsification. The surgeon does not need to alter his or her normal routine.\n Instead of capsulorrhexis forceps or a cystitome, the surgeon simply reaches for Zepto.\n
\n

\n

The Zepto Capsulotomy System consists of a disposable Zepto capsulotomy handpiece that is attached to a small control console. Zepto uses the precision\n pulse capsulotomy method, a proprietary combination of calibrated suction and a 4-millisecond multipulse energy algorithm to produce highly accurate\n capsulotomies. Zepto’s unique single use hand piece can be inserted through incisions as small as 2.2mm, to create a perfectly circular and precisely\n placed capsulotomy that can be centred on the visual axis. Zepto is ideal for surgery using premium lenses as well as difficult cases and creates a\n capsulotomy with an edge strength greater than conventional methods or femtosecond lasers.For more information, please visit https://www.zeptocapsulotomy.ca.\n
\n

\n

About Aequus Pharmaceuticals, Inc.\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage\n pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement\n to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need\n for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in\n Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach\n of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either\n created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information,\n please visit www.aequuspharma.ca\n
\n

\n

 

\n

 

\n

 

\n

 

", "itemId": 8174044, "name": "Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-first-canadian-cataract-procedures-using-zepto-capsulotomy-system", "url": "/en/news/aequus-announces-first-canadian-cataract-procedures-using-zepto-capsulotomy-system", "releaseDate": "2018-06-18T00:00:00", "releaseDate_raw": "2018-06-18T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T15:08:02.597", "lastUpdateDate_raw": "2018-07-27T08:08:02.597", "counter": 15, "weight": 20180618, "commentCount": 0, "editUrl": "/en/news/aequus-announces-first-canadian-cataract-procedures-using-zepto-capsulotomy-system?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8174044&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, the implementation of our business model and strategic plans, Aequus’ sales and marketing efforts. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: the success of Aequus’ sales and marketing efforts, general business and economic conditions, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

Zepto® is a registered trademark of Mynosys Cellular Devices.

\n

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

\n
\n

 

\n

 

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

VANCOUVER, May 31, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),\n a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for\n the first quarter ended March 31, 2018 and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.

\n

Q1 2018 Key Highlights - 4th Consecutive Quarter of Revenue Growth\n
\n

\n\n\n\n\n\n\n

Commercial Update\n
\n

\n

The Company recorded revenue of $375,000 in Q1 2018 compared to $293,002 in Q1 2017, which represents growth of 28% when comparing the year over year change.\n While sales for both products continue to increase with some market volatility, we had expected a modest growth in revenues in the current quarter\n as the tiered portion of revenues payable to Aequus by our partner declined by 10% for Vistitan as of 2018. Despite this, we were able to demonstrate\n growth in revenues to Aequus in the current quarter. The terms of the agreement for both tacrolimus and Vistitan extend to 2020.

\n

Sales from the recently announced Zepto Capsulotomy System are expected to contribute to revenues, and will be accretive to the commercial portfolio, as\n of Q2 2018 with an expected launch date in Canada of June 1, 2018. Zepto is a novel medical device used during cataract surgery to produce a consistent,\n high quality, round capsulotomy in milliseconds. Zepto has been used in thousands of cataract surgeries in the Asia, Europe, and Central America, and\n most recently in the US since its launch in the respective territories in February 2017 and August 2017. In Canada, there is an estimated 300,000 cataract\n procedures annually. Zepto will be marketed by Aequus’ current ophthalmology salesforce and is an attractive complement to its existing product offering.

\n

“For the second consecutive quarter, the commercial division has been profitable and is now contributing in a more meaningful way to the overall business,”\n said Ian Ball, Chief Commercial Officer at Aequus. “We continue to seek additional value add products that will further strengthen our revenues while\n reinforcing our commitment to customers in ophthalmology. We are in active discussions for additional revenue products that would complement this strategy.”\n
\n

\n

Development Program Activities

\n

Aequus’ development efforts in Q1 2018 focused on a pre-Investigational Drug Application (“pre-IND”) meeting with the US Food and Drug Administration (“FDA”)\n for the Company’s lead development program, AQS1303, a long-acting transdermal anti-nausea program. Upon review of the Company’s pre-IND submission,\n the FDA agreed that AQS1303 is a suitable candidate for the 505(b)2 abbreviated regulatory pathway for approval in the United States.

\n

Additionally, Aequus continued to build on its partnerships within the medical cannabis field, making significant steps forward for its cannabinoid-based\n therapeutic program targeting neurological disorders. Aequus announced a collaboration with CannaRoyalty Corp. (“CannaRoyalty”) to\n advance a suite of cannabis-based therapies targeting neurological disorders into clinical trials in Canada, in collaboration with Canadian doctors\n and key opinion leaders, and entered into a collaboration with Ehave to access Ehave’s bioinformatics platform, providing cost effective and clinically\n relevant data collection in Aequus’ anticipated clinical trials in the medical cannabis regulatory regime.

\n

Operating Expenses\n

\n

 Sales and marketing costs for Q1 2018 was $338,447, which is consistent with prior quarters\n and includes non-cash expenses of $56,628 related to amortization and share based payments expenses. Depreciation and amortization, and share-based\n payments for Q1 2018 were $45,917 and $10,711, respectively, compared to $45,917 and $25,097, respectively, in Q1 2017. The amortization costs were\n primarily related to the acquisition costs of TeOra.As the sales and marketing infrastructure is now established, new products, like Zepto, can be\n marketed to the same customer base with relatively little change to sales related costs.

\n

The Company incurred research and development expenses of $192,968 in Q1 2018 as compared to $398,273 in Q1 2017. The decrease was primarily attributable\n to subcontractor costs, specifically reduced regulatory consulting for AQS1301 and AQS1303 Pre-IND related work and no clinical work projected during\n Q1 2018 whereas Q1 2017 included work related to the completion of the initial single dose exposure Proof of Concept study for AQS1301, preclinical\n studies for AQS1302 and AQS1303, and the initiation of clinical trial material development for AQS1303.\n
\n

\n

General administration expenses were $659,370 during Q1 2018 as compared to $559,639 in Q1 2017, an increase of $99,731 or 18%. The increase of $175,093\n was primarily due to an increase in one-time consulting expenses relating to corporate marketing and branding during Q1 2018.\n
\n

\n

Other\n
\n

\n

Additionally, the Company issued Camargo Pharmaceutical Services, LLC 31,683 common shares on May 30, 2018 in connection with a service agreement to provide\n regulatory consulting services for the Company’s product development programs in the United States.\n
\n

\n

ABOUT AEQUUS PHARMACEUTICALS INC.\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its pipeline to include several\n commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology, our most recent addition to the development\n pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of\n products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines\n and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian\n commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining\n focused on highly specialized therapeutic areas. For further information, please visitwww.aequuspharma.ca .\n

\n

 

\n

 

", "itemId": 8151260, "name": "Aequus Provides First Quarter 2018 Financial and Corporate Highlights", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-provides-first-quarter-2018-financial-and-corporate-highlights", "url": "/en/news/aequus-provides-first-quarter-2018-financial-and-corporate-highlights", "releaseDate": "2018-05-31T00:00:00", "releaseDate_raw": "2018-05-31T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T16:26:17.78", "lastUpdateDate_raw": "2018-07-27T09:26:17.78", "counter": 16, "weight": 20180531, "commentCount": 0, "editUrl": "/en/news/aequus-provides-first-quarter-2018-financial-and-corporate-highlights?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8151260&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

FORWARD-LOOKING STATEMENT DISCLAIMER

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; the Company’s expected revenues; Aequus’ sales and marketing efforts; the Company’s potential regional partnerships for its internal programs; the regulatory requirements for its transdermal pyridoxine/doxylamine program; and the Company’s expectations regarding the market potential and launch timing of the Zepto Capsulotomy System. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2018, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

\n

VistitanTM: Trademark owned or used under license by Sandoz Canada Inc.

\n

Zepto® is a registered trademark of Mynosys Cellular Devices.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

CONTACT INFORMATION

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

 

\n

VANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS)\n (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce it will be formally launching the Zepto® Precision Pulse Capsulotomy System (“Zepto”) in Canada on June 1, 2018 during the Canadian Ophthalmological Society’s 2018 Annual Meeting and Exhibition.\n Aequus recently announced being appointed as the exclusive Canadian distributor for this product, under a commercial agreement with Mynosys Cellular\n Devices, an ophthalmology focused medical device company based in Fremont, California (“Mynosys”).

\n

Zepto is a novel medical device used during cataract surgery to produce a consistent, high quality, round capsulotomy in milliseconds. Zepto will be marketed\n by Aequus’ current ophthalmology salesforce and is an attractive complement to its existing product offering.

\n

“We look forward to this exciting cross-Canada launch of Zepto and have already received a high level of interest from our customers to have access to\n this device,” said Ian Ball, Chief Commercial Officer at Aequus. “We are delighted to be able to offer this innovative tool to physicians in Canada.”

\n

“With this launch, we have further expanded the Aequus ophthalmology team by adding key personnel with extensive experience in launching ophthalmology\n devices in Canada. This rounds out our team’s therapeutic experience to ensure the successful execution of this and future anticipated launches in\n this field,” said Doug Janzen, CEO of Aequus. “The entire team has worked tremendously hard to get this product on the market for Canadian patients\n and physicians as quickly as possible, and for shareholders to realize the benefits through its accretive revenues.”

\n

About Zepto Precision Pulse Capsulotomy System

\n

The Zepto capsulotomy system provides consistent, high quality anterior lens capsulotomies during cataract surgery in a convenient, cost-effective, disposable\n format. One of the key features is a collapsible super-elastic nitinol capsulotomy ring element with micron scale elements to create the unique and\n strong Zepto capsulotomy edge. It also has a clear silicone suction cup to enable suction and generate Zepto’s proprietary capsulotomy action and to\n allow Zepto capsulotomies on the patient’s individual visual axis. The AMA has recently given a category III code in the US as they see the distinctive\n application and benefit of aligning on the patient’s own visual axis.

\n

Zepto integrates seamlessly into the routine steps of cataract surgery with phacoemulsification. The surgeon does not need to alter his or her normal routine.\n Instead of capsulorrhexis forceps or a cystitome, the surgeon simply reaches for Zepto.

\n

The Zepto Capsulotomy System consists of a disposable Zepto capsulotomy handpiece that is attached to a small control console. Zepto uses the precision\n pulse capsulotomy method, a proprietary combination of calibrated suction and a 4-millisecond multipulse energy algorithm to produce highly accurate\n capsulotomies. Zepto’s unique single use hand piece can be inserted through incisions as small as 2.2mm, to create a perfectly circular and precisely\n placed capsulotomy that can be centred on the visual axis. Zepto is ideal for surgery using premium lenses as well as difficult cases and creates a\n capsulotomy with an edge strength greater than conventional methods or femtosecond lasers. For more information, please visit https://www.zepto-cataract.com/.

\n

About Aequus Pharmaceuticals, Inc.

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical\n company focused on developing and commercializing high quality, differentiated products. Aequus has grown its pipeline to include several commercial\n products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of addressing the need for improved\n medication adherence through enhanced delivery systems. As a complement to its focus in neurology, our most recent addition to the development pipeline\n was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products\n for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and\n will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial\n platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused\n on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

About Mynosys Cellular Devices

\n

Mynosys Cellular Devices Inc. is a medical device company providing innovative solutions to help surgeons achieve perfection in cataract surgery. Our product\n Zepto®, is a unique micro-fabricated instrument that provides unmatched precision during surgery on a millisecond time scale to tackle routine and\n challenging cases with confidence and efficiency. Zepto technology is patented worldwide and is available in selected markets through local distributors.

\n

 

", "itemId": 8137048, "name": "Aequus Announces Official Launch of Zepto Capsulotomy System in Canada to be June 1, 2018", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-official-launch-of-zepto-capsulotomy-system-in-canada-to-be-june-1-2018", "url": "/en/news/aequus-announces-official-launch-of-zepto-capsulotomy-system-in-canada-to-be-june-1-2018", "releaseDate": "2018-05-16T00:00:00", "releaseDate_raw": "2018-05-16T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T15:12:04.45", "lastUpdateDate_raw": "2018-07-27T08:12:04.45", "counter": 17, "weight": 20180516, "commentCount": 0, "editUrl": "/en/news/aequus-announces-official-launch-of-zepto-capsulotomy-system-in-canada-to-be-june-1-2018?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8137048&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, the implementation of our business model and strategic plans, Aequus’ sales and marketing efforts. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: the success of Aequus’ sales and marketing efforts, general business and economic conditions, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

Zepto® is a registered trademark of Mynosys Cellular Devices.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n
Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906\n

 

" }, { "description": "

Key Highlights

\n\n

VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS)\n (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products,\n announced today that the Company has received positive feedback from the US Food and Drug Administration (“FDA”) on its pre-Investigational New Drug\n (“pre-IND”) submission for the Company’s long-acting anti-nausea transdermal patch, AQS1303. Through the pre-IND feedback, the Company has received\n clear regulatory guidance for AQS1303. The FDA confirmed that the planned Section 505(b)(2) abbreviated regulatory pathway, which allows for the Company\n to reference safety and efficacy data of the original oral tablet Diclegis®, is appropriate for submission in a New Drug Application (“NDA”)\n for the program in the United States.

\n

“We are very encouraged with the responses from the FDA on our anti-nausea program,” said Doug Janzen, Chairman and CEO of Aequus. “The pre-IND feedback\n met our expectations, confirming our planned clinical program and providing a clear regulatory path forward. The feedback signals positive support\n for this program and further confirms our overall strategy of improving patient outcomes through alternative delivery methods. We look forward to using\n this guidance in conjunction with our current development and clinical progress to optimize AQS1303 for success.”

\n

“Camargo’s goal is to guide our clients in the most cost- and time-effective manner through the 505(b)(2) regulatory pathway, while driving commercial\n success for our client-partners,” said Ken Phelps, President and Co-Founder of Camargo Pharmaceutical Services. “We look forward to continuing work\n with Aequus to advance their anti-nausea patch for pregnancy nausea and vomiting, to benefit patients worldwide.”

\n

In support of the Company’s planned clinical strategy, the FDA indicated that a pharmacokinetic bridging strategy, to allow bridging to the safety and\n clinical pharmacology information from Diclegis®, and a single clinical efficacy study, would likely be acceptable for an NDA submission.\n The FDA also outlined additional standard studies required of a transdermal patch to evaluate the local safety and to ensure that consistent and predictable\n dosing is achieved over the dosing period.

\n

Aequus owns global rights to this program and is excited about advancing both clinical and strategic discussions as the Company advances AQS1303 towards\n commercialization in major markets.

\n

ABOUT AQS1303

\n

Aequus’ long-acting transdermal anti-nausea patch, AQS1303, contains the combination of pyridoxine and doxylamine (the active ingredients in Diclegis®/Diclectin®)\n currently used to treat nausea and vomiting of pregnancy. AQS1303 is designed to provide patients with a convenient and reliable delivery system as\n an alternative to the currently marketed oral form, which is dosed up to four times per day. According to IQVIA data, Diclegis® sales in\n the United States were approximately $186M USD for 2017.

\n

Aequus has advanced AQS1303 through an initial Proof of Concept clinical study, completed in September 2017. The Proof of Concept study was a single-dose\n cross-over comparative bioavailability study versus the currently approved oral version, Diclegis®/Diclectin®, and was successfully\n completed in nine healthy female volunteers. The results suggested that sustained delivery of therapeutic levels of the active ingredients through\n the skin over a multi-day period is possible with the current formulation. The formulation was well tolerated with no serious adverse events reported.

\n

Based on FDA feedback, this product is expected to follow a Section 505(b)(2) New Drug Application, an abbreviated clinical pathway in which the FDA would\n allow for the Company to reference safety and efficacy data of the original oral tablet form of the medication.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development\n stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced\n delivery systems. With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form\n of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends\n to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic\n partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the\n launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized\n therapeutic areas. For further information, please visit www.aequuspharma.ca .

\n

ABOUT CAMARGO PHARMACEUTICAL SERVICES, LLC.

\n

Camargo Pharmaceutical Services is the most experienced team of experts providing comprehensive drug development services specialized for the 505(b)(2)\n approval pathway and global equivalent processes. By assessing the scientific, medical, regulatory, and commercial viability of product development\n opportunities, Camargo systematically builds and executes robust development plans that align with business strategies and ensure Agency buy-in every\n step of the way. With alignment through pre-Investigational New Drug (pre-IND) meeting planning and preparations, Camargo maintains and ensures consistency\n throughout the drug development program, which increases the likelihood of NDA and future market success. Routinely holding three to six pre-IND meetings\n a month, Camargo works with product developers across more than 25 countries. For more about Camargo Pharmaceutical Services, visit http://camargopharma.com\n

", "itemId": 8129519, "name": "Aequus Receives Positive FDA Regulatory Guidance for Anti-Nausea Patch", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-receives-positive-fda-regulatory-guidance-for-anti-nausea-patch", "url": "/en/news/aequus-receives-positive-fda-regulatory-guidance-for-anti-nausea-patch", "releaseDate": "2018-05-03T00:00:00", "releaseDate_raw": "2018-05-03T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:13:59.99", "lastUpdateDate_raw": "2018-08-01T07:13:59.99", "counter": 18, "weight": 20180503, "commentCount": 0, "editUrl": "/en/news/aequus-receives-positive-fda-regulatory-guidance-for-anti-nausea-patch?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8129519&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the further advancement of AQS1303, the regulatory requirements for AQS1303, and the Company’s ability to form strategic partnerships for its internal programs . Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

\n

Diclegis® and Diclectin® are registered trademarks of Duchesnay Inc.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

VANCOUVER, April 27, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with\n a focus on developing, advancing and promoting differentiated products, today reported financial results for the full year ended December 31, 2017.\n Unless otherwise noted, all figures are in Canadian currency. \n
\n

\n

“With a now established track record of launching products, a sales and marketing team providing full Canadian coverage, and a history of deals with major\n players, Aequus now finds itself in a strong position as a preferred partner providing a unique and flexible deal structure in the Canadian marketplace,”\n said Doug Janzen, Chairman and CEO of Aequus. “We then leverage those revenues and relationships with Canadian clinicians to fund and inform our reformulated\n drug delivery products, which are global products that have significant revenue potential.”

\n

Key 2017 Financial Highlights

\n

Strongest revenue quarter to date, with fourth quarter 2017 total revenue of $368,682, an increase of 121% over the same quarter in 2016\n
\n

\n

Achieved profitability in commercial division in fourth quarter of 2017\n
\n

\n

Fourth quarter 2017 net loss of $640,770, a decrease of 45% over the same quarter in 2016\n
\n

\n

Full year 2017 total revenue of $1.1 million, an increase of 62% over 2016\n
\n

\n

Full year 2017 net loss of $3.8 million, a decrease of 19% over 2016

\n

Key 2017 Operational Highlights

\n

Acquired rights for a transdermal patch containing cannabinoids for the use in certain neurological disorders, and established a series of collaborative partnerships including Scientus, EHAVE and the CDRD to advance various drug delivery programs for medical cannabis to satisfy prescriber needs;

\n

Closed a $5.2M financing underwritten by Canaccord Genuity Corp.;\n
\n

\n

Successfully completed initial Proof of Concept clinical trial for Aequus’ long-acting transdermal anti-nausea patch, AQS1303, with positive results;\n
\n

\n

Received positive feedback from FDA regarding the suitability of its once-weekly transdermal patch for aripiprazole to follow an abbreviated regulatory pathway for approval in the US;\n
\n

\n

Entered into a commercial collaboration with Santen Inc, the Canadian Branch (“Santen”), a subsidiary of Santen Pharmaceutical Co., Ltd. to become its exclusive promotional and marketing partner for an ophthalmology product in Canada;\n
\n

\n

Subsequent to December 31, 2017 

\n

In January 2018, Aequus announced a collaboration with CannaRoyalty Corp. (“CannaRoyalty”) to advance a suite of cannabis-based therapies targeting neurological disorders into clinical trials in Canada, in collaboration with Canadian doctors and key opinion leaders;

\n

In April 2018, Aequus’ partner, Santen, received a Notice of Non-Compliance by Health Canada for the product contemplated under the previously announced commercialization agreement. The Company expects the current agreement to be wound up following the recent decision by Health Canada. Aequus looks forward to continued discussions with Santen around potential future products;\n
\n

\n

In April 2018, Aequus entered into an exclusive commercial and distribution agreement with Mynosys for the promotion of Zepto Precision Pulse Capsulotomy System in Canada.\n
\n

\n

Commercial Update\n
\n

\n

Revenue during the year ended December 31, 2017 was $1,139,424, an increase of 62% in annual revenues compared to 2016. Q4 of 2017 was the Company’s strongest\n quarter to date, with total revenues of $368,682, an increase of 121% over the same quarter in 2016.

\n

VistitanTM revenues are expected to continue to increase in the current fiscal year as it continues to gain market share held by similar medications\n within the class. Tacrolimus IR sales may be more volatile in 2018 due to competitive dynamics. This volatility is expected to be offset by new revenues\n from Zepto®, which is expected to be launched in Q2 2018.

\n

“We are very pleased with the growth of our commercial franchise achieved in 2017,” says Ian Ball, Chief Commercial Officer of Aequus. “We launched Vistitan\n less than two years ago and have exceeded a million dollars in total annual revenues for the first time. The recently announced Zepto transaction leverages\n our existing sales infrastructure and will begin to generate revenues in Q2, we also have additional commercial products in various stages of negotiation.\n We expect strong revenue growth in 2018 and note that the commercial activities have been cash-flow positive for the past few months based on our expected\n revenues. It is significant to see the commercial arm contributing cash flow to off-set development and administration expenses.”

\n

Aequus looks to leverage its core capabilities, commercial infrastructure and existing product portfolio that it has been growing through promotional partnership\n agreements, asset acquisitions, in-licenses and in the future with the Company’s own internal development programs as they mature and enter the market.\n The Company’s near-term commercial growth strategy includes the progressive build-out of the Company’s commercial platform, including leveraging its\n specialty sales force and relationships with physicians in Canada to enable Aequus to continue to in-license and sell high value branded products in\n Canada.

\n

Alongside the Company’s expected growth in ophthalmology, the Company plans to expand its neurology franchise by advancing clinical studies for its medical\n cannabis program in the coming months, following the completion of several recently announced collaborative partnerships in this field. Namely, Aequus\n formed a collaboration with Scientus Pharma, Inc. (“Scientus”) to be the development and commercial supplier of specific cannabinoid extracts, with\n an option for Scientus to co-fund the development of a cannabinoid containing transdermal formulation that would be designed and optimized to address\n certain neurological disorders. Additionally, the Company entered into a collaboration with Ehave, Inc. (“Ehave”) to access Ehave’s bioinformatics\n platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific cannabinoid-rich formulations for\n treating a number of neurological disorders. On June 1, 2017, Aequus entered into a broad research collaboration with the Centre for Drug Research\n and Development (“CDRD”) to establish pre-clinical safety and efficacy of select cannabinoid-based therapeutics targeting certain neurological movement\n disorders. And most recently, in January 2018, Aequus announced a collaboration with CannaRoyalty Corp. (“CannaRoyalty”) to advance a suite of cannabis-based\n therapies targeting neurological disorders into clinical trials in Canada, in collaboration with Canadian doctors and key opinion leaders.\n
\n

\n

The Company also expects to pursue a small clinical study for Topiramate Extended-Release (“Topiramate XR”) to support a New Drug Submission (“NDS”) in\n 2018, intended for the treatment of epilepsy.\n
\n

\n

Progress of Product Pipeline

\n

The Company continued to invest in its development pipeline in 2017. Aequus completed an initial Proof of Concept clinical trial to evaluate the bioavailability\n and safety of Aequus' long-acting transdermal anti-nausea patch, AQS1303, containing the combination of pyridoxine and doxylamine (the active ingredients\n in Diclegis®/Diclectin®). AQS1303 could provide patients with a more convenient and reliable delivery system as an alternative\n to the currently marketed oral form, which is dosed up to four times per day.This Proof of Concept study was designed as a single-dose cross-over comparative\n bioavailability study versus the currently approved oral version, Diclegis®/Diclectin®, in nine healthy volunteers. The results\n suggested that sustained delivery of therapeutic levels of the active ingredients through the skin over a multi-day period is possible with the current\n formulation. The formulation was well tolerated with no serious adverse events reported.

\n

The Company also advanced AQS1301, a once-weekly transdermal formulation of aripiprazole through a multi-dose Proof of Concept clinical study which was\n completed in February 2017, demonstrating that steady state was achieved in week three of dosing in healthy volunteers, with comparable plasma concentrations\n to the orally delivered form of aripiprazole, Abilify®. Aequus also expanded the patent portfolio for this program with a patent issued/allowed\n in seven major countries or regions to date, namely the United States, Russia, Mexico, Japan, Australia, Canada and China with several other major\n markets pending.

\n

Aequus received positive feedback from the US Food and Drug Administration (“FDA”) in a pre-Investigational Drug Application (“pre-IND”) meeting for the\n Company’s lead development program, AQS1301, a once-weekly transdermal formulation of aripiprazole. Upon review of the Company’s pre-IND submission,\n the FDA agreed that AQS1301 is a suitable candidate for the 505(b)2 abbreviated regulatory pathway for approval in the United States.

\n

Aequus has been engaging with third parties around partnering discussions for each of its internal programs, with a goal of ensuring that the maximum benefit\n is realized by shareholders.

\n

Operating Expenses\n
\n

\n

Research and development expenses in the fourth quarter of 2017 were $19,590, as compared to $295,115 in the same quarter last year, and for the full year\n 2017, $1,414,706, as compared to $1,127,780 for 2016. The increase was primarily attributable to subcontractor costs, specifically regulatory consulting\n for AQS1301 and AQS1303 Pre-IND related work, the development of AQS1303 clinical trial materials and the execution of the Proof of Concept study for\n AQS1303. In Q4 2017, the Company prepared for the Pre-IND meeting for AQS1303 and was active in establishing collaborative partnerships in anticipation\n of advancing its medical cannabis programs.

\n

Sales, marketing and general administration expenses in the fourth quarter of 2017 were $992,882, as compared to $1,059,635 in the same quarter last year,\n and for the full year 2017, $3,727,176 as compared to $4,437,436 in 2016. During Fiscal 2016 the Company incurred relatively high promotional spending\n associated with launch activities for Tacrolimus IR and Vistitan™ in Canada whereas there were no similar start-up costs in Fiscal 2017. Additionally,\n in 2017 there was a decrease in management fees, regulatory consultant spending and share-based payments expense.

\n

Aequus reported a loss before other income of $640,770, a decrease of 45% over the same quarter in 2016, and for the full year 2017 a net loss of $3,882,427, a decrease of 19% over 2016. This\n improvement in loss before other income for both periods is primarily due to growing revenues from its sales and marketing activities in 2017 for its\n two commercially promoted products, Tacrolimus IR and Vistitan™.

\n

About Tacrolimus IR

\n

Tacrolimus immediate release is an immunosuppressant used for the treatment and prevention of acute rejection following organ transplantation. Tacrolimus\n is part of a patient’s immunosuppressive therapy prescribed chronically in their lifelong management to prevent graft rejection. In 2015, the immunosuppressive\n market in Canada reached $241M in sales, with tacrolimus products accounting for $100M. With the assistance of Aequus’ promotional efforts and commercial\n team, the tacrolimus IR generic grew 90% year-over-year by unit volume in 2016 when compared to 2015 based on ex-factory data.

\n

About Vistitan™

\n

Vistitan™(bimatoprost 0.03%, ophthalmic solution), is a branded generic prostaglandin approved by Health Canada for the reduction of elevated IOP\n in patients with open angle glaucoma or ocular hypertension. The Canadian glaucoma market in 2015 was estimated to be over $182 million, of which prostaglandins\n remain one of the primary treatment options for lowering IOP in glaucoma. VistitanTM, which was approved by Health Canada in 2014, is currently\n the only marketed version of 0.03% bimatoprost ophthalmic solution in Canada.

\n

About Zepto Precision Pulse Capsulotomy System 

\n

The Zepto capsulotomy system provides consistent, high quality anterior lens capsulotomies during cataract surgery in a convenient, cost-effective, disposable\n format. One of the key features is a collapsible super-elastic nitinol capsulotomy ring element with micron scale elements to create the unique and\n strong Zepto capsulotomy edge. It also has a clear silicone suction cup to enable suction and generate Zepto’s proprietary capsulotomy action and to\n allow Zepto capsulotomies on the patient’s individual visual axis.The AMA has recently given a category III code in the US as they see the distinctive\n application and benefit of aligning on the patient’s own visual axis.\n
\n

\n

Zepto integrates seamlessly into the routine steps of cataract surgery with phacoemulsification. The surgeon does not need to alter his or her normal routine.\n Instead of capsulorrhexis forceps or a cystitome, the surgeon simply reaches for Zepto.\n
\n

\n

The Zepto Capsulotomy System consists of a disposable Zepto capsulotomy handpiece that is attached to a small control console. Zepto uses the precision\n pulse capsulotomy method, a proprietary combination of calibrated suction and a 4-millisecond multipulse energy algorithm to produce highly accurate\n capsulotomies. Zepto’s unique single use hand piece can be inserted through incisions as small as 2.2mm, to create a perfectly circular and precisely\n placed capsulotomy that can be centred on the visual axis. Zepto is ideal for surgery using premium lenses as well as difficult cases and creates a\n capsulotomy with an edge strength greater than conventional methods or femtosecond lasers.For more information, please visit https://www.zepto-cataract.com/.\n
\n

\n

ABOUT AEQUUS PHARMACEUTICALS INC.\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its pipeline to include several\n commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology, our most recent addition to the development\n pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of\n products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines\n and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian\n commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining\n focused on highly specialized therapeutic areas. For further information, please visitwww.aequuspharma.ca .\n

\n

 

", "itemId": 8128560, "name": "Aequus Provides Fourth Quarter and Fiscal 2017 Financial Highlights, Third Consecutive Quarter of Revenue Growth", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-provides-fourth-quarter-and-fiscal-2017-financial-highlights-third-consecutive-quarter-of-rev", "url": "/en/news/aequus-provides-fourth-quarter-and-fiscal-2017-financial-highlights-third-consecutive-quarter-of-rev", "releaseDate": "2018-04-27T00:00:00", "releaseDate_raw": "2018-04-27T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:12:06.303", "lastUpdateDate_raw": "2018-08-01T07:12:06.303", "counter": 19, "weight": 20180427, "commentCount": 0, "editUrl": "/en/news/aequus-provides-fourth-quarter-and-fiscal-2017-financial-highlights-third-consecutive-quarter-of-rev?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8128560&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

FORWARD-LOOKING STATEMENT DISCLAIMER

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”,“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; the Company’s expected revenues; the timing of public listings; the advancement of the Company’s transdermal pyridoxine/doxylamine program into a Proof of Concept clinical study; the Company’s potential regional partnerships for its internal programs; the timing of public reimbursement decisions for VistitanTM; the timing of the Company’s follow-on, multi-dose bioavailability study for the its transdermal aripiprazole program; and the Company’s expectations regarding the tech transfer to its development partner with respect to the Company’s transdermal patch for clobazam. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements.

", "Forward-Looking Statement Disclaimer 2": "

In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated May 1, 2017, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.\n

\n

VistitanTM: Trademark owned or used under license by Sandoz Canada Inc.\n

", "Contact for Article": "

CONTACT INFORMATION

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

VANCOUVER, British Columbia, April 26, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing\n and promoting differentiated products, today announced that its Chairman and Chief Executive Officer, Doug Janzen, will present at the seventh annual\n Bloom Burton & Co. Healthcare Investor Conference on Wednesday May 2nd, 2017 at 3:30pm EDT in Hall B at the Sheraton Centre Toronto\n Hotel in Toronto, Ontario.

\n

About Aequus Pharmaceuticals

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its pipeline to include several\n commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology, our most recent addition to the development\n pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of\n products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines\n and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian\n commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining\n focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca\n .\n

\n

About the Conference

\n

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments\n in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private\n companies through presentations and private meetings.

\n

About Bloom Burton & Co.

\n

Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies.\n Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence,\n which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its\n affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and\n company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC)\n and is also a member of the Canadian Investor Protection Fund (CIPF).

\n

 

", "itemId": 8125769, "name": "Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 2, 2018", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-to-present-at-bloom-burton-co-healthcare-investor-conference-on-may-2-2018", "url": "/en/news/aequus-to-present-at-bloom-burton-co-healthcare-investor-conference-on-may-2-2018", "releaseDate": "2018-04-26T00:00:00", "releaseDate_raw": "2018-04-26T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:15:24.727", "lastUpdateDate_raw": "2018-08-01T07:15:24.727", "counter": 20, "weight": 20180426, "commentCount": 0, "editUrl": "/en/news/aequus-to-present-at-bloom-burton-co-healthcare-investor-conference-on-may-2-2018?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8125769&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty\n pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has issued Camargo Pharmaceutical\n Services, LLC (“Camargo”) 120,111 common shares on April 11, 2018 in connection with the previously announced completion of a pre-Investigational New\n Drug (“pre-IND”) meeting submission for AQS1303, Aequus’ long-acting transdermal anti-nausea patch for the treatment of nausea and vomiting of pregnancy.\n The Company submitted the pre-IND meeting package to the US Food and Drug Administration (“FDA”) for review and anticipates FDA feedback by the end\n of April 2018, which will define the clinical strategy for regulatory approval in the USA for AQS1303.\n
\n

\n

The product is expected to follow a Section 505(b)(2) New Drug Application (NDA), an abbreviated clinical pathway in which the FDA would allow for the\n Company to reference safety and efficacy data of the original oral tablet form of the medication. Aequus owns the global rights to this program and\n will look to find a strategic partner to advance it towards commercialization in major markets.

\n

The shares issued are as per a previously announced service agreement with Camargo, to provide regulatory consulting services for the Company’s product\n development programs in the United States. 

\n

ABOUT AQS1303\n

\n

Aequus’ long-acting transdermal anti-nausea patch, AQS1303, contains the combination of pyridoxine and doxylamine (the active ingredients in Diclegis®/Diclectin®)\n currently used to treat nausea and vomiting of pregnancy. AQS1303 is designed to provide patients with a convenient and reliable delivery system as\n an alternative to the currently marketed oral form, which is dosed up to four times per day.

\n

Aequus has advanced AQS1303 through an initial Proof of Concept clinical study, completed in September 2017. The Proof of Concept study was a single-dose cross-over comparative bioavailability study versus the currently approved oral version, Diclegis®/Diclectin®, and was successfully completed in nine healthy female volunteers. The results suggested that sustained delivery of therapeutic levels of the active ingredients through the skin over a multi-day period is possible with the current formulation. The formulation was well tolerated with no serious adverse events reported.

\n

This product is expected to follow a Section 505(b)(2) New Drug Application (NDA), an abbreviated clinical pathway in which the FDA would allow for the\n Company to reference safety and efficacy data of the original oral tablet form of the medication.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes\n several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.\n With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis,\n where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that\n would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional\n products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.\n For further information, please visitwww.aequuspharma.ca.

\n

ABOUT CAMARGO PHARMACEUTICAL SERVICES, LLC. \n \n

\n

Camargo Pharmaceutical Services is the most experienced team of experts providing comprehensive drug development services specialized for the 505(b)(2)\n approval pathway and global equivalent processes. By assessing the scientific, medical, regulatory, and commercial viability of product development\n opportunities, Camargo systematically builds and executes robust development plans that align with business strategies and ensure Agency buy-in every\n step of the way. With alignment through pre-Investigational New Drug (pre-IND) meeting planning and preparations, Camargo maintains and ensures consistency throughout the drug development program, which increases the likelihood of NDA and future market success. Routinely holding three to six pre-IND meetings a month, Camargo works with product developers across more than 25 countries. For more about Camargo Pharmaceutical Services, visit http://camargopharma.com\n

\n

 

\n

 

\n

 

\n

 

", "itemId": 8121261, "name": "Aequus and Camargo Complete Pre-Investigational New Drug Submission with FDA for Transdermal Anti-Nausea Program", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-and-camargo-complete-pre-investigational-new-drug-submission-with-fda-for-transdermal-anti-na", "url": "/en/news/aequus-and-camargo-complete-pre-investigational-new-drug-submission-with-fda-for-transdermal-anti-na", "releaseDate": "2018-04-17T00:00:00", "releaseDate_raw": "2018-04-17T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T13:56:01.363", "lastUpdateDate_raw": "2018-08-01T06:56:01.363", "counter": 21, "weight": 20180417, "commentCount": 0, "editUrl": "/en/news/aequus-and-camargo-complete-pre-investigational-new-drug-submission-with-fda-for-transdermal-anti-na?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8121261&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: expected benefits of AQS1303 and transdermal delivery, the further advancement of AQS1303, the regulatory requirements for AQS1303, and the Company’s ability to form strategic partnerships for its internal programs. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

\n

Diclegis® and Diclectin® are registered trademarks of Duchesnay Inc.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

 

\n

VANCOUVER, B.C., April 12, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS)\n (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce it has entered into a commercial agreement with\n Mynosys Cellular Devices, an ophthalmology focused medical device company based in Fremont, California, (“Mynosys”) for the Canadian distribution,\n sales and marketing of the Zepto® Precision Pulse Capsulotomy System (“Zepto”) for cataract surgery. Zepto was approved for sale in Canada\n by the Therapeutic Products Directorate in February 2018, and through this agreement is expected to be launched in Canada by Aequus within the next\n quarter. Zepto will be marketed by Aequus’ current ophthalmology salesforce and is an attractive complement to its existing product offering.

\n

“The addition of the Zepto device expands Aequus’ ophthalmology portfolio into the cataract surgical space and reaffirms our commitment to this therapeutic\n area,” said Anne Stevens, COO and Director of Aequus. “In meetings with Canadian ophthalmologists, clinicians expressed a strong interest for this\n product, particularly in the premium intraocular lens market and the more challenging cases, which we estimate to represent over 20% of cataract cases\n performed each year in Canada.”

\n

Zepto has been used in thousands of cataract surgeries in Asia, Europe, and Central America since February 2017, and most recently in the US since August\n 2017.

\n

John Hendrick, President and CEO of Mynosys, stated: “I am delighted to have Aequus as our partner to bring Zepto to the market in Canada. We have seen\n a significant demand for Zepto around the world and fully expect that Zepto will be embraced by the Canadian market as well”.

\n

This agreement has an initial term of three years, with an automatic and continuous renewal of additional three year terms, provided Aequus meets minimum\n sales targets. Aequus will retain profits on the products sold in Canada.

\n

About Zepto Precision Pulse Capsulotomy System

\n

The Zepto capsulotomy system provides consistent, high quality anterior lens capsulotomies during cataract surgery in a convenient, cost-effective, disposable\n format. One of the key features is a collapsible super-elastic nitinol capsulotomy ring element with micron scale elements to create the unique and\n strong Zepto capsulotomy edge. It also has a clear silicone suction cup to enable suction and generate Zepto’s proprietary capsulotomy action and to\n allow Zepto capsulotomies on the patient’s individual visual axis. The AMA has recently given a category III code in the US as they see the distinctive\n application and benefit of aligning on the patient’s own visual axis.

\n

Zepto integrates seamlessly into the routine steps of cataract surgery with phacoemulsification. The surgeon does not need to alter his or her normal routine.\n Instead of capsulorrhexis forceps or a cystitome, the surgeon simply reaches for Zepto.

\n

The Zepto Capsulotomy System consists of a disposable Zepto capsulotomy handpiece that is attached to a small control console. Zepto uses the precision\n pulse capsulotomy method, a proprietary combination of calibrated suction and a 4-millisecond multipulse energy algorithm to produce highly accurate\n capsulotomies. Zepto’s unique single use hand piece can be inserted through incisions as small as 2.2mm, to create a perfectly circular and precisely\n placed capsulotomy that can be centered on the visual axis. Zepto is ideal for surgery using premium lenses as well as difficult cases and creates\n a capsulotomy with an edge strength greater than conventional methods or femtosecond lasers. For more information, please visit https://www.zepto-cataract.com/.

\n

About Aequus Pharmaceuticals, Inc.

\n

Aequus Pharmaceuticals, Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing\n specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline\n includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery\n systems. With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical\n cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that\n would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional\n products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.\n For further information, please visit www.aequuspharma.ca .

\n

About Mynosys Cellular Devices

\n

Mynosys Cellular Devices Inc. is a medical device company providing innovative solutions to help surgeons achieve perfection in cataract surgery. Our product\n Zepto®, is a unique micro-fabricated instrument that provides unmatched precision during surgery on a millisecond time scale to tackle routine and\n challenging cases with confidence and efficiency. Zepto technology is patented worldwide and is available in selected markets through local distributors.

\n

 

\n

 

", "itemId": 8119639, "name": "Aequus Adds Zepto Capsulotomy System, A Revenue Generating Product, to Commercial Ophthalmology Portfolio", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-adds-zepto-capsulotomy-system-a-revenue-generating-product-to-commercial-ophthalmology-portfo", "url": "/en/news/aequus-adds-zepto-capsulotomy-system-a-revenue-generating-product-to-commercial-ophthalmology-portfo", "releaseDate": "2018-04-12T00:00:00", "releaseDate_raw": "2018-04-12T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T15:12:43.293", "lastUpdateDate_raw": "2018-07-27T08:12:43.293", "counter": 22, "weight": 20180412, "commentCount": 0, "editUrl": "/en/news/aequus-adds-zepto-capsulotomy-system-a-revenue-generating-product-to-commercial-ophthalmology-portfo?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8119639&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, the implementation of our business model and strategic plans, Aequus’ sales and marketing efforts. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: the success of Aequus’ sales and marketing efforts, general business and economic conditions, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

First-to-market generic tacrolimus will be included on Sigma Santé contract as of May 2018, building on continued commercial success of Aequus’ promotional arm

\n

VANCOUVER, BC. March 19, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”\n or the “Company”), announced today that it has been awarded a three-year contract with Sigma Santé for its\n partnered product, tacrolimus immediate-release (“Tacrolimus IR”), an immunosuppressive therapy used concomitantly with adrenal corticosteroids to\n prevent or treat rejection following organ transplant and for the reduction of symptoms experienced by patients with rheumatoid arthritis. Sigma Santé\n is one of the largest healthcare group purchasing organizations (“GPO”) in Quebec and the final GPO in the province to list this first-to-market, generic\n version of Tacrolimus IR. The contract will be effective as of May 2018.\n
\n

\n

“This is a very meaningful award for us, as Quebec is the second largest market in Canada, with Sigma Santé representing a significant amount of volume\n that we have not previously had access to,” said Ian Ball, Chief Commercial Officer of Aequus.Our goal\n has been to provide transplant patients with access to this high-quality and cost-effective treatment option, and to support physicians and payors\n regarding the use of this alternative to branded tacrolimus. We are very proud to see this product available to more Canadian patients in need of treatment.”\n
\n

\n

“This award follows the strongest quarter to date for the Company, based on unaudited revenues in the fourth quarter of 2017. We believe this award will\n help drive revenues in 2018, as we continue along our expected growth trajectory,” said Doug Janzen, CEO and Chairman of Aequus. “Further, this reaffirms\n our commercial capabilities as being a key driver of our business, from market access and reimbursement to sales force execution.”\n
\n

\n

Approved Clinical Uses of Tacrolimus IR in Canada\n
\n

\n

The following information is based on the Product Monograph for tacrolimus IR. Please refer to the full Product Monograph for all labeled safety information for tacrolimus IR.\n
\n

\n

TRANSPLANTATION 

\n

- Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants 

\n

- Treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants

\n

Tacrolimus is to be used concomitantly with adrenal corticosteroids and other immunosuppressive agents. The safety and efficacy of the use of tacrolimus\n with sirolimus has not been established.\n
\n

\n

Only physicians experienced in immunosuppressive therapy and management of organ transplant should prescribe tacrolimus. Patients receiving the drug should\n be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance\n therapy should have complete information requisite for the follow-up of the patient.\n
\n

\n

RHEUMATOID ARTHRITIS 

\n

- Treatment of active rheumatoid arthritis in adult patients for whom disease modifying anti-rheumatic drug (DMARD) therapy is ineffective or inappropriate 

\n

Tacrolimus may be used as monotherapy or in combination with non-steroidal anti- inflammatory drugs (NSAIDs) and/or steroids, although the possibility\n of increased toxicity has not been fully explored.\n
\n

\n

About Aequus Pharmaceuticals, Inc.\n
\n

\n

Aequus Pharmaceuticals, Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated\n products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved\n medication adherence through enhanced delivery systems. With a focus in neurology and other specialty areas, our most recent addition to the development\n pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of\n products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines\n and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian\n commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining\n focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca .\n
\n

\n

 

\n

 

\n

 

\n

 

", "itemId": 8096760, "name": "Aequus Expands Market in Quebec for Tacrolimus IR", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-expands-market-in-quebec-for-tacrolimus-ir", "url": "/en/news/aequus-expands-market-in-quebec-for-tacrolimus-ir", "releaseDate": "2018-03-19T00:00:00", "releaseDate_raw": "2018-03-19T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T15:56:31.737", "lastUpdateDate_raw": "2018-07-27T08:56:31.737", "counter": 23, "weight": 20180319, "commentCount": 0, "editUrl": "/en/news/aequus-expands-market-in-quebec-for-tacrolimus-ir?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8096760&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, the implementation of our business model and strategic plans, Aequus’ sales and marketing efforts. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: the success of Aequus’ sales and marketing efforts, general business and economic conditions, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

VANCOUVER, British Columbia, March 07, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty\n pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the Company has received confirmation\n from the US Food and Drug Administration (“FDA”) that they will be providing feedback to the Company’s pre-Investigational New Drug (“pre-IND”) submission\n by the end of April, 2018 to define the clinical strategy for regulatory approval in the US for AQS1303.

\n

Aequus’ long-acting transdermal anti-nausea patch, AQS1303, contains the combination of pyridoxine and doxylamine (the active ingredients in Diclegis®/Diclectin®).\n AQS1303 is designed to provide patients with a more convenient and reliable delivery system as an alternative to the currently marketed oral form,\n which is dosed up to four times per day.

\n

The product is expected to follow a Section 505(b)2 New Drug Application (NDA), an abbreviated clinical pathway in which the FDA would allow for the Company\n to reference safety and efficacy data of the original oral tablet form of the medication. Aequus owns the global rights to this program, and will look\n to find a strategic partner to advance towards commercialization in major markets.

\n

The Company issued Camargo Pharmaceutical Services, LLC 59,038 common shares on March 7, 2018 in connection with this milestone regulatory event as per\n a previously announced service agreement to provide regulatory consulting services for the Company’s product development programs in the United States. 

\n

ABOUT AEQUUS PHARMACEUTICALS INC.

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes\n several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.\n With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis,\n where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that\n would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional\n products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.\n For further information, please visitwww.aequuspharma.ca.

\n

ABOUT CAMARGO PHARMACEUTICAL SERVICES, LLC. \n \n

\n

Camargo Pharmaceutical Services is the most experienced team of experts providing comprehensive drug development services specialized for the 505(b)(2)\n approval pathway and global equivalent processes. By assessing the scientific, medical, regulatory, and commercial viability of product development\n opportunities, Camargo systematically builds and executes robust development plans that align with business strategies and ensure Agency buy-in every\n step of the way. With alignment through pre-Investigational New Drug (pre-IND) meeting planning and preparations, Camargo maintains and ensures consistency throughout the drug development program, which increases the likelihood of NDA and future market success. Routinely holding three to six pre-IND meetings a month, Camargo works with product developers across more than 25 countries. For more about Camargo Pharmaceutical Services, visit http://camargopharma.com\n

\n

 

\n

 

", "itemId": 8091015, "name": "FDA Confirms Date to Providing Regulatory Guidance for Aequus’ Anti-Nausea Patch", "urlWithHost": "http://www.aequuspharma.ca/en/news/fda-confirms-date-to-providing-regulatory-guidance-for-aequus-anti-nausea-patch", "url": "/en/news/fda-confirms-date-to-providing-regulatory-guidance-for-aequus-anti-nausea-patch", "releaseDate": "2018-03-07T00:00:00", "releaseDate_raw": "2018-03-07T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:16:21.35", "lastUpdateDate_raw": "2018-08-01T07:16:21.35", "counter": 24, "weight": 20180307, "commentCount": 0, "editUrl": "/en/news/fda-confirms-date-to-providing-regulatory-guidance-for-aequus-anti-nausea-patch?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8091015&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: expected benefits of AQS1303 and transdermal delivery, the further advancement of AQS1303, the regulatory requirements for AQS1303, and the Company’s ability to form strategic partnerships for its internal programs. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

\n

Diclegis® and Diclectin® are registered trademarks of Duchesnay Inc.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

Ehave’s Bioinformatics Platform Technology to Be Used to Evaluate Aequus’ Products in Multiple Neurological Disorders

\n

VANCOUVER, BC. March 5, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”\n or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting\n differentiated products, and Ehave, Inc. (OTCQB: EHVVF) (“Ehave”), a healthcare bioinformatics company whose\n platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement\n whereby Aequus will incorporate Ehave’s bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials\n studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously\n announced Letter of Intent established in August 2017.\n
\n

\n

“Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially since we signed the original\n Letter of Intent with Ehave. We have a number of different trials in late-stage planning and see multiple opportunities for us to leverage our traditional\n pharmaceutical expertise in designing and implementing clinical programs, but we also see growing opportunities for us to leverage our existing relationships\n with Canadian clinicians and take advantage of our existing pharmaceutical sales infrastructure to better serve clinicians and Insurers as it relates\n to medical cannabis. We and Ehave are in a unique position to generate meaningful product safety and efficacy data in a variety of trial settings in\n a very efficient and cost-effective way,” says Doug Janzen, Chairman and CEO of Aequus. “In our most recent comprehensive physician survey regarding\n factors that prevent them from recommending medical cannabis products, Canadian clinicians identified the lack of robust clinical data in a real-world\n setting for such products as a significant limiting factor.”\n
\n

\n

\"Our robust bioinformatics platform allows us to provide customized, next-generation clinical solutions that empower pharmaceutical developers such as\n Aequus to be successful,\" said Prateek Dwivedi, CEO of Ehave. \"We are particularly committed to partnering with companies seeking to evaluate medical\n cannabis products, recognizing the specific need within this emerging industry for ‘pharmaceutical-grade’ patient and clinical data informatics to\n help unlock the value of these new therapies for clinicians, patients, and payors. Aequus shares this view based on its strong background, unique capabilities\n and commercial experience in traditional pharmaceutical development, making them an ideal partner for Ehave. We look forward to helping them advance\n their clinical programs and potentially improve outcomes for patients with neurological disorders who may benefit from Aequus’ products.”\n
\n

\n

The terms of the agreement are similar to that of the original Letter of Intent.Aequus will pay Ehave a per-patient fee for trials conducted using Ehave’s\n platform and Aequus will receive patient assessment, diagnostic and therapeutic outcomes and side-effect profile content from formal and informal studies\n conducted using the Ehave platform, subject to standard patient consent and clinical research ethics approvals. Aequus will own all clinical results\n and data generated from trials using the Ehave platform.\n
\n

\n

About Aequus Pharmaceuticals

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes\n several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.\n With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis,\n where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that\n would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional\n products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.\n For further information, please visit www.aequuspharma.ca.

\n
\n

 

\n

 

\n

About Ehave, Inc.Ehave, Inc. (OTCQB: EHVVF) is empowering the mental healthcare community with a next generation of data-rich tools designed\n to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave's mental health informatics platform, clinicians can make objective,\n data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of\n core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health\n Systems (\"MHS\"), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit\n hyperactivity disorder (\"ADHD\"), through its collaboration with the Hospital for Sick Children (\"SickKids\"). Ehave Connect is also being utilized to\n advance the validation and optimization of medical cannabis, through its collaboration with leading medical cannabis licensed producers. For more information,\n visit www.ehave.com .

\n

 

\n

 

\n

 

\n

 

", "itemId": 8084671, "name": "Aequus and EHave enter into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-and-ehave-enter-into-collaboration-agreement-for-comprehensive-patient-data-management-in-c-1", "url": "/en/news/aequus-and-ehave-enter-into-collaboration-agreement-for-comprehensive-patient-data-management-in-c-1", "releaseDate": "2018-03-05T00:00:00", "releaseDate_raw": "2018-03-05T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T14:56:41.73", "lastUpdateDate_raw": "2018-07-27T07:56:41.73", "counter": 25, "weight": 20180305, "commentCount": 0, "editUrl": "/en/news/aequus-and-ehave-enter-into-collaboration-agreement-for-comprehensive-patient-data-management-in-c-1?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8084671&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Aequus Pharmaceuticals Inc. Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, and using results from Ehave’s bioinformatics platform to monitor and assess patient outcomes. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully out-license or sell its current products and in-license and develop new products, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

 

\n

 

", "Forward-Looking Statement Disclaimer 2": "

Ehave, Inc. Forward-Looking Statement Disclaimer

\n

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading \"Risk Factors\" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.

\n
", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

\n

Ehave, Inc. Investor Relations: Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)\n
(212) 375-2664\n
jdrumm@tiberend.com
Janine McCargo (Media)\n
646-604-5150\n
jmccargo@tiberend.com

" }, { "description": "

VANCOUVER, January 31, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty\n pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced plans to advance its transdermal\n patch for pregnancy-related anti-nausea, AQS1303, following positive results from the proof of concept study completed in 2017. The Company will work\n with its regulatory and strategic consulting partner, Camargo Pharmaceutical Services, LLC (“Camargo”), to prepare for a pre-Investigational New Drug\n Application (“pre-IND”) meeting with the US Food and Drug Administration (“FDA”) to define the clinical strategy for approval in the United States.\n The Company anticipates pursuing an abbreviated 505(b)(2) pathway.

\n

“We feel very strongly about the need for this program and are delighted to see its continued progress,” said Anne Stevens, COO and Director of Aequus.\n “We expect a meeting with the FDA in the second quarter of this year and anticipate it will provide clarity on the requirements for AQS1303 in order\n to achieve FDA approval under 505(b)(2).”

\n

AQS1303 is a long-acting transdermal patch intended for the treatment of nausea and vomiting of pregnancy (“NVP”). AQS1303 would provide patients with\n a more convenient and reliable delivery system as an alternative to the currently marketed oral form, which is dosed up to four times per day. Currently,\n the oral form of Diclegis® is the only FDA-approved medication for morning sickness in pregnant women and in 2015 reached sales in the United\n States of approximately U.S.$120 million, according to IMS data. It is estimated that 70% of women experience NVP, and in some severe cases it may\n persist throughout their entire pregnancy, having a significant impact on expectant mothers’ quality of life. A long-acting transdermal form of pyridoxine/doxylamine\n is being developed by Aequus to address the risk of missed doses due to emesis (vomiting) and to provide consistent and sustained symptomatic relief.\n

\n

Aequus owns global rights to this program.

\n

ABOUT AQS1303\n

\n

Aequus has advanced the multi-day transdermal patch, AQS1303, containing the combination of pyridoxine hydrochloride and doxylamine succinate (the active ingredients in Diclegis®/Diclectin®) through an initial Proof of Concept clinical study, completed in September 2017. The Proof of Concept study was a single-dose cross-over comparative bioavailability study versus the currently approved oral version, Diclegis®/Diclectin®, and was successfully completed in nine healthy female volunteers. The results suggested that sustained delivery of therapeutic levels of the active ingredients through the skin over a multi-day period is possible with the current formulation. The formulation was well tolerated with no serious adverse events reported.\n

\n

This product is expected to follow a Section 505(b)(2) New Drug Application (NDA), an abbreviated clinical pathway in which the FDA would allow for the\n Company to reference safety and efficacy data of the original oral tablet form of the medication. \n

\n

ABOUT AEQUUS PHARMACEUTICALS INC.\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes\n several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.\n With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis,\n where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that\n would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional\n products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.\n For further information, please visit www.aequuspharma.ca.

\n

ABOUT CAMARGO PHARMACEUTICAL SERVICES, LLC. \n \n

\n

Camargo Pharmaceutical Services is the most experienced team of experts providing comprehensive drug development services specialized for the 505(b)(2)\n approval pathway and global equivalent processes. By assessing the scientific, medical, regulatory, and commercial viability of product development\n opportunities, Camargo systematically builds and executes robust development plans that align with business strategies and ensure Agency buy-in every\n step of the way. With alignment through pre-Investigational New Drug (pre-IND) meeting planning and preparations, Camargo maintains and ensures consistency\n throughout the drug development program, which increases the likelihood of NDA and future market success. Routinely holding three to six pre-IND meetings\n a month, Camargo works with product developers across more than 25 countries. For more about Camargo Pharmaceutical Services, visit http://camargopharma.com\n

\n

 

\n
\n

 

\n

 

", "itemId": 8063910, "name": "Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-and-camargo-prepare-for-meeting-with-fda-to-advance-anti-nausea-patch", "url": "/en/news/aequus-and-camargo-prepare-for-meeting-with-fda-to-advance-anti-nausea-patch", "releaseDate": "2018-01-31T00:00:00", "releaseDate_raw": "2018-01-31T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T15:14:06.25", "lastUpdateDate_raw": "2018-07-27T08:14:06.25", "counter": 26, "weight": 20180131, "commentCount": 0, "editUrl": "/en/news/aequus-and-camargo-prepare-for-meeting-with-fda-to-advance-anti-nausea-patch?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8063910&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

 

\n

FORWARD-LOOKING STATEMENT DISCLAIMER

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”,“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: expected benefits of AQS1303 and transdermal delivery, the further advancement of AQS1303, the regulatory requirements for AQS1303, and the Company’s ability to form strategic partnerships for its internal programs. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.\n

\n

Diclegis® and Diclectin® are registered trademarks of Duchesnay Inc.

\n

 

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

CONTACT INFORMATION

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES

\n

VANCOUVER, BC. January 25, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”\n or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting\n differentiated products, is pleased to announce that, further to its news release dated January 11, 2018 announcing a proposed $300,000 equity financing,\n it now intends to complete the equity financing of 1,000,000 units of the Company (the \"Units\") at a price of $0.30 per Unit (the \"Offering Price\"),\n for aggregate gross proceeds of $300,000 (the \"Offering\") to a single subscriber that has recently been engaged by Aequus as a branding and marketing\n consultant under a prospectus supplement to the Company’s base shelf prospectus dated August 15, 2017, which prospectus supplement will be filed in\n the provinces of British Columbia, Alberta, Ontario, Saskatchewan and Manitoba. Each Unit shall consist of one common share of the Company and one\n non-transferrable common share purchase warrant (each, a \"Warrant\"). Each Warrant shall entitle the holder thereof to purchase one common share at\n an exercise price of $0.50 for a period of twenty-four (24) months following the Closing Date. The Warrants will include an acceleration provision,\n exercisable at the Company’s option, if the Company's daily volume weighted average share price is greater than $0.85 for 10 consecutive trading days. \n
\n

\n

Aequus intends to use the net proceeds of the Offering for general corporate purposes, including branding and marketing. Securities issued under the Offering\n will be \"restricted securities\" as defined in U.S. federal securities laws. The Offering is expected to close on or about the week of January 29, 2018.\n Completion of the Offering subject to a number of conditions, including the execution of definitive documentation and receipt of any required regulatory\n approvals, including receipt of the approval of the TSX Venture Exchange for the listing of the common shares issuable on closing and issuable upon\n the exercise of the Warrants.

\n

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, and may not be\n offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not\n constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such\n offer, solicitation or sale would be unlawful.

\n

About Aequus Pharmaceuticals

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its\n current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or\n brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

 

", "itemId": 8055313, "name": "Aequus Announces Change to Proposed $300,000 Equity Financing", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-change-to-proposed-300-000-equity-financing", "url": "/en/news/aequus-announces-change-to-proposed-300-000-equity-financing", "releaseDate": "2018-01-25T00:00:00", "releaseDate_raw": "2018-01-25T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T13:58:44.797", "lastUpdateDate_raw": "2018-08-01T06:58:44.797", "counter": 27, "weight": 20180125, "commentCount": 0, "editUrl": "/en/news/aequus-announces-change-to-proposed-300-000-equity-financing?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8055313&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the Offering, including the use of proceeds of the Offering and the successful completion of the Offering; and the Company’s intention to commercialize its internal programs in Canada, form strategic partnerships and build its Canadian commercial platform. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully market it services and in-license and develop new products, the assumption that the Company’s current good relationships with third party suppliers or service providers will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated May 1, 2017, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com , and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "\n

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

\n" }, { "description": "

CannaRoyalty to contribute Bodhi Research position into the JV in exchange for equity

\n

Ottawa, Canada – January 11, 2018 – CannaRoyalty Corp. (CSE: CRZ) (OTCQX: CNNRF) (“CannaRoyalty”) and Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) (“Aequus”) (together the “Partners”), today announced a collaboration (the “JV”) to advance a suite of cannabis-based therapies targeting neurological\n disorders into clinical trials in Canada, in collaboration with Canadian doctors and key opinion leaders.

\n

CannaRoyalty and Aequus have formed this collaboration to clinically advance a number of cannabis-based therapies in partnership with Canadian clinicians\n to create truly differentiated products supported by clinical data focused on the medical community. The collaboration will leverage CannaRoyalty’s\n deep expertise in identifying, funding and commercializing cannabis related products in California and Aequus’ expertise in clinical development and\n drug delivery, and commercializing differentiated therapeutics in Canada.

\n

CannaRoyalty intends to contribute its 10% equity stake in Bodhi Research & Development Inc. (“Bodhi”) into the JV in exchange for an initial ownership\n position in the JV, subject to conditions and approvals. CannaRoyalty made a $250,000 investment in Bodhi in 2016 in exchange for 10% equity in the\n company. Bodhi has completed a research trial into the use of cannabis in the treatment of concussion and post-concussive syndrome. The JV has been\n identifying additional capital from third-party investors that will be invested directly into the collaboration and used to advance those clinical\n trial programs that the Partners agree to fund.

\n

“We see a significant opportunity for validated, research-based data regarding cannabinoid-based treatments and commend the group at Bodhi for the progress\n they have made to date,” said Marc Lustig, CEO of CannaRoyalty. “In the near-term, the JV will provide Bodhi with the drug development and commercial\n expertise to progress its research toward further validation and commercialization, while freeing-up our in-house team to continue building our leading\n platform of value-add cannabis businesses in California. I intend to commit significant personal capital as a lead third-party investor and I expect\n CannaRoyalty shareholders to benefit in several ways from the JV: continued progress at Bodhi; exposure to an expanded range of cannabis-based therapies\n targeted at neurological disorders; the potential for CannaRoyalty to introduce proven in-house and investee products to the JV over time; and the\n potential to introduce JV-developed products through CannaRoyalty’s growing distribution network.”

\n

Doug Janzen, CEO of Aequus added, “Aequus and CannaRoyalty have complementary business models and geographic focuses, and we are excited about the potential\n for this collaboration to offer patients in Canada and California differentiated and clinically validated cannabis-based therapeutics targeting a number\n of neurological conditions. We have been in discussions with Canadian clinicians with extensive experience in treating patients with cannabis-based\n therapies for their neurological and pain-based conditions. We see the opportunity to collaborate with these clinicians to identify and advance the\n most efficacious formulations into clinical trials to validate safety and efficacy.”

\n

Mr. Janzen continued, “In a 2017 survey we completed with 400 specialists and general practitioners in Canada and the US, the lack of clinical safety and\n efficacy data and dosing data were the top reasons why clinicians were reluctant to recommend cannabis to their patients. We see a clear opportunity\n through this JV with CannaRoyalty to meet the requests of the clinical community by providing improved forms of dosing, clinical data showing safety\n and efficacy, and then working closely to commercialize these validated products in Canada through our existing sales infrastructure and relationships\n with Licensed Producers and potentially elsewhere, where Aequus and CannaRoyalty and our various partners operate.”

\n

About Bodhi

\n

Bodhi Research and Development, Inc. is an Ontario-based research company that is conducting research trials for exploring the use of cannabis in the treatment\n of concussions and post-concussive syndromes. Bodhi's research has been done in collaboration with some of the world's foremost experts in concussions\n and pain management.

\n

About CannaRoyalty

\n

CannaRoyalty is an active investor and operator in the legal cannabis industry. Our focus is building and supporting\n a diversified portfolio of growth-ready assets in high-value segments of the cannabis sector, including research, consumer brands, devices and intellectual\n property. Our management team combines a hands-on understanding of the cannabis industry with seasoned financial know-how, assembling a platform of\n holdings via royalty agreements, equity interests, secured convertible debt, licensing agreements and its own branded portfolio. CannaRoyalty’s shares\n trade on the Canadian Stock Exchange (CSE) under the symbol CRZ and internationally on the OTCQX under the symbol CNNRF.

\n

About Aequus Pharmaceuticals Inc.\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes\n several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.\n With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis,\n where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that\n would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional\n products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.\n For further information, please visit www.aequuspharma.ca.\n

", "itemId": 8044917, "name": "CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders", "urlWithHost": "http://www.aequuspharma.ca/en/news/cannaroyalty-and-aequus-pharmaceuticals-announce-joint-venture-to-develop-and-commercialize-cannabis", "url": "/en/news/cannaroyalty-and-aequus-pharmaceuticals-announce-joint-venture-to-develop-and-commercialize-cannabis", "releaseDate": "2018-01-11T00:00:00", "releaseDate_raw": "2018-01-11T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:16:05.373", "lastUpdateDate_raw": "2018-08-01T07:16:05.373", "counter": 28, "weight": 20180111, "commentCount": 0, "editUrl": "/en/news/cannaroyalty-and-aequus-pharmaceuticals-announce-joint-venture-to-develop-and-commercialize-cannabis?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8044917&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward Looking Statements

\n

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CannaRoyalty's and Aequus’ periodic filings with Canadian securities regulators. When used in this news release, words such as \"will, could, plan, estimate, expect, intend, may, potential, believe, should,\" and similar expressions, are forward- looking statements.

\n

Forward-looking statements may include, without limitation, statements including the CannaRoyalty’s and Aequus’ expectations with respect to pursuing new opportunities and future growth and other statements of fact.

\n

Although CannaRoyalty and Aequus have attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US Federal Laws; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

\n

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

\n

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CannaRoyalty and Aequus disclaim any intention or obligation to update or revise such information, except as required by applicable law, and CannaRoyalty and Aequus do not assume any liability for disclosure relating to any other company mentioned herein.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

For further inquiries, please contact:

\n

CannaRoyalty:

\n

Marc Lustig, CEO\n
info@cannaroyalty.com\n
1-844-556-5070\n
www.cannaroyalty.com

\n

Jonathan Ross, CFA\n
LodeRock Advisors Inc.\n
jon.ross@loderockadvisors.com
416-283-0178

\n

Aequus:

\n

Aequus Investor Relations\n
investors@aequuspharma.ca\n
604-336-7906

" }, { "description": "

VANCOUVER, BC. January 11, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”\n or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting\n differentiated products, is pleased to announce that it intends to complete a non-brokered private placement of 1,000,000 units of the Company (the\n \"Units\") at a price of $0.30 per Unit (the \"Offering Price\"), for aggregate gross proceeds of $300,000 (the \"Private Placement\") to a single subscriber\n that has recently been engaged by Aequus as a branding and marketing consultant. Each Unit shall consist of one common share of the Company and one\n non-transferrable common share purchase warrant (each, a \"Warrant\"). Each Warrant shall entitle the holder thereof to purchase one common share at\n an exercise price of $0.50 for a period of twenty-four (24) months following the Closing Date. The Warrants will include an acceleration provision,\n exercisable at the Company’s option, if the Company's daily volume weighted average share price is greater than $0.85 for 10 consecutive trading days.\n

\n

Aequus intends to use the net proceeds of the Offering for general corporate purposes. Securities issued under the Private Placement will be subject to\n a four month hold period in Canada following the date of closing and will be \"restricted securities\" as defined in U.S. federal securities laws. The\n Private Placement is expected to close on or about the week of January 22nd, 2018. Completion of the Private Placement subject to a number of conditions,\n including the execution of definitive documentation and receipt of any required regulatory approvals, including receipt of the approval of the TSX\n Venture Exchange for the listing of the common shares issuable on closing and issuable upon the exercise of the Warrants.

\n

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, and may not be\n offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not\n constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such\n offer, solicitation or sale would be unlawful.

\n

About Aequus Pharmaceuticals \n

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its\n current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or\n brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

 

\n

 

\n

 

", "itemId": 8044916, "name": "Aequus Announces Proposed $300,000 Equity Financing", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-proposed-300-000-equity-financing", "url": "/en/news/aequus-announces-proposed-300-000-equity-financing", "releaseDate": "2018-01-11T00:00:00", "releaseDate_raw": "2018-01-11T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T15:28:05.783", "lastUpdateDate_raw": "2018-07-27T08:28:05.783", "counter": 29, "weight": 20180110, "commentCount": 0, "editUrl": "/en/news/aequus-announces-proposed-300-000-equity-financing?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=8044916&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the Private Placement, including the use of proceeds of the Private Placement and the successful completion of the Private Placement; and the Company’s intention to commercialize its internal programs in Canada, form strategic partnerships and build its Canadian commercial platform. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. \n

", "Forward-Looking Statement Disclaimer 2": "

In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully out-license or sell its current products and in-license and develop new products, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated May 1, 2017, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com , and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements. SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of

", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

VANCOUVER, December 8, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),\n a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the issuance of stock\n options to directors, officers, staff and consultants. The stock options give the holders the right to purchase up to an aggregate of 2,302,941 common\n shares of the Company. These stock options are exercisable at a price of $0.195 per share, for a term of eight years, and vest in tranches over 2 to\n 3 year periods. The terms of the stock options granted on December 7, 2017 are in accordance with the Company’s Stock Option Plan.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes\n several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.\n With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis,\n where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that\n would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional\n products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.\n For further information, please visit www.aequuspharma.ca.\n

\n
\n

 

\n

 

", "itemId": 7998393, "name": "Aequus announces the issuance of stock options", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-the-issuance-of-stock-options", "url": "/en/news/aequus-announces-the-issuance-of-stock-options", "releaseDate": "2017-12-08T00:00:00", "releaseDate_raw": "2017-12-08T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T15:48:30.143", "lastUpdateDate_raw": "2018-07-27T08:48:30.143", "counter": 30, "weight": 20171208, "commentCount": 0, "editUrl": "/en/news/aequus-announces-the-issuance-of-stock-options?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7998393&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

CONTACT INFORMATION

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

VANCOUVER, November 29, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),\n a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for\n the three months ended September 30, 2017 and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.

\n

Corporate and Commercial Highlights

\n

The Company continues to grow revenues from its Canadian commercial arm through the on-going promotion of Vistitan™ and Tacrolimus IR. Vistitan™\n (bimatoprost 0.03%) is a treatment for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension,\n a market estimated to be over $185 million in 2015 in Canada. Since its launch, and with the support of Aequus’ promotional efforts, Vistitan™\n has been successfully listed among 90% of private payor groups as well as a benefit under key provincial formularies, including the Ontario Drug Benefit\n Plan, Alberta Health and Manitoba Health. Tacrolimus IR is the first to market, and currently the only available generic version of tacrolimus immediate\n release in Canada, a product used for the treatment and prevention of acute rejection following organ transplantation. Tacrolimus IR, promoted by Aequus,\n continues to grow as it gains market share from branded tacrolimus alternatives. Aequus splits revenues of these two products with its partner based\n on a tiered royalty structure.

\n

Revenue for the current quarter was $291,154, a 56% increase compared to revenues of $186,586 in the immediately preceding second quarter of 2017. Aequus\n recorded a decrease of 13% in net loss compared to the same quarter in 2016, primarily due to continued efforts to optimize general and administration\n spending as well as sales force efficiencies achieved throughout the reported period.\n
\n

\n

Aequus plans to launch an additional product in ophthalmology that is currently under review by Health Canada, through a previously announced partnership\n with Santen. This product is expected to enter into a growing market that is currently valued at approximately $72 million in Canada, according to\n 2016 IMS data. This launch will leverage our existing commercial ophthalmology infrastructure and build on the relationships we have established with\n Canadian Key Opinion Leaders and therapeutic specialists. The Company also continues to work with Health Canada on the submissions for the once-daily,\n extended-release versions of topiramate and oxcarbazepine, licensed from Supernus for the Canadian market.\n
\n

\n

Aequus continues to advance creative business development discussions and expects to further maximize the efficiency and revenue generated by its specialty\n sales force with additional complementary products.\n
\n

\n

Development Highlights\n
\n

\n

During the reported quarter, Aequus advanced the long-acting transdermal doxylamine/pyridoxine combination patch program, AQS1303, for the treatment of\n nausea and vomiting in pregnancy through an initial proof of concept clinical study that was initiated in July 2017. Results from this study suggested\n that sustained delivery of therapeutic levels of the active ingredients through the skin over a multi-day period is possible with the current formulation.\n The formulation was well tolerated with no serious adverse events reported.

\n

The Company also received positive feedback from the US Food and Drug Administration (“FDA”) in a pre-Investigational Drug Application (“pre-IND”) meeting\n for the Company’s lead development program, AQS1301, a once-weekly transdermal formulation of aripiprazole. Upon review of the Company’s pre-IND submission,\n the FDA agreed that AQS1301 is a suitable candidate for the 505(b)2 abbreviated regulatory pathway for approval in the United States. Aequus has also\n since expanded the patent portfolio for this program with a patent granted in China which adds to the previously issued/allowed countries or regions\n namely the United States, Russia, Mexico, Japan, Australia and Canada with several other major markets pending.

\n

Aequus has accelerated business development discussions for AQS1301 and AQS1303 in response to inbound interest following the successful completion of\n both Proof of Concept studies, and will look to execute regional partnerships in the first half of 2018.

\n

In connection with the Company’s previously announced medical cannabis program, Aequus formed a collaboration with Scientus Pharma, Inc. (“Scientus”) to\n be the development and commercial supplier of specific cannabinoid extracts, with an option for Scientus to co-fund the development of a cannabinoid\n containing transdermal formulation that would be designed and optimized to address certain neurological disorders. Additionally, the Company entered\n into a collaboration with Ehave, Inc. (“Ehave”) to access Ehave’s bioinformatics platform, providing cost effective and clinically relevant data collection\n in Aequus’ anticipated clinical trials in the medical cannabis regulatory regime.

\n

“We continue to stay focused on our growth trajectory in specialty therapeutic areas, listening to the needs of our clinical customers. Our strategy is to leverage Canadian revenues to fund new product development concepts informed by our clinician customer base, for which we would own global rights,” said Doug Janzen, CEO and Chairman of Aequus. “Our primary focus for the remainder of 2017 and 2018 is to continue to build revenues, which we expect will come from the existing base business, the Santen product launch, other potential in-licensing transactions currently under discussion, as well as the out-licensing efforts from our development programs.”

\n

FINANCIAL STATEMENTS AND MD&A\n
\n

\n

Investors are encouraged to review Aequus’ complete Condensed Consolidated Interim Financial Statements and Management’s Discussion and Analysis (“MD&A”)\n for the three and nine months ended September 30, 2017, which are available on the Company’s website at www.aequuspharma.ca and on SEDAR at www.sedar.com.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes\n several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.\n With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis,\n where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that\n would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional\n products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.\n For further information, please visitwww.aequuspharma.ca.\n

\n
\n

 

", "itemId": 7988319, "name": "Aequus Provides Third Quarter 2017 Operational Highlights", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-provides-third-quarter-2017-operational-highlights", "url": "/en/news/aequus-provides-third-quarter-2017-operational-highlights", "releaseDate": "2017-11-29T00:00:00", "releaseDate_raw": "2017-11-29T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T16:36:31.15", "lastUpdateDate_raw": "2018-07-27T09:36:31.15", "counter": 31, "weight": 20171129, "commentCount": 0, "editUrl": "/en/news/aequus-provides-third-quarter-2017-operational-highlights?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7988319&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

FORWARD-LOOKING STATEMENT DISCLAIMER

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”,“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; the Company’s expected revenues; the timing of public listings; the timing of results of the Company’s transdermal pyridoxine/doxylamine program’s Proof of Concept clinical study; the Company’s potential regional partnerships for its internal programs; the timing of public reimbursement decisions for VistitanTM; the regulatory requirements for the its transdermal aripiprazole program; and the Company’s expectations regarding the medical cannabis portfolio. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.\n
\n

\n

VistitanTM: Trademark owned or used under license by Sandoz Canada Inc.

\n

 

\n

 

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

CONTACT INFORMATION

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

VANCOUVER, BC. November 16th, 2017 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“\n Aequus ” or the “Company”), a specialty pharmaceutical company with a focus on developing,\n advancing and promoting differentiated products, announced today that the European Patent Office has issued an intention to grant a European patent\n for AQS1301, Aequus’ once-weekly transdermal patch containing aripiprazole. AQS1301 is in development for the treatment of certain psychiatric\n disorders and is intended to provide patients with a long-acting dosing alternative that is a comfortable, convenient and easy-to-use in an effort\n to promote medication adherence.

\n

This is the eighth regional patent issued or granted for AQS1301, following US, Russia, Mexico, Japan, China, Canada and Australia.

\n

“With this patent, Aequus has now achieved intellectual property that spans across all major pharmaceutical markets for its once-weekly transdermal aripiprazole\n program,” said Anne Stevens, COO and Director of Aequus Pharmaceuticals. “This patent grant coincides nicely with our accelerated business development\n efforts, as we look to further develop this program in collaboration with regional partners.”

\n

This patent covers 37 nations across Europe and provides intellectual property protection in the second largest antipsychotic market globally, a market\n where peak sales of Abilify® (branded oral aripiprazole) reached approximately $750 million USD in 2013 before patent expiry, according\n to IMS data. Although Abilify® is a market leader, Aequus believes it has limitations due to its daily dosing regimen which is associated\n with a high rate of non-adherence and associated likelihood of relapse due to non-adherence. Aequus’ proposed transdermal, once-weekly aripiprazole\n patch is designed to consistently deliver aripiprazole over a seven-day period at levels comparable to currently marketed once-daily formulations.\n

\n

Aequus owns worldwide rights to the formulation described in the patent.

\n

About AQS1301

\n

Aripiprazole is an atypical anti-psychotic sold as a once daily, oral tablet under the brand name Abilify®. Originally approved and marketed\n in 2002 for schizophrenia, Abilify® is currently sold in over 65 countries and regions. Since its initial approval, aripiprazole has seen\n a label expansion in the United States to include acute treatment of manic and mixed episodes associated with bipolar I, adjunctive treatment of major\n depressive disorder, irritability associated with autistic disorder, and treatment of Tourette’s disorder.

\n

Aequus successfully completed an initial Proof of Concept clinical study for AQS1301 in December 2015, demonstrating that sustained, seven-day delivery\n of therapeutic doses may be possible with the current formulation. A follow-on Proof of Concept clinical study in healthy volunteers was completed\n in February 2017, demonstrating that steady state plasma concentrations were achieved by week three with relative concentrations of\n aripiprazole and its active metabolite, dehydroaripiprazole, comparable to oral dosing of Abilify®.

\n

About Aequus Pharmaceuticals\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS,OTCQB:\n AQSZF)is a growing specialty pharmaceutical\n company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes several products\n in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. With a focus in\n neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is\n a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal\n programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize\n the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products\n that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For\n further information, please visit www.aequuspharma.ca

\n

 

", "itemId": 7970126, "name": "Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-granted-european-patent-for-once-weekly-transdermal-aripiprazole", "url": "/en/news/aequus-granted-european-patent-for-once-weekly-transdermal-aripiprazole", "releaseDate": "2017-11-16T00:00:00", "releaseDate_raw": "2017-11-16T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T16:00:27.317", "lastUpdateDate_raw": "2018-07-27T09:00:27.317", "counter": 32, "weight": 20171116, "commentCount": 0, "editUrl": "/en/news/aequus-granted-european-patent-for-once-weekly-transdermal-aripiprazole?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7970126&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n
This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to the expected benefits of AQS1301 and transdermal delivery, the ability of the Company to add significant shareholder value in the near term, the Company’s intention to commercialize its internal programs in Canada, ability to form strategic partnerships in other markets, and the advancement of its technologies, products and product candidates. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to the market for Aequus’ common shares, preferred shares, debt securities, subscription receipts, units and warrants; obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully out-license or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated May 3, 2017, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n
\n
Abilify® is a registered trademark of Otsuka Pharmaceutical Co., Ltd.\n
", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

Continues to build patent portfolio and strengthen protection for antipsychotic transdermal program following completion of proof of concept clinical trials\n

\n

VANCOUVER, BC. October 10th, 2017 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“\n Aequus\n ” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting\n differentiated products, announced today that the State Intellectual Property Office of the People’s Republic of China (SIPO) has granted a Chinese\n patent for Aequus’ once-weekly transdermal patch containing aripiprazole, in development for the treatment of certain psychiatric disorders. The\n patent, granted under No. 201180052667.0, is titled “Aripiprazole compositions and methods for its transdermal delivery”. This patent has been\n granted in six other major countries or regions, including the US, Russia, Mexico, Japan, Canada and Australia, and is pending in multiple additional\n territories.\n
\n

\n

“We continue to globally expand and strengthen our patent portfolio for our once-weekly transdermal aripiprazole program,” said Anne Stevens, COO and Director\n of Aequus Pharmaceuticals. “This Chinese patent not only secures key elements of our formulation in a significant market, it also expands regional\n out-licensing and partnering opportunities. This comes at an important time as we accelerate our business development efforts for this program, a key\n initiative for increasing shareholder value.”

\n

Aequus owns worldwide rights to the formulation described in the issued patent.

\n

About AQS1301\n
\n

\n

Aripiprazole is an atypical anti-psychotic sold as a once daily, oral tablet under the brand name Abilify®. Originally approved and marketed\n in 2002 for schizophrenia, Abilify® is currently sold in over 65 countries and regions. Since its initial approval, aripiprazole has seen\n a label expansion in the United States to include acute treatment of manic and mixed episodes associated with bipolar I, adjunctive treatment of major\n depressive disorder, irritability associated with autistic disorder, and treatment of Tourette’s disorder. Although Abilify® is a market\n leader in the US, Aequus believes it has limitations due to its daily dosing regimen which is associated with a high rate of non-adherence and relapse.\n Aequus’ proposed transdermal, once-weekly aripiprazole patch is designed to consistently deliver aripiprazole over a seven-day period at levels comparable\n to currently marketed once-daily formulations. By delivering aripiprazole over seven days in a comfortable, convenient and easy-to-use weekly patch,\n AQS-1301 is intended to promote enhanced patient compliance.

\n

About Aequus Pharmaceuticals\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS,OTCQB:\n AQSZF)is a growing specialty pharmaceutical\n company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes several products\n in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. With a focus in\n neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is\n a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal\n programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize\n the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products\n that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For\n further information, please visit www.aequuspharma.ca\n

", "itemId": 7924377, "name": "Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-granted-chinese-patent-for-once-weekly-transdermal-aripiprazole", "url": "/en/news/aequus-granted-chinese-patent-for-once-weekly-transdermal-aripiprazole", "releaseDate": "2017-10-10T00:00:00", "releaseDate_raw": "2017-10-10T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2017-10-10T09:34:27.76", "lastUpdateDate_raw": "2017-10-11T02:34:27.76", "counter": 33, "weight": 20171010, "commentCount": 0, "editUrl": "/en/news/aequus-granted-chinese-patent-for-once-weekly-transdermal-aripiprazole?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7924377&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact,including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to the expected benefits of AQS1301 and transdermal delivery, the ability of the Company to add significant shareholder value in the near term, the Company’s intention to commercialize its internal programs in Canada, ability to form strategic partnerships in other markets, and the advancement of its technologies, products and product candidates. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to the market for Aequus’ common shares, preferred shares, debt securities, subscription receipts, units and warrants; obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully out-license or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated May 3, 2017, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

Abilify® is a registered trademark of Otsuka Pharmaceutical Co., Ltd.\n

\n

 

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

Vancouver, BC. September 7, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),\n a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced positive results from an\n initial Proof of Concept clinical study for its long-acting transdermal anti-nausea patch, AQS1303, containing the combination of pyridoxine hydrochloride\n and doxylamine succinate (the active ingredients in Diclegis®/Diclectin®). This single-dose cross-over comparative bioavailability study versus the\n currently approved oral version, Diclegis®/Diclectin®, was successfully completed in nine healthy female volunteers. The results suggested that sustained\n delivery of therapeutic levels of the active ingredients through the skin over a multi-day period is possible with the current formulation. The formulation\n was well tolerated with no serious adverse events reported.

\n

“We are greatly encouraged by the results of this initial Proof of Concept clinical study and believe the study clearly demonstrated the feasibility of\n a fixed dose combination patch containing doxylamine and pyridoxine for the treatment of nausea and vomiting of pregnancy,” said Dr. Donald McAfee,\n Chief Scientific Officer of Aequus.

\n

“We are very excited about the potential for this product and these initial results bring us one step closer to providing an elegant solution for pregnant\n women suffering from nausea and vomiting,” said Doug Janzen, CEO and Chairman of Aequus. “We look forward to the continued advancement of this program\n and will be engaging with both potential partners and the FDA over the coming months.”

\n

AQS1303 is a long-acting transdermal patch intended for the treatment of nausea and vomiting of pregnancy (“NVP”). AQS1303 would provide patients with\n a more convenient and reliable delivery system as an alternative to the currently marketed oral form, which is dosed up to four times per day. Currently,\n the oral form of Diclegis® is the only FDA approved medication for morning sickness in pregnant women and in 2015 reached sales in the United States\n of approximately U.S.$120 million, according to IMS data. A long-acting transdermal form of pyridoxine/doxylamine is being developed by Aequus to address\n the risk of missed doses due to emesis (vomiting) and to provide consistent and sustained symptomatic relief.

\n

The primary objectives for the Proof of Concept study was to assess the bioavailability, safety and tolerability of Aequus’ long-acting transdermal formulation\n containing doxylamine succinate and pyridoxine hydrochloride compared to that of a single oral dose of Diclegis®. Aequus will incorporate the results\n from this study into a pre-Investigational New Drug (pre-IND) submission with the US Food and Drug Administration (FDA) to define the clinical strategy\n for regulatory approval in the US. This product is expected to follow a Section 505(b)2 New Drug Application (NDA), an abbreviated clinical pathway\n in which the FDA would allow for the Company to reference safety and efficacy data of the original oral tablet form of the medication. Aequus owns\n the global rights to this program, and will look to find a strategic partner to advance towards commercialization in major markets.

\n

ABOUT AEQUUS PHARMACEUTICALS

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes\n several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.\n Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to\n form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform\n through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on\n highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

", "itemId": 7888431, "name": "Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-positive-results-for-proof-of-concept-clinical-trial-of-anti-nausea-patch", "url": "/en/news/aequus-announces-positive-results-for-proof-of-concept-clinical-trial-of-anti-nausea-patch", "releaseDate": "2017-09-07T00:00:00", "releaseDate_raw": "2017-09-07T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:01:19.877", "lastUpdateDate_raw": "2018-08-01T07:01:19.877", "counter": 34, "weight": 20170907, "commentCount": 0, "editUrl": "/en/news/aequus-announces-positive-results-for-proof-of-concept-clinical-trial-of-anti-nausea-patch?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7888431&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: expected benefits of AQS1303 and transdermal delivery, the further advancement of AQS1303, and the Company’s ability to form strategic partnerships for its internal programs. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to general business and economic conditions and the anticipated results of the Phase I clinical trial. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Short-Form Prospectus dated June 30, 2015, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

CONTACT INFORMATION

\n

Aequus Investor Relations

\n

Email: investors@aequuspharma.ca

\n

Phone: 604-336-7906

" }, { "description": "

VANCOUVER, August 29, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical\n company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended June\n 30, 2017 and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.

\n

Key Highlights\n

\n\n\n\n\n\n\n

Commercial Activities\n

\n\n

Since the initiation of Aequus’ promotional efforts in December 2015, the generic version of the most commonly used dose of tacrolimus IR (1mg) has experienced\n growth of 103% to date and continues to gain market share from branded tacrolimus alternatives.Since the launch of Vistitan™ in April 2016, and\n with the support of Aequus’ promotional efforts, Vistitan™ has been successfully listed among 90% of private payor groups as well as a benefit\n under key provincial formularies, including the Ontario Drug Benefit Plan, Alberta Health and Manitoba Health.

\n

The Company expects revenues from the promotional activities of these two products to continue to grow in the current year as they continue to penetrate\n market share held by the branded equivalent and similar medications within the class.

\n

In Q2 2017, the Company added to its commercial pipeline as it entered into a promotional agreement with Santen, a market leader in Japan for prescription\n ophthalmology therapies, where Aequus will build on its existing sales infrastructure to promote and support the launch of an undisclosed ophthalmology\n product which is currently under review by Health Canada.

\n

\"The agreement with Santen that we entered into this quarter reinforces our commitment to provide patients with high-quality therapeutics, and adds to the commercial ophthalmology franchise we have been building at Aequus since the launch of Vistitan in 2016,” said Doug Janzen, CEO and Chairman of Aequus. “We look forward to seeing continued growth on the revenue side of our business as we look to add additional products in the near term.\"\n

\n

Development Program Activities\n

\n

The Company incurred research and development (“R&D”) expenses of $581,670 in Q2 2017 as compared to $291,748 in Q2 2016. The increase was attributable\n to the Company completing the follow-on Proof of Concept clinical study for AQS 1301 (a once-weekly transdermal formulation of aripiprazole), the preparation\n for and attendance of the AQS1301 Pre-IND Meeting, the development of clinical trial materials and the initiation of the Proof of Concept study for\n AQS1303 (a long-acting transdermal anti-nausea patch).

\n

The Company recently completed its Proof of Concept study for AQS1303 and expects results to be announced within the current quarter.

\n

The Company continued to progress its cannabinoid development program since licensing the rights to a cannabinoid transdermal patch in the first quarter\n of 2017. The Company entered into a research collaboration for cannabinoid-based therapeutics with the Centre for Drug Research and Development in\n the quarter to establish pre-clinical safety and efficacy of select cannabinoid-based therapeutics targeting neurological movement disorders. The Company\n further validated the need for improved delivery methods, quality controlled ingredients, and clinical data to support safety and efficacy in key therapeutic\n areas through a market research survey involving 410 physicians in both Canada and the United States in the quarter. These activities have allowed\n The Company to calibrate its approach to the burgeoning sector to ensure value is brought to both patient and physician in this unique therapeutic\n space.

\n

Since the end of Q2 2017, the Company announced a strategic supply agreement with Scientus, a biopharmaceutical company focused on R&D and product\n commercialization for extracts and formulations related to medical cannabinoids; and a collaboration around clinical trial management with Ehave, a\n healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools. Aequus\n looks to continue to build on this momentum in the coming quarters.

\n

FINANCIAL STATEMENTS AND MD&A

\n

Investors are encouraged to review Aequus’ complete Financial Statements and Management’s Discussion and Analysis (“MD&A”) for the three and six months\n ended June 30, 2017, which are available on the Company’s website at www.aequuspharma.ca and on SEDAR\n at www.sedar.com.

\n

ABOUT AEQUUS PHARMACEUTICALS INC.

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB:  AQSZF ) is a growing\n specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline\n includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery\n systems. With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical\n cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that\n would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional\n products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.\n For further information, please visit   www.aequuspharma.ca .\n

", "itemId": 7883211, "name": "Aequus Provides Second Quarter 2017 Operational Highlights", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-provides-second-quarter-2017-operational-highlights", "url": "/en/news/aequus-provides-second-quarter-2017-operational-highlights", "releaseDate": "2017-08-29T00:00:00", "releaseDate_raw": "2017-08-29T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:12:31.48", "lastUpdateDate_raw": "2018-08-01T07:12:31.48", "counter": 35, "weight": 20170829, "commentCount": 0, "editUrl": "/en/news/aequus-provides-second-quarter-2017-operational-highlights?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7883211&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; the Company’s expected revenues; the timing of public listings; the timing of results of the Company’s transdermal pyridoxine/doxylamine program’s Proof of Concept clinical study; the Company’s potential regional partnerships for its internal programs; the timing of public reimbursement decisions for VistitanTM; the regulatory requirements for the its transdermal aripiprazole program; and the Company’s expectations regarding the medical cannabis portfolio. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements. VistitanTM: Trademark owned or used under license by Sandoz Canada Inc.\n

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

CONTACT INFORMATION

\n

Aequus Investor Relations

\n

Email: investors@aequuspharma.ca

\n

Phone: 604-336-7906

" }, { "description": "

VANCOUVER, BC. August 24, 2017 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),\n a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has received\n positive feedback from the US Food and Drug Administration (FDA) to pursue the abbreviated 505(b)(2) clinical pathway for the company’s once-weekly\n transdermal aripiprazole patch, AQS1301, in development for the treatment of certain psychotic disorders.

\n

Upon review of the Company’s pre-Investigational New Drug Application (Pre-IND) submission, the FDA agreed that AQS1301 is a suitable candidate for the\n 505(b)(2) regulatory pathway for approval in the United States. The FDA advised that a relative bioavailability (BA) study in patients comparing steady\n state pharmacokinetic (PK) between AQS1301 and the oral form would be acceptable if bioequivalence is established. This would provide a bridge to the\n aripiprazole safety and efficacy data from the approved Abilify® label at the target therapeutic doses. The FDA outlined additional standard\n studies required of a transdermal reservoir patch to evaluate the local safety and to ensure that consistent and predictable dosing is maintained over\n the seven day dosing period without leakage or damage while being worn. Aequus’ development and manufacturing partner, Corium International, Inc. (NASDAQ:\n CORI) has extensive experience in the area of developing and manufacturing commercial stage transdermal patches meeting FDA requirements.

\n

“We are encouraged by the feedback from the FDA on the acceptability of an abbreviated clinical path forward for AQS1301,” said Anne Stevens, Chief Operating\n Officer and Director of Aequus. “This provides validation for our organization to accelerate partnership discussions for this program as we look to\n collaboratively advance AQS1301 through clinical studies.”

\n

“The outcome of the interaction with the FDA provides clarity on the requirements for Aequus and the development goals for AQS1301 in order to achieve\n FDA approval under 505(b)(2),” said Gary Barnette, Senior Vice President of Scientific and Regulatory Affairs, Camargo Pharmaceutical Services, LLC.\n “We are pleased to be partnered with Aequus and to assist in achieving this important milestone.”

\n

Aequus owns the global rights to this program, and will look to find a strategic partner to advance AQS1301 through the planned clinical studies and towards\n commercialization in major markets.

\n

A Section 505(b)(2) NDA is a new drug application in which the FDA and applicant may rely on certain investigations of safety and effectiveness that were\n previously conducted by someone other than the applicant, and is often applicable to an active drug substance that has previously been approved in\n a different dosage form.

\n

About AQS1301

\n

Aripiprazole is an atypical anti-psychotic sold under the brand name Abilify®. Originally approved and marketed in 2002 for schizophrenia, Abilify® is currently sold in over 65 countries and regions. Since its initial approval, aripiprazole has seen a label expansion in the United States to include\n acute treatment of manic and mixed episodes associated with bipolar I, adjunctive treatment of major depressive disorder, irritability associated with\n autistic disorder, and treatment of Tourette’s disorder. In 2015, Abilify® saw its first generic competition in the USA as its patent exclusivity\n expired. For 2015, aripiprazole US sales totaled $6.3 billion, with branded Abilify® representing 70% of sales revenues. Aripiprazole remains\n one of the most commonly prescribed anti-psychotics globally, with the compound currently available in oral tablets, oral solution, and intramuscular\n injection.

\n

 

\n

AQS1301 is designed to consistently deliver aripiprazole over a seven-day period at levels comparable to currently marketed once-daily formulations. By\n delivering aripiprazole over seven days in a comfortable, convenient and easy-to-use weekly patch, AQS1301 is intended to promote enhanced patient\n compliance.

\n

 

\n

Aequus has advanced the once-weekly, transdermal aripiprazole patch with its development and manufacturing partner, Corium. Aequus successfully completed\n an initial Proof of Concept clinical study for AQS1301 in December 2015, demonstrating that sustained, seven-day delivery of therapeutic doses may\n be possible with the current formulation. A follow-on Proof of Concept clinical study in healthy volunteers was completed in February 2017,\n demonstrating that steady state plasma concentrations were achieved by week three with relative concentrations of aripiprazole and its active metabolite,\n dehydroaripiprazole, comparable to oral dosing of Abilify®.

\n

About Aequus

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its\n current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or\n brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

About Camargo Pharmaceutical Services 

\n

Camargo Pharmaceutical Services is the most experienced team of experts providing comprehensive drug development services specialized for the 505(b)(2)\n approval pathway and global equivalent processes. By assessing the scientific, medical, regulatory, and commercial viability of product development\n opportunities, Camargo systematically builds and executes robust development plans that align with business strategies and ensure Agency buy-in every\n step of the way. With alignment through pre-Investigational New Drug (pre-IND) meeting planning and preparations, Camargo maintains and ensures consistency throughout the drug development program, which increases the likelihood of NDA and future market success. Routinely holding three to six pre-IND meetings a month, Camargo works with product developers across more than 25 countries. For more about Camargo Pharmaceutical Services, visit http://camargopharma.com

\n

The Company issued Camargo Pharmaceutical Services, LLC 47,004 common shares on August 21, 2017 in connection with a service agreement to provide regulatory consulting services for the Company’s product development programs in the United States.\n

", "itemId": 7868028, "name": "Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-abbreviated-development-path-for-transdermal-aripiprazole", "url": "/en/news/aequus-announces-abbreviated-development-path-for-transdermal-aripiprazole", "releaseDate": "2017-08-24T00:00:00", "releaseDate_raw": "2017-08-24T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T13:58:09.67", "lastUpdateDate_raw": "2018-08-01T06:58:09.67", "counter": 36, "weight": 20170824, "commentCount": 0, "editUrl": "/en/news/aequus-announces-abbreviated-development-path-for-transdermal-aripiprazole?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7868028&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:\n

This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact,including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to our clinical trial and regulatory timing and plans, the achievement of clinical and commercial milestones, and the advancement of our technologies and our products and product candidates. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to the market for Aequus’ common shares, preferred shares, debt securities, subscription receipts, units and warrants; obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully out-license or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated May 3, 2017, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n

\n

 

\n

Abilify® is a registered trademark of Otsuka Pharmaceutical Co., Ltd.\n

\n

 

\n

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "\n

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

\n" }, { "description": "

VANCOUVER, BC. August 16, 2017 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),\n a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has received\n a receipt for its final short form base shelf prospectus (the “Prospectus”). The Prospectus will allow Aequus\n to offer up to C$20,000,000 of common shares, preferred shares, debt securities, subscription receipts, units and warrants from time to time, in each\n of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, until the Prospectus expires on September 16, 2019. This new filing replaces the\n Company’s existing base shelf prospectus, which expired on August 6, 2017. This shelf prospectus is intended to give Aequus the flexibility to take\n advantage of financing opportunities when market conditions are favourable.

\n

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities\n have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or\n any state securities laws and may not be offered or sold to or for the account or benefit, of persons within the United States or, in certain circumstances,\n U.S. persons (as such term is defined in the U.S. Securities Act), unless registered under the U.S. Securities Act and applicable state securities\n laws or an exemption from such registration is available.

\n

A copy of the Prospectus may be obtained from the Company by directing a request to Aequus at 2820 – 200 Granville Street, Vancouver, British Columbia,\n Canada, V6C 1S4 or can be found on SEDAR at www.sedar.com

\n

About Aequus

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its\n current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or\n brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

 

\n

 

\n

 

\n
\n

 

\n

 

", "itemId": 7862564, "name": "Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to C$20,000,000", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-receives-approval-for-short-form-base-shelf-prospectus-to-raise-up-to-c-20-000-000", "url": "/en/news/aequus-receives-approval-for-short-form-base-shelf-prospectus-to-raise-up-to-c-20-000-000", "releaseDate": "2017-08-17T00:00:00", "releaseDate_raw": "2017-08-17T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:13:08.127", "lastUpdateDate_raw": "2018-08-01T07:13:08.127", "counter": 37, "weight": 20170817, "commentCount": 0, "editUrl": "/en/news/aequus-receives-approval-for-short-form-base-shelf-prospectus-to-raise-up-to-c-20-000-000?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7862564&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact,including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to the implementation of our business model and strategic plans, and the base shelf prospectus and the offerings thereunder. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to the market for Aequus’ common shares, preferred shares, debt securities, subscription receipts, units and warrants; obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully out-license or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated May 3, 2017, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n

\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

\n
", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

" }, { "description": "

 

\n

Vancouver, BC., August 1, 2017 – Aequus Pharmaceuticals Inc., (“Aequus”) (TSX-V:AQS), a specialty life sciences company focused on providing\n patients with differentiated and enhanced delivery systems for existing and approved drugs, and Scientus Pharma Inc., (“Scientus”), a biopharmaceutical\n company focused on R&D and product commercialization for extracts and formulations related to medical cannabinoids and their derivatives, announced\n today that they have signed a non-binding term sheet on a collaboration to develop, assess clinical performance, and commercialize a cannabinoid containing\n transdermal formulation designed and optimized to address both acute and chronic treatment of Resistant Epilepsy, and certain other neurological disorders.\n

\n

Scientus will be the supplier of specific cannabinoid extracts and will have an option to co-fund the clinical development of this program. The parties\n expect to expand the collaboration to additional product development programs in the future.

\n

“We are delighted to collaborate with Scientus for development and commercial supply as we advance this first product, a pharmaceutical-grade, transdermal\n cannabinoid based therapy for use in epilepsy and potentially other additional neurological disorders,” said Doug Janzen, Chairman and CEO of Aequus.\n “Within only three months of announcing our involvement in the medical cannabis space, we’ve completed a comprehensive survey with physicians identifying\n current challenges and validating our product concepts, partnered with the Centre for Drug Research and Development (CDRD) for formulation development,\n and have now formed a product specific relationship with a high quality, medically focused Licensed Dealer who shares our vision to improve the quality\n of cannabis-based options currently available in progressive markets, such as Canada.”

\n

Scientus Pharma, a vertically-integrated biopharmaceutical company is both a Licensed Dealer under the Controlled Substances Act, and a Licensed Producer\n Applicant under the ACMPR. Scientus is raising the bar of cannabinoid products from medical-grade to pharmaceutical-grade. Leveraging its proprietary,\n patent-pending formulation and processing technologies, Scientus Pharma is committed to leading the medical cannabis market towards pharmaceutical\n standards in manufacturing, formulations and dosing.

\n

“Our product pipeline includes a range of dosing forms in solid, liquid and aerosolized forms targeting a number of indications, including neuropathic\n pain. We are excited about broadening that pipeline to include transdermal technologies through a collaboration with Aequus” said Trevor Folk, President\n and CEO of Scientus. “Transdermal approaches have significant potential for safe, effective therapies in a number of disease indications and we are\n looking forward to leveraging Aequus’ expertise to advance the science in the area of refractive epilepsy.”

\n

The economics of each product development program under this agreement will be allocated based on the respective party’s contribution of funding, resources\n and intellectual property made during product development.

\n

About Aequus Pharmaceuticals

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its\n current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or\n brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

 

\n

About Scientus

\n

Scientus Pharma is a vertically-integrated biopharmaceutical Licensed Dealer under the Narcotics Control Regulations of Canada with a focus on developing\n and commercializing pharmaceutical-grade cannabinoid derivative products. Being one of a limited number of Licensed Dealers in Canada authorized to\n handle cannabinoid products, Scientus Pharma has the ability to wholesale, buy, process and sell cannabinoid derivatives, from and to Licensed Producers,\n as well as international markets.

\n

 

\n
\n

 

\n

 

", "itemId": 7850948, "name": "Aequus and Scientus Agree to Terms for a Medical Cannabis Commercial Supply and Product Development Collaboration", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-and-scientus-agree-to-terms-for-a-medical-cannabis-commercial-supply-and-product-development-", "url": "/en/news/aequus-and-scientus-agree-to-terms-for-a-medical-cannabis-commercial-supply-and-product-development-", "releaseDate": "2017-08-01T00:00:00", "releaseDate_raw": "2017-08-01T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T14:57:22.783", "lastUpdateDate_raw": "2018-07-27T07:57:22.783", "counter": 38, "weight": 20170801, "commentCount": 0, "editUrl": "/en/news/aequus-and-scientus-agree-to-terms-for-a-medical-cannabis-commercial-supply-and-product-development-?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7850948&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, using results from the medical cannabis primary research study to guide development efforts in medical cannabis, and enhancing delivery systems used with medical cannabis. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully out-license or sell its current products and in-license and develop new products, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n

\n

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations

\n

Email: investors@aequuspharma.ca

\n

Phone: 604-336-7906

" }, { "description": "

\n

Vancouver, BC. July 5, 2017Aequus Pharmaceuticals Inc. (TSX-V:AQS,\n OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a\n focus on developing, advancing and promoting differentiated products, announced today that it has received approval from Health Canada to initiate\n a Proof of Concept clinical trial to evaluate the bioavailability and safety of Aequus’ long-acting transdermal anti-nausea patch, AQS1303, containing\n the combination of pyridoxine and doxylamine (the active ingredients in Diclegis®/Diclectin®). AQS1303 is designed to provide\n patients with a more convenient and reliable delivery system as an alternative to the currently marketed oral form, which is dosed up to four times\n per day.

\n

As previously announced, this first Proof of Concept study will be a single-dose cross-over comparative bioavailability study versus the currently\n approved oral version, Diclegis®/Diclectin®, in nine healthy volunteers. Results from this study are expected to be released\n by the end of this current quarter.

\n

“Diclegis®/Diclectin® has provided symptomatic relief to millions of women to date, but in its current form it is dosed orally\n multiple times per day which can induce gag reflexes in women experiencing nausea during pregnancy,” said Anne Stevens, Chief Operating Officer\n and Director at Aequus. “We are very excited about the potential for this program and believe a long-acting patch could provide a much needed solution\n for this medication, giving patients a more comfortable and convenient dosing alternative.”

\n

In parallel to this study, Aequus is preparing for a pre-Investigational New Drug (pre-IND) meeting with the US Food and Drug Administration (FDA)\n to define the clinical strategy for regulatory approval in the US. The product is expected to follow a Section 505(b)2 New Drug Application (NDA),\n an abbreviated clinical pathway in which the FDA would allow for the Company to reference safety and efficacy data of the original oral tablet\n form of the medication. Aequus owns the global rights to this program, and will look to find a strategic partner to advance towards commercialization\n in major markets.

\n

Additionally, the Company issued Camargo Pharmaceutical Services, LLC 80,676 common shares on June 27, 2017 in connection with a service agreement\n to provide regulatory consulting services for the Company’s product development programs in the United States.  \n

\n

About Aequus\n

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high\n quality, differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing\n the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside\n its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product\n candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created\n internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information,\n please visit www.aequuspharma.ca.

\n

", "itemId": 7827419, "name": "Aequus Receives Approval from Health Canada to Initiate Proof of Concept Clinical Trial of Anti-Nausea Patch", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-receives-approval-from-health-canada-to-initiate-proof-of-concept-clinical-trial-of-anti-naus", "url": "/en/news/aequus-receives-approval-from-health-canada-to-initiate-proof-of-concept-clinical-trial-of-anti-naus", "releaseDate": "2017-07-05T00:00:00", "releaseDate_raw": "2017-07-05T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T16:45:08.457", "lastUpdateDate_raw": "2018-07-27T09:45:08.457", "counter": 39, "weight": 20170705, "commentCount": 0, "editUrl": "/en/news/aequus-receives-approval-from-health-canada-to-initiate-proof-of-concept-clinical-trial-of-anti-naus?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7827419&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the implementation of our business model and strategic plans, the initiation and parameters of the Proof of Concept clinical trial, the completion of the analysis of the Proof of Concept clinical trial and the next steps in connection therewith. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to general business and economic conditions and the anticipated results of the Phase I clinical trial. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated May 3, 2017, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n

\n

Diclegis® and Diclectin® are registered trademarks of Duchesnay Inc

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

 

\n

Vancouver, BC. June 15, 2017Aequus Pharmaceuticals Inc. (TSX-V:AQS,\n OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus\n on developing, advancing and promoting differentiated products, announced today that is has filed a Clinical Trial Application (“CTA”) with Health\n Canada in preparation for a Proof of Concept clinical study for its long-acting transdermal anti-nausea patch, AQS1303, containing the combination\n of pyridoxine and doxylamine (the active ingredients in Diclegis®/Diclectin®). Upon approval of the CTA, which is expected in\n early July, the Company plans to initiate a single-dose cross-over comparative bioavailability study versus the currently approved oral version, Diclegis®/Diclectin®,\n in nine healthy volunteers.

\n

“We are very excited to see the continued advancement of this program,” said Anne Stevens, Chief Commercial Officer at Aequus. “A long-acting patch that\n reliably delivers a sustained dose of pyridoxine and doxylamine will benefit patients by reducing both the pill burden and maintaining a steady state\n of therapeutic delivery, while treating symptoms of nausea and vomiting.”

\n

AQS1303 is a long-acting transdermal patch intended for the treatment of nausea and vomiting of pregnancy (“NVP”). AQS1303 would provide patients with\n a more convenient and reliable delivery system as an alternative to the currently marketed oral form, which is dosed up to four times per day. Currently,\n the oral form of Diclegis® is the only FDA approved medication for morning sickness in pregnant women and in 2015 reached sales in the United\n States of approximately U.S.$120 million. A long-acting transdermal form of pyridoxine/doxylamine is being developed by Aequus to address the risk\n of missed doses due to emesis (vomiting) and to provide consistent and sustained symptomatic relief.

\n

The primary objectives for the Proof of Concept study will be to assess the bioavailability, safety and tolerability of Aequus’ long-acting transdermal\n formulation containing doxylamine succinate and pyridoxine hydrochloride. Study results are expected in Q3 2017, following approval of the CTA by Health\n Canada. In parallel to this study, Aequus is preparing for a pre-Investigational New Drug (pre-IND) meeting with the US Food and Drug Administration\n (FDA) to define the clinical strategy for regulatory approval in the US. This product is expected to follow a Section 505(b)2 New Drug Application\n (NDA), an abbreviated clinical pathway in which the FDA would allow for the Company to reference safety and efficacy data of the original oral tablet\n form of the medication. Aequus owns the global rights to this program, and will look to find a strategic partner to advance towards commercialization\n in major markets.

\n

About Aequus

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its\n current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or\n brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

 

\n

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

\n

 

", "itemId": 7793554, "name": "Aequus Advances Clinical Development of Transdermal Anti-Nausea Patch", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-advances-clinical-development-of-transdermal-anti-nausea-patch", "url": "/en/news/aequus-advances-clinical-development-of-transdermal-anti-nausea-patch", "releaseDate": "2017-06-15T00:00:00", "releaseDate_raw": "2017-06-15T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T14:42:12.233", "lastUpdateDate_raw": "2018-07-27T07:42:12.233", "counter": 40, "weight": 20170615, "commentCount": 0, "editUrl": "/en/news/aequus-advances-clinical-development-of-transdermal-anti-nausea-patch?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7793554&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "\n

Forward-Looking Statements:

\n

This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the implementation of our business model and strategic plans, the initiation and parameters of the Phase I clinical trial, the completion of the analysis of the Phase I clinical trial and the next steps in connection therewith. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to general business and economic conditions and the anticipated results of the Phase I clinical trial. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Short-Form Prospectus dated June 30, 2015, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

 

\n

Diclegis® and Diclectin® are registered trademarks of Duchesnay Inc

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

\n

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

\n
\n

" }, { "description": "

Vancouver, BC – June 13, 2017 – Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB: AQSZF) (“Aequus”\n or the “Company”), today announced that it has entered into an exclusive agreement in Canada with Santen Incorporated, the Canadian Branch (“Santen”),\n a subsidiary of Santen Pharmaceutical Co., Ltd., an international market leader in ophthalmology headquartered in Osaka, Japan. Under the agreement,\n Aequus and Santen will plan to co-commercialize an undisclosed ophthalmology therapeutic product currently under review by Health Canada for marketing\n approval in Canada.

\n

“We are delighted to collaborate with Santen, a company with a rich history and focus in ophthalmology, as it seeks to bring innovative eye care therapies\n to patients in Canada affected by ophthalmic diseases. This agreement recognizes and builds upon the commitment of both companies to provide patients\n with high-quality and differentiated therapies, and will add to the commercial ophthalmology franchise we have been building at Aequus since the successful\n launch of Vistitan in 2016,” said Doug Janzen, Chairman and CEO of Aequus.\n
\n

\n

“We have a proven track record and well established relations with key Canadian stakeholders in ophthalmology,” said Ian Ball, Chief Commercial Officer\n at Aequus. “The addition of Santen’s ophthalmology product and experience to Aequus’ existing product offering will further strengthen our growing\n ophthalmology portfolio and demonstrates our commitment to grow in this important therapeutic area.”

\n

“Santen is pleased to partner with Aequus and looks forward to leveraging our joint expertise and resources to make important treatment options available\n for patients in Canada,” said Akihiro Tsujimura, Executive Corporate Officer and Head of Santen North America. “Aequus is an ideal partner for a specialty\n ophthalmic company, given their well-established sales force and relationships with eye care specialists. This collaboration further reinforces Santen’s\n mission to bring ophthalmic therapies to patients around the world.”

\n

Under the terms of this agreement, Aequus and Santen will share the strategic responsibility associated with promotional activities for a currently undisclosed\n ophthalmic product in Canada. Santen will be responsible for product manufacturing and distribution, while Aequus will be mainly responsible for the\n field activities. Net product revenues will be split between Aequus and Santen over a ten-year term. The agreement also contemplates fees to Aequus\n in the event of Santen internalizing the asset prior to the end of the term. 

\n

About Aequus\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF)\n is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development\n stage pipeline includes several products in neurology, psychiatry and women’s health with a goal of addressing the need for improved medication adherence\n through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established\n medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on\n its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition\n or license; remaining focused on highly specialized therapeutic areas, including neurology and ophthalmology. For further information, please visit\n www.aequuspharma.ca. 

\n

About Santen\n
\n

\n

As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, marketing, and sales of pharmaceuticals and devices.\n Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in approximately 60 countries. As a leading company\n in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For\n more details, please see Santen’s website (www.santen.com). 

\n

 

", "itemId": 7782935, "name": "Santen and Aequus Enter Into a Commercial Collaboration in Canada", "urlWithHost": "http://www.aequuspharma.ca/en/news/santen-and-aequus-enter-into-a-commercial-collaboration-in-canada", "url": "/en/news/santen-and-aequus-enter-into-a-commercial-collaboration-in-canada", "releaseDate": "2017-06-13T00:00:00", "releaseDate_raw": "2017-06-13T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:17:05.947", "lastUpdateDate_raw": "2018-08-01T07:17:05.947", "counter": 41, "weight": 20170613, "commentCount": 0, "editUrl": "/en/news/santen-and-aequus-enter-into-a-commercial-collaboration-in-canada?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7782935&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the implementation of our business model and strategic plans, the launch and potential market potential for Santen’s therapeutic products in Canada and the next steps in connection therewith. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to general business and economic conditions and the anticipated results of the Phase I clinical trial. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Short-Form Prospectus dated June 30, 2015, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations\n
Email: investors@aequuspharma.ca\n
Phone: 604-336-7906

\n

Santen Pharmaceutical Co., Ltd.

\n

Christopher Hohman, General Manager, Corporate Communications Group\n
Email: ir@santen.co.jp
Phone: +81-6-4802-9360

" }, { "description": "

VANCOUVER, BC. June 12, 2017 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”\n or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting\n differentiated products, today announced that its board of directors has adopted an advance notice policy (the “Advance Notice Policy”).\n

\n

The purpose of the Advance Notice Policy is to provide shareholders, directors and management of the Company with direction on the procedure for shareholder\n nomination of directors. The Advance Notice Policy is the framework by which the Company seeks to fix a deadline by which registered or beneficial\n holders of common shares of the Company must submit director nominations to the Company prior to any annual or special meeting of shareholders and\n sets forth the information that a shareholder must include in the notice to the Company for the notice to be in proper written form. No person will\n be eligible for election as a director of the Company unless nominated in accordance with the provisions of the Advance Notice Policy.

\n

With respect to the annual meeting of shareholders of the Company to be held on July 12, 2017 (the “Meeting”), notice of any proposed\n nominations must be provided to the Company no later than June 22, 2017.

\n

For all subsequent meetings of shareholders of the Company:

\n

In the case of an annual meeting of shareholders, notice to the Company must be made not less than 30 days prior to the date of the annual meeting; provided,\n however, that in the event that the annual meeting is to be held on a date that is less than 50 days after the date on which the first public announcement\n of the date of the annual meeting was made, notice may be made not later than the close of business on the 10th day following such public announcement.

\n

In the case of a special meeting of shareholders (which is not also an annual meeting), notice to the Company must be made not later than the close of\n business on the 15th day following the day on which the first public announcement of the date of the special meeting was made.

\n

The Advance Notice Policy is effective immediately. At the Meeting, Aequus is seeking shareholder approval and ratification of the Advance Notice Policy.\n In the event that shareholders determine not to ratify the Advance Notice Policy by ordinary resolution, the Advance Notice Policy shall terminate\n and be void and of no further force and effect following the termination of the Meeting.\n
\n

\n

The full text of the Advance Notice Policy is available via SEDAR at www.sedar.com or upon request by contacting the Chief Financial Officer of the Company\n at (604) 336-7906 or by e-mail at afehr@aequuspharma.ca. Further details on the Meeting and the Advance\n Notice Policy will be contained in a Management Information Circular to be mailed to shareholders of the Company in connection with the Meeting. The\n Management Information Circular will also be available on SEDAR.

\n

About Aequus Pharmaceuticals

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its\n current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or\n brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

 

\n

 

", "itemId": 7782543, "name": "Aequus Approves Advance Notice Policy", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-approves-advance-notice-policy", "url": "/en/news/aequus-approves-advance-notice-policy", "releaseDate": "2017-06-12T00:00:00", "releaseDate_raw": "2017-06-12T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T15:52:22.277", "lastUpdateDate_raw": "2018-07-27T08:52:22.277", "counter": 42, "weight": 20170612, "commentCount": 0, "editUrl": "/en/news/aequus-approves-advance-notice-policy?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7782543&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:\n

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the date of the Meeting; and the Company’s intention to commercialize its internal programs in Canada, form strategic partnerships and build its Canadian commercial platform. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully out-license or sell its current products and in-license and develop new products, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated May 1, 2017, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com , and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations

\n

Email: investors@aequuspharma.ca

\n

Phone: 604-336-7906

" }, { "description": "

June 1, 2017 – Vancouver, BC: Today Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) a specialty pharmaceutical company with expertise\n in drug delivery and clinical development, and the Centre For Drug Research and Development (“CDRD”), Canada’s national drug development and commercialization\n centre, announced a broad research collaboration to establish pre-clinical safety and efficacy of select cannabinoid-based therapeutics targeting neurological\n movement disorders including epilepsy, Multiple Sclerosis, Parkinson’s disease and Huntington’s disease.

\n

Aequus has initiated a research program of cannabinoid-based therapeutics targeting neurological disorders. In 2016, Health Canada provided patients in\n Canada the ability to access cannabis for medical purposes when recommended by their physician. There are insufficient data, however, for proper therapeutic\n treatment protocols regarding the proper dosage and frequency for patients dealing with a wide variety of symptoms and disease areas. Aequus recently\n published a survey that confirms the medical need for improved clinical trial data supporting safety and efficacy of medical cannabis, reliability\n of dose delivery systems, high quality data collection tracking real world clinical outcomes, physician education, and quality controlled ingredients.

\n

The goal of the Aequus/CDRD partnership is to address many of these deficiencies. The preclinical studies, including in-vitro and in-vivo toxicology, pharmacology, and formulation optimization in relevant disease models, will be conducted at CDRD’s facilities in Vancouver, BC, pending\n Health Canada approvals. This initial project leverages CDRD’s expertise in pre-clinical development and target validation for new products, and demonstrates\n CDRD’s ongoing engagement with life sciences companies in the Canadian marketplace. Products advanced through the collaboration will be commercialized\n by Aequus.

\n

Aequus intends to leverage its expertise in developing and commercializing regulated prescription therapeutics and will work with sophisticated third party\n partners like the CDRD to develop pharmaceutical grade products for patients seeking the use of optimized delivery versions of clinically validated\n formulations of medical cannabis.

\n

\"This is an exciting step as we advance toward our goal of providing patients and physicians with clinically validated cannabinoid containing treatments\n delivered in a more precise and optimized manner than inhaling or ingesting, the most common current methods of delivery,” said Doug Janzen. “We view\n the clinician community as being important stakeholders, and we are excited to work with a world class drug research and development organization like\n CDRD as we strive to provide the medical community with validated and improved alternatives to existing products. Together our two organizations have\n proven expertise in taking drugs from discovery and preclinical trials all the way through clinical trials to regulatory launch and commercial sales\n – a potent combination for advancing cannabinoid containing therapeutics for Neurologic Movement Disorders.”

\n

Gordon McCauley, CDRD’s President and CEO commented, “Our partnership with Aequus is a great example of the work we do with biotech across the country.\n There is a clear unmet medical need in the area of medical cannabinoid research and development where CDRD and Aequus can collaborate and share their\n respective expertise that could lead to new cannabinoid therapeutics and a pathway to clinical trials, particularly in neurological movement disorders.”\n

\n

About The Centre for Drug Research and Development (CDRD)

\n

CDRD is Canada’s national drug development and commercialization centre working in partnership with academia, industry, government and foundations. CDRD\n provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially\n viable investment opportunities for the private sector — and ultimately into new therapies for patients. Canada’s Networks of Centres of Excellence\n Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). www.cdrd.ca

\n

About Aequus Pharmaceuticals

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its\n current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or\n brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

 

", "itemId": 7727112, "name": "Aequus Pharmaceuticals and CDRD Announce Research Collaboration to Improve Cannabinoid-Based Therapeutics", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-pharmaceuticals-and-cdrd-announce-research-collaboration-to-improve-cannabinoid-based-therape", "url": "/en/news/aequus-pharmaceuticals-and-cdrd-announce-research-collaboration-to-improve-cannabinoid-based-therape", "releaseDate": "2017-06-01T00:00:00", "releaseDate_raw": "2017-06-01T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:07:33.243", "lastUpdateDate_raw": "2018-08-01T07:07:33.243", "counter": 43, "weight": 20170601, "commentCount": 0, "editUrl": "/en/news/aequus-pharmaceuticals-and-cdrd-announce-research-collaboration-to-improve-cannabinoid-based-therape?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7727112&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n
This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, using the results from this study to guide development efforts in medical cannabis, and enhancing delivery systems used with medical cannabis. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully out-license or sell its current products and in-license and develop new products, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n
 \n
", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Julia White\n
Manager, Communications – CDRD\n
jwhite@cdrd.ca
604-827-1226

\n

Aequus Investor Relations\n
investors@aequuspharma.ca\n
604-336-7906

" }, { "description": "

 

\n

VANCOUVER, BC - May 30, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company\n with a focus on developing, advancing and promoting differentiated products, today reported financial results for the first quarter ended March 31,\n 2017 and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.

\n

Q1 2017 Key Highlights\n

\n

Corporate Finance\n

\n

On March 13, 2017, the Company closed an agreement with Canaccord Genuity Corp. (“Canaccord\") to which they agreed to purchase, on a bought deal basis,\n 17,250,000 units at a price of $0.30 per unit, for aggregate gross proceeds to the Company of $5,175,000. Net proceeds of the offering will be used\n for the development of the Company’s drug pipeline, business development and other general corporate purposes.

\n

Commercial Activities 

\n

The Company recorded revenue of $293,002 in Q1 2017 compared to $116,083 in Q1 2016, representing a growth of 152% when comparing the two quarters. Revenues\n are attributable to its promotional activities for Tacrolimus IR, which launched in December 2015, and PRVistitanTM, which launched\n in April 2016.

\n

Sales and marketing costs for Q1 2017 were $349,145, which included $71,014 in amortization and share based payments expenses. Depreciation and amortization,\n and share-based payments for Q1 2017 were $45,917 and $25,097, respectively, compared to $42,398 and $60,444, respectively, in Q1 2016. The amortization\n costs were primarily related to the acquisition costs of TeOra.

\n

Aequus incurred sales and marketing expenses in Q1 2017 of $349,145 in Q1 2017 compared to $443,863 in Q1 2016, a decrease associated with launch related\n expenses that had been incurred in Q1 2016.

\n

\"We are pleased with the first year of progress of our commercial activities and the execution of our overall strategy to date,” said Ian Ball, Chief Commercial Officer at Aequus. “In the currently reported quarter and on a cash flow basis, our commercial revenues have covered the costs associated with our commercial infrastructure. We expect to add additional commercial products in 2017 that will leverage our existing salesforce giving us further confidence in our continued growth.\"\n

\n

Revenues are expected to continue to grow in the current year as these products continue to penetrate market share held by the branded equivalents and\n similar medications within the class, along with new prescription products that Aequus is currently negotiating for the Canadian market. Sales levels\n are expected to be inconsistent and unpredictable over the next twelve months as reimbursement activities and inventory stock-up occurs for each product.

\n

Development Program Activities\n

\n

 The Company incurred research and development expenses of $398,273 in Q1 2017 as compared to $169,093\n in Q1 2016. The increase in research and development expenses by $229,180 was attributable to the successful completion of the second Proof of Concept\n clinical study for AQS 1301 (a once-weekly transdermal formulation of aripiprazole), FDA Pre-IND meeting preparations for AQS1302 (a long-acting transdermal\n formulation of clobazam) and ASQ1303 (a long-acting formulation of pyridoxine/doxylamine) and manufacturing of Clinical Trial Materials for AQS1303\n in preparation of a Proof of Concept clinical study expected in mid-2017.

\n

On March 2, 2017, Aequus acquired a license from Transdermal Pharma Research Laboratories LLC to a transdermal patch containing cannabinoids for the use\n in epilepsy, Multiple Sclerosis (“MS”), and certain other neurological disorders, broadening the Company’s pipeline and a complement to its growing\n neurology franchise. Aequus recently published a survey involving over 400 physicians in Canada and the United States which validated the medical need\n for improved clinical trial data supporting safety and efficacy of medical cannabis, reliability of dose delivery systems, high quality data collection\n tracking real world clinical outcomes, physician education, and quality controlled ingredients.

\n

“Our entrance into the medical cannabis space is based on our ability to leverage our internal expertise in drug delivery to address the concerns identified by physicians,” said Doug Janzen, Chairman and CEO of Aequus. “We are confident that we can bring new revenue generating prescription products to Canada, advance novel cannabinoid formulations, add partnerships in the neurology and ophthalmology areas, and bring new drug delivery platforms to market in 2017.”\n

\n

 Other\n

\n

 Additionally, the Company issued Camargo Pharmaceutical Services, LLC 158,437 common shares on\n May 29, 2017 in connection with a service agreement to provide regulatory consulting services for the Company’s product development programs in the\n United States. 

\n

ABOUT AEQUUS PHARMACEUTICALS INC.\n

\n

 Aequus Pharmaceuticals Inc. (TSX-V:AQS , OTCQB:AQSZF) is a growing specialty pharmaceutical\n company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes several products\n in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. With a focus in\n neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is\n a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal\n programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize\n the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products\n that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For\n further information, please visitwww.aequuspharma.ca.\n

", "itemId": 7702337, "name": "Aequus Provides First Quarter 2017 Financial Highlights", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-provides-first-quarter-2017-financial-highlights", "url": "/en/news/aequus-provides-first-quarter-2017-financial-highlights", "releaseDate": "2017-05-30T00:00:00", "releaseDate_raw": "2017-05-30T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T16:24:46.85", "lastUpdateDate_raw": "2018-07-27T09:24:46.85", "counter": 44, "weight": 20170530, "commentCount": 0, "editUrl": "/en/news/aequus-provides-first-quarter-2017-financial-highlights?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7702337&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

FORWARD-LOOKING STATEMENT DISCLAIMER

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”,“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; the Company’s expected revenues; the timing of public listings; the advancement of the Company’s transdermal pyridoxine/doxylamine program into a Proof of Concept clinical study; the Company’s potential regional partnerships for its internal programs; the timing of public reimbursement decisions for VistitanTM; the regulatory requirements for the its transdermal aripiprazole program; and the Company’s expectations regarding the tech transfer to its development partner with respect to the Company’s transdermal patch for clobazam and doxylamine/pyridoxine transdermal patch. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.\n

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

VANCOUVER, BC. May 15, 2017 - Aequus Pharmaceuticals Inc. (TSX-V: AQS,\n OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products,\n today announced results from a medical cannabis needs assessment survey it deployed involving 410 physicians in Canada and the United States. Aequus\n sought to understand the current attributes and therapeutic use of cannabis in the medical community including the delivery of cannabis, the limitations\n of use, the perceived benefits and risks in specific indications, and the gaps in knowledge in the field from a prescriber’s perspective.

\n

“The results from this survey are timely, as Canada and other territories continue to evolve their regulations to improve and increase access to cannabis.\n To date, medical practitioners have been largely left out of the legislative process, and as a result, the challenges physicians are facing in recommending\n medical cannabis seem to be wide spread,” said Doug Janzen, Chairman and CEO of Aequus.\n
\n

\n

“This survey highlights physicians’ concerns around the currently available forms of cannabis, which were recognized to be unreliably administered and\n thus difficult to be measured for accurate dose-response in a clinical setting,” said Anne Stevens, COO and Director of Aequus. “Drug delivery is an\n area where Aequus has demonstrable expertise, and we are excited about the opportunity to work with the medical community in advancing pharmaceutical\n grade, quality medical cannabis products.”\n
\n

\n

Findings from this survey highlight the medical need for improved clinical trial data supporting safety and efficacy of medical cannabis, reliability of\n dose delivery systems, high quality data collection tracking real world clinical outcomes, physician education, and quality controlled ingredients.\n Aequus intends to leverage its expertise in developing and commercializing regulated prescription therapeutics and will work with third party partners,\n and the physician community, to develop pharmaceutical grade products for patients seeking the use of medical cannabis and to re-engage the physician\n in the treatment journey.\n
\n

\n

Key Survey Highlights:\n
\n

\n

Participant Demographics\n
\n

\n

The survey consisted of 202 physicians in Canada and 208 physicians in the USA – specifically in the state of California. The survey targeted primary care\n practitioners (36%), medical oncologists (24%), neurologists (20%), and psychiatrists (20%).\n
\n

\n

Experiences\n
\n

\n

The majority of physicians (>90%) reported having been approached by a patient to discuss the use of medical cannabis in both Canada and the USA. Of\n the physicians surveyed, 46% reported providing patients with a medical note, while the other 54% were not comfortable for a variety of reasons. Physicians\n reported that 20% of cannabis medical documents provided are based on their own recommendation, typically treating chronic pain, weight loss, nausea\n and vomiting, and multiple sclerosis. Meanwhile, patients that requested medical cannabis for treatment typically presented with chronic pain, anxiety,\n stress, and insomnia. The majority of Canadian physicians (51%) indicated that they recommend medical cannabis as a last resort treatment option as\n opposed to first line, second line, and adjunctive treatment.\n
\n

\n

Patient Journey\n
\n

\n

The survey identified the patient therapeutic journey to be unique in nature, with professional healthcare support lacking when it comes to product selection,\n dose, and administration. The survey found that only 19% of physicians in Canada recommend a specific dosing regimen for patients, 38% recommend a\n specific form of medical cannabis, and 43% refer patients to a certain licensed producer. This data suggests that the patient is largely responsible\n for determining their own course of therapy with limited advice from physicians, and no support available from pharmacists.\n
\n

\n

Barriers to Use\n
\n

\n

Physicians emphasized concern over cannabis products; consistently rating clinical data, reliability of quantity delivered, and dose ingredient quality\n as areas that require the most improvement. In conjunction, 43% of prescribing physicians are concerned over the current delivery methods used to administer\n medical cannabis, commonly citing smoking, potency, and contamination as areas of concern. When asked to select preferred potential routes of delivery\n for cannabis, oral tablets, sublingual tablets and nasal spray were commonly chosen for acute conditions such as pain and movement disorders. For chronic\n disorders, transdermal patch delivery (both reservoir and matrix) were preferred along with oral tablets.\n
\n

\n

Aequus expects to publish the full results from this survey in the coming weeks.\n
\n

\n

About Aequus Pharmaceuticals\n
\n

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB:\n AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development\n stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through\n enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established\n medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build\n on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition\n or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.\n
\n

\n

 

", "itemId": 7643119, "name": "Aequus Validates Need for Improved Delivery Methods of Medical Cannabis", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-validates-need-for-improved-delivery-methods-of-medical-cannabis", "url": "/en/news/aequus-validates-need-for-improved-delivery-methods-of-medical-cannabis", "releaseDate": "2017-05-15T00:00:00", "releaseDate_raw": "2017-05-15T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T16:53:08.98", "lastUpdateDate_raw": "2018-07-27T09:53:08.98", "counter": 45, "weight": 20170515, "commentCount": 0, "editUrl": "/en/news/aequus-validates-need-for-improved-delivery-methods-of-medical-cannabis?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7643119&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward Looking Statement

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the Company’s intention to form strategic partnerships to develop medical cannabis products. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: the Company’s ability to develop new products, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements. 

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

 

\n

VANCOUVER, May 1, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a\n focus on developing, advancing and promoting differentiated products, today reported financial results for the full year ended December 31, 2016 and\n associated Company developments. Unless otherwise noted, all figures are in Canadian currency.

\n

Key 2016 Highlights\n

\n\n\n\n\n\n

Commercial Update\n
\n

\n

Aequus initiated its promotional activities for Tacrolimus IR in December 2015, and has since been awarded three major hospital tenders in the two largest\n provinces in Canada. Tacrolimus IR, promoted by Aequus, grew 90% year-over-year in unit volume in 2016 when compared to 2015 based on ex-factory data.\n Additional growth for this product is expected as patient switch programs are implemented in hospitals where tenders have been awarded.

\n

Promotional efforts for VistitanTM began in May 2016, with an initial focus on gaining provincial listings for reimbursement of this product.\n Aequus’ market access team has successfully gained formulary listings in five major provinces across Canada, improving access for patients in those\n areas. We anticipate additional provincial listings in 2017 to contribute to the continued growth of this product.

\n

The two products are within their initial launch period of promotional efforts and are therefore expected to have variable revenues quarter over quarter\n due to stock-ins and other one-time events such as sample costs. Aequus receives a tiered revenue split on incremental sales of the products from its\n partner. Fourth quarter 2016 total revenues reported were $166,901, with full year 2016 revenues of $701,633 which includes twelve months of Tacrolimus\n IR and six months of Vistitan™ revenues to Aequus.

\n

“Our sales team have performed strongly in 2016, gaining access to physicians and other important customers. As each month passes we have a growing number\n of customers who are prescribing our products and building a stable base of sales,” said Ian Ball, Chief Commercial Officer for Aequus. “2016 has seen\n us achieve significant market access milestones, particularly in Ontario, our biggest province for sales. We continue to look for additional commercial\n stage programs to add to our established ophthalmology sales force,with a number of discussions underway.”

\n

The company has also progressed discussions with Health Canada around the acceptability of the FDA clinical package and foreign market experience for its\n recently in-licensed products, Topiramate Extended-Release and Oxcarbazepine Extended-Release, and expects to file a New Drug Submission (“NDS”) in\n 2017or early 2018.

\n

Progress of Product Pipeline\n

\n

The Company continued to invest in its development pipeline in 2016. Aequus advanced AQS1301, a once-weekly transdermal patch which is currently in development\n for the treatment of certain psychiatric disorders, through a second successful Proof of Concept clinical study completed in March 2017. The two completed\n studies to date for AQS1301 have suggested that therapeutic levels of aripiprazole, the active agent in AQS1301, is achievable with the current formulation\n for the target patient populations. The Company plans to engage with the FDA in a pre-IND meeting to define the clinical study requirements for approval\n in the United States, following a 505(b)(2) pathway.

\n

Investments were also made by Aequus in 2016 for its additional two development programs, primarily associated with the formulation optimization, prototype\n development and manufacturing of clinical trial material of AQS-1303, as well as continued formulation optimization of AQS-1302. AQS1302, a once-daily\n transdermal patch for clobazam, is intended for the treatment of certain epilepsies, including a rare and severe form called Lennox Gastaut Syndrome.\n AQS1303 is being advanced as a once-daily and up to a twice-weekly transdermal doxylamine and pyridoxine combination patch for the treatment of nausea\n and vomiting in pregnancy (NVP). We anticipate initiating a Proof of Concept clinical study for AQS1303 by mid-2017.

\n

Aequus has been engaging with third parties around partnering discussions for each of its internal programs, with a goal of ensuring the maximum benefit\n is realized by shareholders.

\n

Operating Expenses\n

\n

Research and development expenses in the fourth quarter of 2016 were $295,115, as compared to $454,557 in the same quarter last year, and for the full\n year 2016, $1,127,780, as compared to $2,144,488 for 2015. The decrease in expenditures were attributable to slower development activities by the Company\n as it prepared for its next Proof of Concept study for AQS1301, and as it tech transferred AQS1302 and AQS1303 for further optimization and the manufacturing\n of clinical trial materials.

\n

Selling, general and administrative expenses in the fourth quarter of 2016 were $1,059,635, as compared to $919,095 in the same quarter last year, and\n for the full year 2016, $4,437,436 as compared to $2,910,662 in 2015. The increase in expenditures were primarily due to work done in anticipation\n of launching Tacrolimus IR, brand development of Vistitan™, and building out of the sales and marketing team in Canada.

\n

Aequus reported a loss before other income of ($1,187,849) in the fourth quarter of 2016, a decrease of 15% compared to ($1,373,652) in the same quarter\n last year, and for the full year 2016, ($4,863,583), as compared to ($5,055,150) for 2015. This improvement in loss before other income for both periods\n is primarily due to the recognition of revenues from its sales and marketing activities in 2016 for its two commercially promoted products, tacrolimus\n IR and VistitanTM .

\n

“2016 was a productive year for Aequus as we established our commercial infrastructure, launched our first two products and began our transition to being\n a revenue generating specialty pharma company. In 2017 we hope to add additional revenue generating products into our Canadian sales infrastructure,\n continue to advance our internal programs, potentially add new drug delivery technologies to complement our current transdermal delivery platform,\n including the exploration of a number of exciting complementary opportunities in the medical cannabis space,” said Doug Janzen, Chairman and CEO of\n Aequus. “Subsequent to the end of 2016 we raised $5.2 million in an equity financing and we are well placed to make 2017 a transformative year for\n Aequus and want to thank shareholders and employees for their support and contributions.”

\n

About Tacrolimus IR\n

\n

Tacrolimus immediate release is an immunosuppressant used for the treatment and prevention of acute rejection following organ transplantation. Tacrolimus\n is part of a patient’s immunosuppressive therapy prescribed chronically in their lifelong management to prevent graft rejection. In 2015, the immunosuppressive\n market in Canada reached $241M in sales, with tacrolimus products accounting for $100M. With the assistance of Aequus’ promotional efforts and commercial\n team, the tacrolimus IR generic grew 90% year-over-year by unit volume in 2016 when compared to 2015 based on ex-factory data.

\n

About Vistitan™\n

\n

Vistitan™(bimatoprost 0.03%, ophthalmic solution), is a branded generic prostaglandin approved by Health Canada for the reduction of elevated IOP\n in patients with open angle glaucoma or ocular hypertension. The Canadian glaucoma market in 2015 was estimated to be over $182 million, of which prostaglandins\n remain one of the primary treatment options for lowering IOP in glaucoma. VistitanTM, which was approved by Health Canada in 2014, is currently\n the only marketed version of 0.03% bimatoprost ophthalmic solution in Canada.

\n

 \n

\n

ABOUT AEQUUS PHARMACEUTICALS INC. \n

\n

Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB:AQSZF) is a growing specialty\n pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes\n several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems.\n With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis,\n where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that\n would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional\n products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.\n For further information, please visit www.aequuspharma.ca.\n

\n

 

\n

VistitanTM: Trademark owned or used under license by Sandoz Canada Inc.

\n

 

\n

 

\n
\n

 

", "itemId": 7595918, "name": "Aequus Provides Fourth Quarter and Fiscal 2016 Financial Highlights", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-provides-fourth-quarter-and-fiscal-2016-financial-highlights", "url": "/en/news/aequus-provides-fourth-quarter-and-fiscal-2016-financial-highlights", "releaseDate": "2017-05-01T00:00:00", "releaseDate_raw": "2017-05-01T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:11:48.17", "lastUpdateDate_raw": "2018-08-01T07:11:48.17", "counter": 46, "weight": 20170501, "commentCount": 0, "editUrl": "/en/news/aequus-provides-fourth-quarter-and-fiscal-2016-financial-highlights?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7595918&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statement Disclaimer

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”,“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; the Company’s expected revenues; the timing of public listings; the advancement of the Company’s transdermal pyridoxine/doxylamine program into a Proof of Concept clinical study; the Company’s potential regional partnerships for its internal programs; the timing of public reimbursement decisions for VistitanTM; the timing of the Company’s follow-on, multi-dose bioavailability study for the its transdermal aripiprazole program; and the Company’s expectations regarding the tech transfer to its development partner with respect to the Company’s transdermal patch for clobazam. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

CONTACT INFORMATION

\n

Aequus Investor Relations

\n

Email: investors@aequuspharma.ca

\n

Phone: 604-336-7906

" }, { "description": "

 

\n
\n

Vancouver, BC. April 5, 2017– Aequus Pharmaceuticals Inc. (TSX-V: AQS,\n OTCQB: AQSZF) (“Aequus”) announced today they will fund market research targeting up\n to 500 physicians across Canada and certain US states to further understand their current prescribing experience and perceptions around medical\n cannabis. It is estimated that only 5% of current prescribers in Canada recommend the use of medical cannabis, despite new regulations by Health\n Canada announced in August of 2016 which provide patients in Canada with an ability to access cannabis for medical purposes when recommended by\n their physician.

\n

This research will serve as a tool to identify barriers to current use and potential product offerings that could address those concerns in specific\n therapeutic areas. Aequus is committed to advancing patient-centric products and intends to use the results from this study to guide in their development\n efforts with medical cannabis. The research will target physicians across a number of specialties, including pain, oncology, movement disorders,\n family medicine and natural health practitioners, in both Canada and certain states in the US.

\n

“Aequus has a continued commitment to developing a pipeline of products that is supported by significant physician, patient and payor insights,” said\n Doug Janzen, President and CEO of Aequus Pharmaceuticals. “We are applying the same methodology that we use to develop our current prescription\n therapeutics to this rapidly evolving medical cannabis field. As we look to enhance the delivery systems used with medical cannabis, we will be\n engaging with physicians and patients alike to ensure they are satisfied by the products we expect to advance.”

\n

About Aequus

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF)\n is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development\n stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through\n enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established\n medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build\n on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition\n or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

 

\n
\n
", "itemId": 7488536, "name": "Aequus Launches Medical Cannabis Physician Research in US and Canada", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-launches-medical-cannabis-physician-research-in-us-and-canada", "url": "/en/news/aequus-launches-medical-cannabis-physician-research-in-us-and-canada", "releaseDate": "2017-04-05T00:00:00", "releaseDate_raw": "2017-04-05T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T16:01:50.953", "lastUpdateDate_raw": "2018-07-27T09:01:50.953", "counter": 47, "weight": 20170404, "commentCount": 0, "editUrl": "/en/news/aequus-launches-medical-cannabis-physician-research-in-us-and-canada?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7488536&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:\n

\n
\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, using the results from this study to guide development efforts in medical cannabis, and enhancing delivery systems used with medical cannabis. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully out-license or sell its current products and in-license and develop new products, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

\n
\n
", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

Contact Information:

\n

Aequus Investor Relations

\n

Email: investors@aequuspharma.ca

\n

Phone: 604-336-7906

" }, { "description": "

Vancouver, BC. April 3, 2017– Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”),\n today announced results from its second Proof of Concept study designed to evaluate the pharmacokinetics (PK), safety and tolerability following repeat\n exposure of its once-weekly aripiprazole transdermal patch, AQS1301, for the treatment of certain psychiatric disorders. Aripiprazole is among the\n most commonly prescribed anti-psychotics globally under the trade name Abilify®, however the once-daily oral delivery system of Abilify® can be limited\n by low rates of patient adherence. Aequus’ market research involving over 250 psychiatrists indicates that up to 42% of patients in certain populations\n experience a relapse at least once a year due to non-adherence to their oral medication. These physicians provided strong feedback around the need\n for a non-invasive, long-acting alternative to this important medication, such as a once-weekly patch.

\n

The purpose of this multi-dose study was to evaluate the bioavailability of AQS1301 following four weeks of exposure in order to establish steady state\n plasma levels. This was achieved in healthy male volunteers aged 45-65.

\n

As predicted, steady state of the current formulation was reached in week three of dosing, with relative concentrations of aripiprazole and its active\n metabolite, dehydroaripiprazole, comparable to oral dosing of Abilify®. There were no serious adverse events or safety concerns.

\n

“We are pleased that results from the study met our expectations,” said Doug Janzen, President and CEO at Aequus. “We continue to work with patient groups\n and physicians to ensure the commercial presentation of our product meets the needs of the patient populations that we have identified as the best\n suited potential candidates for a transdermal patch, namely major depressive disorder in elderly patients in a homecare setting, autistic patients\n suffering from irritability, as well as newly diagnosed and mild bipolar patients.”

\n

Following the results of this study, Aequus anticipates meeting with the US Food and Drug Administration (FDA) for a pre-Investigational New Drug (pre-IND)\n meeting to define the clinical strategy and path forward for regulatory approval in the US.

\n

STUDY DESIGN

\n

The multi-dose Proof of Concept clinical trial was intended to evaluate the bioavailability and safety of Aequus’ once-weekly transdermal patch for aripiprazole,\n AQS1301. The study was a follow-on to the successfully completed single-dose exposure proof of concept study which suggested that the current formulation\n delivers sustained levels of therapeutic doses of aripiprazole over a seven-day period. This repeat dose, 28-day study enrolled eight healthy male\n volunteers who were dosed with four successive applications of a once-weekly patch followed by a wash out period. One subject was removed for protocol\n violation during the study period, seven subjects completed the study. Blood samples for both aripiprazole and dehydroaripiprazole were drawn, and\n the plasma concentrations compared against published PK profiles for both the oral and once-monthly injectable formulations.

\n

ABOUT ARIPIPRAZOLE

\n

Aripiprazole is an atypical antipsychotic and the active ingredient in Abilify®, a leading medication in the US used for the treatment of a number of psychiatric\n disorders including bipolar I disorder, schizophrenia, major depressive disorder and irritability associated with autistic disorder. Aripiprazole is\n currently available in once-daily oral tablets and a once-monthly injectable form, however, medication adherence continues to be a significant challenge\n for patients. Aequus has developed and owns global rights to a seven-day patch application of aripiprazole intended to provide patients with a convenient\n and easy to use long acting alternative, in an effort to reduce the rate of relapse that may result from patients not adhering to their prescribed\n dosing schedule.

\n

ABOUT AEQUUS PHARMACEUTICALS

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a specialty pharmaceutical company focused on developing and commercializing\n high quality, differentiated products. Aequus’ development stage pipeline includes several products in neurology, psychiatry and women’s health with\n a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs\n in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach\n of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either\n created internally or brought in through an acquisition or license, remaining focused on highly specialized therapeutic areas. For further information,\n please visit www.aequuspharma.ca.

", "itemId": 7483239, "name": "Aequus Announces Positive Results from Second Proof of Concept Study for Long-Acting Aripiprazole Transdermal Patch", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-positive-results-from-second-proof-of-concept-study-for-long-acting-aripiprazole-tr", "url": "/en/news/aequus-announces-positive-results-from-second-proof-of-concept-study-for-long-acting-aripiprazole-tr", "releaseDate": "2017-04-03T00:00:00", "releaseDate_raw": "2017-04-03T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:01:32.947", "lastUpdateDate_raw": "2018-08-01T07:01:32.947", "counter": 48, "weight": 20170403, "commentCount": 0, "editUrl": "/en/news/aequus-announces-positive-results-from-second-proof-of-concept-study-for-long-acting-aripiprazole-tr?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7483239&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release contains forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the implementation of our business model and strategic plans and the next steps in connection with AQS1301 following the Proof of Concept clinical trial results. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to general business and economic conditions and the anticipated results of the Phase I clinical trial. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Short-Form Prospectus dated June 30, 2015, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "

CONTACT INFORMATION

\n

Aequus Investor Relations

\n

Email: investors@aequuspharma.ca

\n

Phone: 604-336-7906

" }, { "description": "

\n

VANCOUVER, BC--(Marketwired - March 13, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS)\n (\n OTCQB: AQSZF) (\"Aequus\" or the \"Company\"),\n a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce the closing\n today of its previously announced public offering (the \"Offering\"). Pursuant to the Offering, the Company issued 17,250,000 units\n (the \"Units\") at a price of $0.30 per Unit, for aggregate gross proceeds to Aequus of $5,175,000. Canaccord Genuity Corp. (the\n \"Underwriter\") acted as underwriter for the Offering. The 17,250,000 Units issued include 2,250,000 Units issued and sold pursuant\n to the over-allotment option granted by the Company to the Underwriter, which was exercised in full.

\n

Each Unit is comprised of one common share of the Company (a \"Common Share\") and one-half of one Common Share purchase warrant (each\n whole Common Share purchase warrant, a \"Warrant\"). Each Warrant is exercisable to acquire one Common Share (a \"Warrant Share\")\n for a period of two years at an exercise price of $0.45 per Warrant Share, subject to adjustment in certain events. In the event that the volume\n weighted average trading price of the Company's Common Shares on the TSX Venture Exchange is greater than $0.80 per Common Share for a period of\n 15 consecutive trading days, the Company may accelerate the expiry date of the Warrants by giving notice to the holders thereof by way of press\n release and in such case the Warrants will expire on the 30th day after such notice is given.

\n

In addition, Aequus issued to the Underwriter a total of 862,500 broker warrants (the \"Broker Warrants\") in connection with the Offering.\n Each such Broker Warrant entitles the holder to acquire a Unit at an exercise price of $0.30 per Unit for a period of two years following the closing\n of the Offering.

\n

Net proceeds of the Offering are to be used for the development of the Company's drug pipeline and other general corporate purposes.

\n

The Units were offered by way of a prospectus supplement and an accompanying short form base shelf prospectus of the Company, in the provinces of Alberta,\n British Columbia, Saskatchewan, Manitoba and Ontario, and in the United States by way of private placement to qualified institutional investors.

\n

The Units issued pursuant to the Offering have not been, nor will they be, registered under the U.S. Securities Act of 1933, as amended, or applicable\n state securities laws, and may not be offered or sold to persons in the United States absent registration or an exemption from such registration\n requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the\n securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

\n

About Aequus Pharmaceuticals\n

\n

Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (\n OTCQB: AQSZF) is a growing specialty pharmaceutical company focused\n on developing and commercializing high quality, differentiated products. Aequus' development stage pipeline includes several products in neurology\n and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize\n its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships\n that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch\n of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized\n therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

", "itemId": 7196602, "name": "Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-raises-5-2-million-through-bought-deal-financing-including-full-exercise-of-the-over-allotmen", "url": "/en/news/aequus-raises-5-2-million-through-bought-deal-financing-including-full-exercise-of-the-over-allotmen", "releaseDate": "2017-03-13T00:00:00", "releaseDate_raw": "2017-03-13T17:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-26T16:41:11.8", "lastUpdateDate_raw": "2018-07-27T09:41:11.8", "counter": 49, "weight": 20170313, "commentCount": 0, "editUrl": "/en/news/aequus-raises-5-2-million-through-bought-deal-financing-including-full-exercise-of-the-over-allotmen?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7196602&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words \"believe\", \"may\", \"plan\", \"will\", \"estimate\", \"continue\", \"anticipate\", \"intend\", \"expect\", \"potential\" and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the use of proceeds of the Offering; and the Company's intention to commercialize its internal programs in Canada, form strategic partnerships and build its Canadian commercial platform. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company's ability to successfully out-license or sell its current products and in-license and develop new products, the assumption that the Company's current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company's ability to attract and retain skilled staff, market competition, the products and technology offered by the Company's competitors and the Company's ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading \"Risk Factors\" in the Company's Annual Information Form dated April 29, 2016, a copy of which is available on Aequus' profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus' SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n

", "Forward-Looking Statement Disclaimer 2": "", "Contact for Article": "" }, { "description": "

 

\n

VANCOUVER, March 3, 2017 /CNW/ - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (\"Aequus\" or the \"Company\"),\n a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has entered\n into a revised agreement with Canaccord Genuity Corp., to increase the size of the Company's previously announced bought deal of Units from C$3.0 million\n to C$4.5 million (the \"Offering\").

\n

In addition, the Company has granted the Underwriter an option (the \"Over-Allotment Option\"), to purchase up to 2,250,000 additional Units at the Offering\n Price for a period of 30 days after and including the closing date. In the event that the option is exercised in its entirety, the aggregate gross\n proceeds of the Offering to the Company will be approximately $5.2 million.

\n

Each Unit will be comprised of one common share of the Company (a \"Common Share\") and one-half of one Common Share purchase warrant (each whole Common\n Share purchase warrant, a \"Warrant\"). Each Warrant will be exercisable to acquire one Common Share (a \"Warrant Share\") for a period of two years following\n the closing date of the Offering at an exercise price of $0.45 per Warrant Share, subject to adjustment in certain events. The Warrants will be subject\n to a forced exercise provision if the Company's daily volume weighted average share price on the TSX Venture Exchange (or such other stock exchange\n the Company may be trading on) is greater than $0.80 for 15 consecutive trading days.

\n

Net proceeds of the Offering will be used for the development of the Company's drug pipeline and other general corporate purposes. Closing of the Offering\n is expected to occur on or about March 13, 2017.

\n

The Units will be offered by way of a prospectus supplement and an accompanying short form base shelf prospectus of the Company, in the provinces of Alberta,\n British Columbia, Saskatchewan, Manitoba and Ontario, and in the United States by way of private placement to qualified institutional investors and\n outside of Canada and the United States on a private placement or equivalent basis.

\n

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, and may not be\n offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not\n constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such\n offer, solicitation or sale would be unlawful.

\n

About Aequus Pharmaceuticals

\n

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,\n differentiated products. Aequus' development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need\n for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its\n current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates\n worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or\n brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

\n

 

", "itemId": 7173680, "name": "Aequus Announces Upsizing of Previously Announced Bought Deal of Units to $4.5 Million", "urlWithHost": "http://www.aequuspharma.ca/en/news/aequus-announces-upsizing-of-previously-announced-bought-deal-of-units-to-4-5-million", "url": "/en/news/aequus-announces-upsizing-of-previously-announced-bought-deal-of-units-to-4-5-million", "releaseDate": "2017-03-03T00:00:00", "releaseDate_raw": "2017-03-03T18:00:00", "expiryDate": "9999-01-01T00:00:00", "expiryDate_raw": "9999-01-01T00:00:00", "lastUpdateDate": "2018-07-31T14:03:53.7", "lastUpdateDate_raw": "2018-08-01T07:03:53.7", "counter": 50, "weight": 20170303, "commentCount": 0, "editUrl": "/en/news/aequus-announces-upsizing-of-previously-announced-bought-deal-of-units-to-4-5-million?A=Edit", "isCustomerModule": false, "editParams": "", "edit": "", "deleteUrl": "/CustomContentProcess.aspx?CCID=14242&OID=7173680&A=Delete", "deleteParams": "", "delete": "", "Forward-Looking Statement Disclaimer 1": "

Forward-Looking Statements:

\n

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words \"believe\", \"may\", \"plan\", \"will\", \"estimate\", \"continue\", \"anticipate\", \"intend\", \"expect\", \"potential\" and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: the Offering, including the use of proceeds of the Offering, the proposed closing date of the Offering and the successful completion of the Offering; and the Company's intention to commercialize its internal programs in Canada, form strategic partnerships and build its Canadian commercial platform. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. \n

", "Forward-Looking Statement Disclaimer 2": "

\n

In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company's ability to successfully out-license or sell its current products and in-license and develop new products, the assumption that the Company's current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company's ability to attract and retain skilled staff, market competition, the products and technology offered by the Company's competitors and the Company's ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading \"Risk Factors\" in the Company's Annual Information Form dated April 29, 2016, a copy of which is available on Aequus' profile on the SEDAR website at \n www.sedar.com , and as otherwise disclosed from time to time on Aequus' SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements. SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.\n

\n

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\n

\n

", "Contact for Article": "" } ], "pagination": { "currentPage": 1, "itemsPerPage": 50, "numberOfPages": 2, "totalItemsCount": 97, "previousPageUrl": null, "nextPageUrl": "/Default.aspx?PageID=17453309&A=WebApp&CCID=14242&Page=2&Items=50" }, "params": { "id": "14242", "filter": "all", "resultsPerPage": "50", "collection": "news", "template": "" } }